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Abstract
Breast cancer (BC) patient management has been transformed over the last two decades due
to the development and application of genome-wide technologies. The vast amounts of data
generated by these assays, however, create new challenges for accurate and comprehensive
analysis and interpretation. This thesis describes novel methods for fluorescence in-situ
hybridization (FISH), array comparative genomic hybridization (aCGH), and next generation
DNA- and RNA-sequencing, to improve upon current approaches used for these
technologies. An ab initio algorithm was implemented to identify genomic intervals of single
copy and highly divergent repetitive sequences that were applied to FISH and aCGH probe
design. FISH probes with higher resolution than commercially available reagents were
developed and validated on metaphase chromosomes. An aCGH microarray was developed
that had improved reproducibility compared to the standard Agilent 44K array, which was
achieved by placing oligonucleotide probes distant from conserved repetitive sequences.
Splicing mutations are currently underrepresented in genome-wide sequencing analyses, and
there are limited methods to validate genome-wide mutation predictions. This thesis
describes Veridical, a program developed to statistically validate aberrant splicing caused by
a predicted mutation. Splicing mutation analysis was performed on a large subset of BC
patients previously analyzed by the Cancer Genome Atlas. This analysis revealed an elevated
number of splicing mutations in genes involved in NCAM pathways in basal-like and HER2enriched lymph node positive tumours. Genome-wide technologies were leveraged further to
develop chemosensitivity models that predict BC response to paclitaxel and gemcitabine. A
type of machine learning, called support vector machines (SVM), was used to create
predictive models from small sets of biologically-relevant genes to drug disposition or
resistance. SVM models generated were able to predict sensitivity in two groups of
independent patient data.
High variability between individuals requires more accurate and higher resolution genomic
data. However the data themselves are insufficient; also needed are more insightful analytical
methods to fully exploit these data. This dissertation presents both improvements in data
quality and accuracy as well as analytical procedures, with the aim of detecting and
ii

interpreting critical genomic abnormalities that are hallmarks of BC subtypes, metastasis and
therapy response.

Keywords
genomic technology, breast cancer, nucleic acid hybridization, fluorescence in-situ
hybridization, microarray, copy number changes, next generation sequencing, splicing
mutations, NCAM, mutation validation, chemosensitivity, support vector machines, machine
learning, paclitaxel, gemcitabine, formalin fixed paraffin embedded tissue
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Chapter 1
1

Introduction

1.1 Breast Cancer Overview
Breast cancer is the most frequently diagnosed cancer worldwide (1). In Canada, 1 in 9
women are expected develop breast cancer in their lifetime, with 24,000 new cases (26%
of all cancer cases) in 2014 (2). Advancements in prevention, screening, and treatment
strategies over the past 20 years have led to a steady decrease in mortality rates from
breast cancer, yet it still accounts for 14% of cancer deaths in Canada (2). These rates are
similar to those of the United States and other economically developed countries (1).
After diagnosis, clinicians rely on multiple parameters to direct treatment strategies and
predict prognosis, including clinical factors, such as patient age, lymph node status
(positive or negative), tumour size, and histological grade, as well as the status of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2) in the tumour.

1.1.1 Gene Expression Subtypes of Breast Cancer
Although all breast tumours are grouped under the umbrella of one disease, breast cancer
is remarkably complex. The traditional markers used for tumour classification are not
able to fully portray the biological variability observed among breast tumours (including
genomic alterations, cellular composition, and response to treatment). With the
advancement of microarray technology, gene expression profiling led to the sub
classification of breast cancer into 5 categories: Luminal A, Luminal B, HER2-enriched,
Basal-like, and Normal-like (3,4). More recently, an additional subtype was identified,
Claudin-low (5), to make up the 5 intrinsic subtypes of breast cancer, and the additional
Normal Breast-like group. These subtypes are now well-characterized, and have distinct
gene expression patterns (3), require different treatment regimens (6) and vary in
prognoses (7).
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Luminal A tumours make up approximately 30% of breast cancer cases, and have the
longest relapse-free and overall survival, whereas Luminal B tumours have lower relapsefree survival, similar to the other subtypes (8). The large majority (at least >90%) of
Luminal A and B tumours are ER+ and can be identified by their gene expression
signatures characteristic of luminal epithelial cells. These genes include a group of
transcription factors, including ER, which can be used to differentiate between Luminal
A and B tumours, because this proliferation signature is expressed at higher levels in the
Luminal B subtype (3,8). HER2-enriched tumours are characterized by the amplification
of the HER2 gene and historically, they have had low relapse-free and overall survival
(8). However, the development of Trastuzumab, a monoclonal antibody against HER2,
improved response rate and reduced the risk of death for this subtype by 20% when used
in conjunction with chemotherapy (9). Basal-like and Claudin-low subtypes are similar in
that they have low expression in both the Luminal and HER2-enriched intrinsic
expression signatures, but differ in at least two groups of genes. Unlike the Basal-like
subtype, Claudin-low tumours show low expression in a gene cluster enriched with cellto-cell adhesion proteins, and high expression of a group of genes enriched with immune
system response genes (8). Both Basal-like and Cluadin-low subtypes have poorer
prognoses compared to Luminal A tumours, and similar to the outcomes of Luminal B
tumours (8). Normal-like tumours are those that cluster with normal breast tissue in gene
expression profiling. They have expression of genes that are characteristic of basal
epithelial and adipose cells, and low expression of genes usually observed in Luminal
cells. The intrinsic subtypes of breast cancer only consider tumour differences at the gene
expression level and do not fully portray the molecular complexity of tumours at the
genomic level.

1.1.2 Genomic Analyses of Breast Cancer Tumours
Genome instability is one of the major mechanisms that allows cells to develop into
cancer (10). The cellular characteristics that enable malignant growth are known as the
hallmarks of cancer, and include: the evasion of apoptosis, self-sufficiency in growth
signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative
potential, tissue invasion and metastasis, reprogramming of energy metabolism and
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evading immune destruction (10,11). Our understanding of tumour genomes, and the
specific types of aberrations and mutations driving tumourigenesis, is increasing rapidly
as next generation sequencing is becoming more advanced and affordable.
At least five major genomic studies have begun to elucidate commonly mutated genes
that may be causing or perpetuating tumour development in breast cancer (12-16). Two
of these studies focused on tumours with specific pathological markers: one assessed 37
Basal-like and 28 other triple negative breast cancer (ER, PR and HER2 are not
expressed) (15), and the other study analyzed 77 ER positive (Luminal) tumours (13).
The remaining three sequencing studies assessed either all intrinsic subtypes (12,14), or
did not perform subtyping analysis (16). Between all five studies, whole genome or
exome sequencing was performed on a total of 860 tumours, and reported a combined
46,167 mutations (See Table 1.1 for a summary/breakdown of each study).
These sequencing studies demonstrated that mutations in different tumour suppressor or
oncogenes can lead to the same breast cancer phenotypes. A total of 55 genes were cited
as frequently mutated, although many were mutated in less than 10% of tumours (see
Table 1.2 for a list of all genes and their mutation frequencies). At least 33 genes were
statistically significantly mutated in the breast cancer tumours assessed, and there was
considerable overlap between the five studies (Figure 1.1). Not surprisingly, PIK3CA and
TP53 were both identified to be significantly mutated in breast tumours across all five
studies. TP53 was identified as a tumour suppressor gene more than two decades ago, and
at that time, was observed to be the most commonly altered gene in tumours (17).
Frequent mutations in PIK3CA in breast cancer were observed as early as 2004, where
25% of the tumours assessed contained somatic mutations in the gene (18). Additional
genes that were highlighted in at least two of the five studies included known breast
cancer genes (GATA3, RB1, AKT1, CDH1, MAP3K1, MLL3, CDKN1B and PTEN) and
newly identified ones (CBFB, RUNX1, TBX3 and SF3B1).
These sequencing studies highlight the genomic diversity of mutations among breast
cancer tumours. Of particular interest are the 40 (or more) genes that were identified as
potential breast cancer genes in only one of five the studies. Discordance between the
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Table 1.1 Summary of large-scale breast cancer sequencing studies.
Paper

Banerji
(B)

Ellis

13

Shah

Subtypes

No. Mut.

Ave No.
Mut. / Tum.

108

Lum A = 38
Lum B = 22
HER2 = 21
Basal = 13
Norm = 5

4985

77

Lum A/B =
77

65

Basal = 37

12

(E)

15

No. Tum.

(Sh)

Stephens
(St)

14

Significantly Mutated Genes

Method to Identify Sig.
Mutated Genes

46

Known: PIK3CA, TP53, AKT1, GATA3,
MAP3K1
New: CBFB

MutSig Algorithm FDR <0.1

3208

42

Known: PIK3CA, TP53, GATA3, CDH1,
RB1, MLL3, MAP3K1, CDKN1B
New: TBX3, RUNX1, LDLRAP1, STMN2,
MYH9, AGTR2, SF3B1, CBFB, ATR

MuSiC - Convolution
Test FDR <0.26

2414

37

Known: TP53, PIK3CA, RB1, PTEN
New: MYO3A, GH1

Considered background
21
mutation rates q < 0.1

72

Known*: PIK3CA, TP53, CDH1, GATA3,
MLL3, AKT1
New^: ARID1B, CASP8, MAP3K1,
MAP3K13, NCOR1, SMARCD1, CDKN1B,
AKT2, TBX3

* cited as frequently
mutated
^ Searched for nonrandom clustering of
22,23
somatic mutations

56

Known: PIK3CA, PTEN, AKT1, TP53,
GATA3, CDH1, RB1, MLL3, MAP3K1,
CDKN1B
New: TBX3, RUNX1, CBFB, AFF2, PIK3R1,
PTPN22, PTPRD, NF1, SF3B1, CCND3

MuSiC - Convolution
and Likelihood Ratio
Tests FDR <0.05

16

TCGA (T)

100

N/A

510

Lum A = 225
Lum B = 126
HER2 = 57
Basal = 93

7241

28319

N/A = subtyping analysis was not reported.
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19

20

20

Table 1.2 Frequency of commonly mutated genes in breast cancer tumours (refer to Table 1.1 for study abbreviations and citations)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.

Gene
PIK3CA
TP53
CDH1
GATA3
MAP3K1
MLL3
RB1
AKT1
CBFB
CDKN1B
NCOR1
PTEN
SF3B1
TBX3
ARID1A
ARID2
ATR
BAP1
BRCA2
CASP8
ERBB2
MAP2K4
MLL2
MYH9
NF1
PIK3R1
PTPRD
RUNX1

B
27%
27%
4%
3%

6%
4%

E
58%
23%
10%
10%
17%
6%
5%

Sh
11%
54%
3%

3%
8%

3%
3%
2%
8%
4%
5%

8%

5%

2%
3%
6%
2%
5%
3%
3%
2%
2%

St
30%
37%
7%
14%
6%
5%
2%
4%
1%
3%
3%
4%
3%
3%
1%
1%
0%
3%
1%
4%
1%
2%

3%
2%
5%

T
36%
37%
7%
11%
8%
7%
2%
2%
2%
1%
3%
3%
2%
3%

4%

3%
3%
2%
4%

29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.

Gene
SETD2
AFF2
AGTR2
AKT2
APC
ARID1B
ASXL1
BRAF
BRCA1
CCND3
COL6A3
ERBB3
GH1
KRAS
LDLRAP1
MAP3K13
MYO3A
NRAS
PTPN22
SMAD4
SMARCD1
STK11
STMN2
SYNE1
SYNE2
UBR5
USH2A

5

B

E

Sh
2%

St
1%

T
3%

3%
1%
1%
3%
1%
3%
1%
<1%
6%
3%
5%
1%
3%
2%
9%
3%
1%
1%
1%
1%
3%
6%
5%
6%
9%

Figure 1.1 Significantly mutated genes in breast cancer tumours.

Genes identified as

significantly or commonly mutated were extracted from five major sequencing studies (found
within each circle and colour coded according to the legend on the top right): Banerji et al. (2012),
Ellis et al. (2012), Shah et al. (2012), Stephens et al. (2012), and the Cancer Genome Atlas
(2012). The number of studies the gene was identified in is indicated by the bottom legend on the
right.

6

studies may be due to low mutation rates, ranging from 1-9%, or differences in the
methods of variant calling, variant filtering, and identifying common/significantly
mutated genes. Of the five papers, four unique methods were used to identify which
genes were “commonly” or “significantly” mutated, which in some cases lead to
discrepancies as to which genes were included as significant. For example, CASP8 was
mutated in 3% of breast cancer tumours in two studies (Shah (15) and Stephens (16)), but
only one study (Stephens) cited it as a potential new breast cancer gene. Shah et al.,
(2012), considered background mutation rates when identifying new breast cancer genes
(q < 0.1) (21), whereas Stephens et al., (2012), searched for non-random clustering of
somatic mutations (22,23).
Regardless of the differences between the five studies, the long list of potential driver
genes created from these studies provides a new gene set to be explored and analyzed by
the breast cancer community. Mutations in newly recognized genes may have
implications in prognosis, treatment response, or provide the opportunity to identify new
pathways for therapeutic targeting. For example, Stephens et al., (2012), identified 9 new
potential driver genes that have not been previously noted in either breast or other cancer
types. These genes are involved in pathways regulating the JUN kinases MAP2K7 and
MAP2K8. Mutations in the mitogen-activated protein kinase (MAPK) signaling pathway
genes have been suggested to be associated with drug resistance (24), which could have
implications for breast cancer treatment if tumours contain mutations in these genes.
Copy number analyses identified commonly deleted or amplified genes, including well
known tumour suppressor or oncogenes (TP53, PIK3CA, NRAS, EGFR, RB1, and ATM),
as well as new genes of interest that were not identified through DNA sequence analysis
(PRPS2, NRC31, and four PKC-related genes) (15). These results were similar to the
Cancer Genome Atlas (TCGA) study that confirmed previously reported copy number
variations, and highlighted many of the same genes affected by copy number changes
(including PIK3CA, EGFR, FOXA1, and HER2 in amplified regions, as well as MLL3,
PTEN, and RB1 in deleted regions) (14). The TCGA study also identified five copy
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number clusters that correlated with the gene expression subtypes, which had been
observed before (25).

1.2 Genomic technologies used in breast cancer research
and clinical management
It is possible that in order to achieve the greatest overall success when treating patients,
tumours will need to be characterized at the genomic and/or transcriptomic level to guide
treatment. This is the basis behind the NCI-Molecular Analysis for Therapy Choice
(NCI-MATCH) trial that was recently announced in the United States, which aims to
personalize drug selection based on analyzing patient’s tumours for specific genetic
abnormalities for which a targeted drug exists. There are a number of cytogenetic and
molecular techniques that can be used in both research and clinical settings to analyze
tumours for different types of mutations, guide diagnosis, predict prognosis and select
treatment. Among the most common include fluorescence in-situ hybridization, genomic
or gene expression microarrays, and next generation sequencing.

1.2.1 Fluorescence in-Situ Hybridization
Fluorescent in situ hybridization (FISH) uses fluorescently labeled nucleic acid probes to
detect targeted genomic or transcriptomic sequences. FISH can be used to localize
specific DNA sequences on interphase or metaphase chromosomes, or RNA sequences in
cells or tissue samples. FISH was first reported in 1980, by a group that used 3’
fluorescently labeled RNA to bind specific DNA sequences (26). Prior to the use of
fluorophores, similar hybridization methods used radiolabelled probes, which was not
optimal due to the instability of radiolabelled probes, low resolution, long exposure
times, and the costs and risks associated with radioactive material (27). Before FISH was
developed, conventional cytogenetic methods, such as karyotype analysis, were
commonly used for disease research and diagnosis. Given its higher resolution, FISH can
be used to detect structural rearrangements in chromosomes including translocations,
inversions, insertions, and microdeletions, identify marker chromosomes, and delineate
chromosomal breakpoints.
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The first draft of the human genome provided the opportunity to develop thousands of
DNA clones (primarily bacterial artificial chromosomes, or BACs) that contain genomic
sequence tags, and have been mapped to specific chromosome bands (28). Libraries of
BAC probes are commercially available, and can also be produced in the laboratory in
high quantities using a polymerase with strand displacement activity (29). There have
been numerous disease-specific FISH reagents and methods have been developed with
proven clinical significance and higher resolution over conventional cytogenetic
karyotyping (30,31). Although these BAC FISH probes are still commonly used, the
majority of theses clones are greater than 100 kb, so their use is usually restricted to
detecting larger rearrangements (Figure 1.2). For the majority of probe labeling and
hybridization techniques, detecting small sequences (<10 kb) has been difficult, because
smaller probes are often inconsistent and have low sensitivity (32). More recently,
methods and techniques have been developed to improve the throughput, or resolution of
FISH. For example, labeling probes using nick translation with an excess of DNA
polymerase I has increased signal intensities of a 30 kb probe (32), using single copy
DNA sequences has enabled FISH probe design where the exact DNA sequence and
genomic location are known (33), and an automated analysis method using grid sampling
was developed that reduced the time of analysis and evaluation of results down to 9
minutes per sample (34).
FISH is commonly used in clinical diagnosis for birth defects and developmental delay,
prenatal testing, and acquired diseases. It is a main test for disorders caused by
microdeletions (35) (such as Williams, Prader-Willi, Angelman, Miller-Dieker,
DiGeorge,

Wolf-Hirschhorn,

Cri-du-chat,

and

Smith-Magenis

Syndromes)

or

microduplications (35) (such as Charcot-Marie-tooth 1A and Pelizaeus-Merzbacher), and
also has many different applications in oncology (36). For example, FISH is commonly
used to detect specific gene fusions known to occur in certain types of cancers, such as
the EML4-ALF fusion in non-small-cell lung cancer (37) and the BCR-ABL fusion (ie.
the Philadelphia chromosome) in chronic myeloid leukemia (38). In breast cancer, the
American Society of Clinical Oncology/College of American Pathologists has
recommended that the HER2 status (amplified or not) should be tested for all invasive
breast cancer (39). They consider tumours to be HER2-positive if there are more than 6
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copies of HER2 per nucleus, or if the HER2 gene signal to chromosome 17 ratio is more
than 2.2. FISH results are typically used to confirm, or are confirmed with
immunohistochemical assays, which were 92% concordant when assessing hundreds of
samples (40). Even so, as much as 20% of HER2 testing may be inaccurate (39), and
probes with higher resolution to the HER2 gene may be useful in improving the precision
of these tests.

1.2.2 Array Comparative Genomic Hybridization
Comparative genomic hybridization (CGH) was developed for use on solid tumours in
1992, and was initially performed genome wide using metaphase chromosomes (41). The
technique involves differentially labeling normal and tumour genomic DNA that are
simultaneously hybridized to normal metaphase chromosomes in the presence of
unlabeled Cot-1 DNA, which is used to block repetitive regions in the genome. Normal
and tumour DNA are detected with red and green fluorophores, which allows
quantification of the relative amount of normal versus tumour DNA using the ratio of
green-to-red fluorescence. The resolution of CGH using metaphase chromosomes is low,
detecting copy number changes greater than 20 megabases (Mb). However, at the time, it
was still able to identify amplifications in tumours in regions containing oncogenes,
including HER2 in breast cancer (41). The resolution of CGH was improved through it’s
application to microarrays, where targeted P1 phage or BAC clones were spotted on glass
slides, hybridized to the sample and reference genome, and then imaged to derive
fluorescence ratios of each clone (42). The approach was validated, in part, through more
accurately detecting HER2 amplification in a breast cancer cell line and four breast
cancer tumours. The resolution and genomic coverage of chromosomal microarrays,
including array comparative genomic hybridization (aCGH) was developed further, using
cDNA as probes (43), as well as oligonucleotides, which continue to be the current
design today (44).
Chromosomal microarrays are now a first tier test to detect genomic aberrations
associated with intellectual disability, autism, and many congenital disorders (45,46).
aCGH can be used to determine major chromosomal aneuploidy as well as
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Figure 1.2 Example of BAC end pairs and FISH clones overlapping ERBB2. A screen shot of
the UCSC Genome Browser displays the length of BAC probes (black with arrows and green
bars) relative to small genes, such as ERBB2 (highlighted in navy blue). The chromosome and
scale along the top depict the genomic chromosomal and genomic location in the region
displayed.
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submicroscopic duplications and deletions that can not be elucidated using conventional
karyotyping. More recently, single polymorphism nucleotide (SNP) arrays were
developed, which can provide similar chromosomal information, but also can identify
genomic regions with loss of heterozygosity or mosaicism. The number of
oligonucleotides on one array now ranges from hundreds of thousands to millions,
depending on the commercial platform, which allows for reliable detection of copy
changes as small as 25 kb. Reliable detection of small chromosomal gains and losses are
important in clinical diagnosis, as it is estimated that submicroscopic deletions and
duplications may be the underlying cause of up to 15% of genetic diseases (47).
Before the wide-spread adoption of next generation sequencing, aCGH in conjunction
with gene expression data was used to segregate breast cancer tumours based on their
copy number changes, and to identify likely “driver” or commonly dysregulated genes
(48). Andre et al. (2009) found the number of copy number aberrations in any given
tumour can range dramatically, from 1 to 318 copy number changes, and averaged 76.
There were a total of 48 minimum common regions with frequent copy number changes
(11 gains, 37 losses) that were found in >20% of samples. In addition, 20 genes were
amplified in at least 10 cases, of which 15 genes were overexpressed at the mRNA level.
Tumours were classified based their copy number profile, and there was partial overlap
between the gene expression subtypes and aCGH-based classifications: basal-like
tumours were more frequently class I (77%), 53% of Luminal A cancers were in class III,
and 67% of HER2 tumours were class II (48).

1.2.3 Gene Expression Microarrays
Gene expression microarrays involve hybridizing fluorescently labelled complementary
DNA (cDNA) to microarrays slides containing probes of mRNA sequences, and use
similar principles as chromosomal microarrays. cDNA Microarrays used to analyze gene
expression were first described by Schena and colleagues in 1995 (49). Forty-five cloned
cDNA transcripts from Arabidopsis, a small flowering plant, were printed onto a glass
slide for subsequent gene expression measurement using fluorescently labeled probes
using reverse transcription of mRNA. Only one year later, microarrays containing 1,046
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human cDNAs were described by the same group, representing one of the first parallel
gene analyses that measured differential gene expression patterns under given
experimental conditions (50). In this study, control treated (37°C) and heat-treated (43°C)
human T (Jurkat) cells were fluorescently labeled with different fluorophores to identify
gene expression changes in the heat shock response. The technique of measuring
expression levels relative to a control sample is still widely used today. As with
chromosomal microarrays, the resolution and capabilities of gene expression microarray
have been significantly advanced with the application of oligonucleotide-spotted arrays
that contain thousands of individual probes (51). Normalized gene expression values
measured from signal intensities of the array are commonly clustered to visualize and
quantitatively identify differences between two samples or states (52). Groups of genes
that share biological function, chromosomal location or regulation within the differential
gene sets can be determined, which helps infer the biological processes contributing to
the two conditions measured (53). Gene expression microarrays have been particularly
impactful in breast cancer, and have led to the identification of the intrinsic subtypes of
breast cancer (3) (see section 1.1.1) and the development of gene expression signatures
that are used for patient management and prognosis, and are described in detail in section
1.4.

1.2.4 Next Generation Sequencing
DNA sequencing was first described by Sanger et al. in 1977, where chain-terminating
dideoxynucleotides were incorporated into DNA strands by DNA polymerase during in
vitro DNA replication (54). The first human genome was published over twenty years
later in 2001, which was the result of a decade-long international collaboration of 20
groups (55,56). The availability of this, and other, whole genome reference assemblies
allow short DNA strands to be mapped, or aligned, to already known sequences in the
genome. The possibility of short-read sequencing enabled the advancement of nextgeneration DNA sequencing, which has been rapidly developed in recent years. Many
sequencers now take less than a week to complete a reaction (57), and consequently, the
cost per reaction has fallen dramatically, making it accessible for both research and
clinical applications.
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Next generation sequencing involves a multi-step process where the sample is prepared,
sequenced, and then analyzed. Initially, DNA template preparation is required to ready
the DNA sample for the specific sequencing platform being used. Briefly, this involves
shearing the DNA to a smaller fragment size, ligating common primers (adapters) to both
ends of the DNA fragments, and amplifying the template being sequenced (most
commonly through emulsion PCR or solid-phase amplification) (58). DNA samples are
also often enriched for a target sequence, such as all coding regions (whole exome
sequencing) (59) or specific genomic loci of interest using customized capture methods
(60). There are currently multiple next-generation platforms that can be used to perform
sequencing, including ion semiconductor (Ion Torrent sequencing), Pyrosequencing (454
Life Sciences), sequencing by synthesis (Illumina), and sequencing by ligation (SOLiD
sequencing). Sequences are generated using the detection of individual nucleotides or
oligonucleotides at sequential positions in the nucleic acid fragments being sequenced.
For example, sequencing by synthesis employs nucleotides that are fluorescently
modified with a reversible chain terminator, each nucleotide with a different colour (61),
resulting in the addition of only a single nucleotide with DNA polymerase in a given
cycle. The reaction is performed over millions of clusters, each containing many identical
copies of a DNA fragment. Clusters are imaged during each cycle, and the colour the
cluster emits indicates the nucleotide at that position. At the end of the cycle, the
terminator is cleaved, allowing for the next nucleotide to be added.
Once the sequencing portion is complete, the DNA sequences obtained (or “reads”) must
be aligned to the human reference assembly to determine their specific genomic location.
Reads can be single-end (one end of the DNA library is sequence), or paired-end (both
ends of the DNA fragments are sequenced, meaning the sequences are in close
chromosomal proximity to each other), and can range from 35-150 bp (ie. Illumina) to an
average of 400 bp (ie. 454 Life Sciences). Mapping reads to the correct location of the
approximately 3 billion nucleotides in the genome with high accuracy is an enormous
task. For this reason, there have been over twenty sequence alignment software programs
developed (62) (for example, Bowtie (63), Bowtie2 (64), SOAP2 (65), MAQ (66), BWA
(67) and RMAP (68)). Many of these programs apply or improve upon the Burrows
Wheeler Transformation, which is an algorithm that can be used to compress character
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strings (or in this case the DNA sequence) using runs of similar characters (69). Each tool
has strengths and caveats. Mapping quality, in many cases, is compromised for shorter
runtimes through neglecting base quality scores, limiting the number of tolerated base
mismatches, disabling gapped alignment or limiting gap length, and ignoring SNP
information (62). A study comparing 6 common alignment programs found that most
tools underestimate their mapping quality, and inaccurate alignments can be eliminated
by removing reads with a mapping quality of less than 1 (70).
After sequencing reads have been aligned to the genome, DNA variants, which are
nucleotides or sets of nucleotides that differ from the reference genome, can be detected
(most commonly SNPs, insertions, and deletions). Similar to the abundance of sequence
alignments programs that are available, there are over thirty different programs that
perform variant calling (71,72). The Genome Analysis Toolkit (GATK) (71), which was
developed at the Broad Institute in Cambridge, Massachusetts, has become one of the
most common and recommended programs used for variant calling (73,74). However,
many other programs have strengths and are useful for certain types of experiments. For
example, determining somatic mutations in cancer can be performed more effectively
with programs specifically designed to compare tumour and matched normal sequences
(75-78).
One of the largest hurdles the genomics community will likely face over the next decade
is the clinical interpretation of variants in genomes, exomes, and transcriptomes that
result from next generation sequencing studies. Differentiating between non-pathogenic,
natural variation and likely damaging mutations can be extremely difficult, and has
significant implications for disease-related research. Once a variant list is compiled,
which can contain thousands of variants per sample, there are a number of different
software programs that can aid in variant interpretation. Usually, variants are assessed to
determine whether they are common polymorphisms (79,80) (natural variation in the
population), and whether they are likely to be pathogenic. Software programs have been
designed for a number of different purposes, for example: to annotate whether the variant
resides in an exon or within other genomic regions (promoters, splice sites, CpG islands)
(81,82), to predict the effect of the variant on the protein product (83-85), and to assess
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whether the variant is likely to cause defects in mRNA splicing (86,87). With the
development of numerous software programs with overlapping functions, selecting which
programs to use for sequencing analyses can be difficult. Between the numerous options
for sequencing platforms, read alignment algorithms, and variant calling and
interpretation software, there are hundreds of potential pipelines or combinations of
analyses that can be performed (Table 1.3). For clinical laboratories, the American
College of Medical Genetics does not recommend any specific software programs for
next-generation sequencing analysis, rather, it is recommended to select programs based
on what type of genomic variation you are expecting and the depth of sequencing
coverage, and to explain any variant filtering criteria while clearly outlining limitations of
the approach (89).

1.3 DNA Variants
Advancements in our technical ability to reliably detect mutations in thousands of genes
in a given patient has greatly outpaced our ability to interpret and report on the data
collected in a clinical setting (90). Single nucleotide variants (SNVs) or small
insertions/deletions (indels) can be located in exons (protein coding regions), introns
(between exons), or non-coding regions. A typical sequencing study usually does not
analyze mutations in non-genic regions, given the low likelihood of pathogenicity and
difficulty to predict its affect on cellular function.

1.3.1 Protein Coding Mutations
There are three possible amino acid consequences for a single nucleotide variant found in
a coding region of a gene, and they can be classified as silent, missense, and nonsense
(stop) mutations. Silent mutations arise when a single nucleotide is altered, but the
mutated codon results in the incorporation of the wild-type amino acid into the protein.
Conversely, missense mutations occur when the mutation leads to an alteration of the
amino acid at the position of the variant. Nonsense mutations lead to a premature stop
codon within the coding sequencing, which results in protein truncation. Small indels can
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Table 1.3 DNA sequencing software
Program

Citations*

Reference**
ALIGNMENT SOFTWARE
Bowtie
4176 / 5854 Langmead B. Genome Biol. 2009;10:R25.
BWA
3930 / 5715 Li H. Bioinformatics 2009;25:1754–1760.
MAQ
1367 / 1975 Li H. Genome Res. 2008;18:1851–1858.
Bowtie2
1173 / 1887 Langmead B. Nat. Methods 2012;9:357–359.
SOAP2
997 / 1438
Li R. Bioinformatics 2009;25:1966–1967.
BWA-SW
938 / 1412
Li H. Bioinformatics 2010;26:589–595.
SSAHA2
563 / 828
Ning Z. Genome Res. 2001;11:1725–1729.
BFAST
231 / 367
Homer N. PLoS ONE 2009;4:e7767.
Stampy
227 / 333
Lunter G. Genome Res. 2011;21:936–939.
ELAND
NA / NA
Cox AJ. Illumina. 2007
Novoalign
NA / NA
Novoalign. http://novocraft.com.
VARIANT CALLERS
SAMtools
3953 / 5624 Li H. Bioinformatics 2009;25:2078–2079.
GATK
1207 / 1756 DePristo MA. Nat. Genet. 2011;43:491–498.
SOAP SNP
997 / 1438
Li R. Bioinformatics 2009;25:1966–1967.
IMPUTE2
701 / 997
Howie BN. PLoS Genet. 2009;5:e1000529.
VarScan 2
280 / 427
Koboldt DC. Genome Res. 2012;22:568–576.
Dindel
174 / 237
Albers CA. Genome Res. 2011;21:961–973.
CORTEX
83 / 143
Iqbal Z. Nat. Genet. 2012;44:226–232.
SomaticSniper
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also lead to missense or nonsense changes, insertions or deletions of one or a group of
amino acids, or can result in a frameshift mutation, where the 3-nucleotide frame of the
coding region is altered, leaving the portion of the protein after the mutation with an
incorrect amino acid sequence.
It is generally accepted that frameshift and nonsense mutations are the coding mutations
most likely to be pathogenic or damaging to a protein. The clinical relevance or
interpretation of these variants depends on the protein the mutation is found in, and
whether that protein has a known cellular function or is cited to play a role in the
phenotype being assessed. For example, a germ-line nonsense mutation in BRCA1 in an
individual or family would be reported to the patient, as the mutation puts the individual
at risk for developing breast or ovarian cancer (91). Correlating phenotype to genotype is
much more difficult in the case of missense and silent mutations, as the effect on the
protein’s function, if any, is hard to predict. However, clear and easy to interpret
mutations account for a very low number of the overall mutational load that is detected in
patients. In breast cancer, only 5-10% of families with a strong history of ovarian or
breast cancer ever learn what the causal mutation is (92). For this reason, there have been
many computational approaches, both sequence- and structure-based, that have attempted
to assess the pathogenicity of missense mutations (93). Programs predicting splicing
mutations or assessing their transcriptional effect, however, have been much more
limited.

1.3.2 Splicing Mutations
Before proteins are translated, genes are transcribed and modified in a number of
different ways: pre-mRNA splicing joins coding regions to be used during protein
translation, and a 5’ cap and 3’ poly A tail are added to promote translation, and enable
transcript transport and stability. Splicing involves over 100 factors (94), and is a multistep process that results in the removal of introns from RNA transcripts, adjoining
neighbouring exons contained in the final mRNA. Splicing machinery, known as
splicesomes, are made up of multiple proteins and recognize key sequences to delineate
the intron/exon junctions. The 5’ and 3’ ends of the intron (known as 5’ donor or 3’
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acceptor sites) contain canonical dinucleotides “GT” and “AG” (95), respectively, which
identify the intron boundaries (Figure 1.3). Within the intron there is a polypyrimidine
tract, (Py)n, and an adenine (A), known as the “branch site” that is used for lariat
formation. Briefly, splicing is carried out using two transesterification steps, whereby a
2’-hydroxyl group of the adenine residue at the branch site attacks the phosphate at the
donor site, leading to cleavage of the 5’ exon-intron boundary and lariat formation, and
then subsequent attachment to the 3’ exon (as depicted in Figure 1.3) (96). The sequences
spanning the intron/exon boundaries are conserved, but do have natural variation among
different splice sites, which can be displayed as sequence logos (Figure 1.4 A). These
sequences are 28 (acceptor) and 10 (donor) nucleotides in length, and dictate the overall
strength of the splice site (or the likelihood of the splicing machinery recognizing the
site) (98).
Splicing is used in the cell as an additional level of protein diversity and regulation.
Various protein isoforms can be produced from the same gene through the inclusion of
different combinations of exons in the final mRNA transcript used for protein translation.
Alternative splicing is suggested to be one of the most important components of the
functional complexity of the human genome, and is estimated to affect 40-60% of all
human genes (99). This natural alternative splicing is usually not pathogenic, as different
transcripts of the same gene are often expressed in tissue specific patterns (100).
Because splicing machinery relies on the pre-mRNA sequence to correctly remove an
intron, mutations in these regions can lead to aberrant splicing that can damage or alter
protein function. For example, if any of the highly conserved “GT” (or U in RNA) or
“AG” nucleotides were altered, splicing would not properly occur at that intron (101).
Although less common, mutations beyond these highly conserved dinucleotides in the
splice site sequences (donor and acceptor) can lead to aberrant splicing and pathogenicity
(97). The number of deleterious SNV splicing mutations described in the literature
generally relates to the information content at each position of the sequence logo (Figure
1.4 B).
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Figure 1.3 Basic schematic of pre-mRNA splicing. Diagram depicts an overview of mRNA
splicing. Exons are indicated by the large blue-outlined boxes (as labeled), and introns are
displayed as thin blue lines. Key nucleotides are labeled as “A”,”G”, and “U”, polypyrimidine tracts
“(Py)n”.
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Figure 1.4 Splicing 5’ donor and 3’ acceptor sequence logos and frequency of reported
mutations. A sequence logo for human acceptor (left) and donor (right) splice sites is displayed
in A. The height of each nucleotide represents its frequency and the error bars indicate the
standard deviation at that position. The distribution of deleterious single nucleotide variants
reported in the literature to negatively affect splicing are displayed in B. This figure was adapted
from Caminsky et al. (2014) (97) and Rogan et al. (2003) (98).
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Splicing mutations can result in large changes to the final gene product, and hence, are
commonly pathogenic. Up to 15% of all disease-causing mutations affect mRNA splicing
(102), and this number is higher for certain genes, where splicing mutations can account
for as many as 50% of the mutations reported (103). A number of different outcomes can
arise from mutations that affect mRNA splicing. Mutations can inactivate a natural splice,
which can result in the splicing machinery missing the corresponding donor or acceptor
leading to intron retention (Figure 1.5 B), or the splicing machinery using a donor or
acceptor from a neighbouring intron which would lead to exon skipping (Figure 1.5 C).
An inactivating mutation at a natural splice site can also lead to the recognition of a
weaker, so-called cryptic splice site in either the intron or exon, which would be
recognized by the splicing machinery and result in the extension or truncation of the exon
(termed cryptic splicing, Figure 1.5 D). A mutation may also activate a cryptic splice site,
which would lead to a cryptic splicing phenotype (Figure 1.5 E).
Numerous software programs have been developed to analyze mutations and their
potential effect on mRNA splicing. Commonly, splicing software programs require a
DNA sequence containing the mutation as the input (Table 1.4). The program then
determines the presence of splice sites or splicing regulatory factor binding sites, such as
exonic splicing enhancers. The effect of the mutation on splicing can be determined by
comparing the mutated sequence versus the wild-type sequence. Because of the nature of
these programs, genome-wide capabilities are limited, and analysis of thousands of
mutations filtered from next generation sequencing studies would be extremely laborious.
There are also programs that analyze mutations, or lists of mutations, to determine if any
affect splicing. Many of the common variant annotation and interpretation software
programs are limited to identifying mutations that are likely to alter splicing by their
location at the conserved dinucleotides (for example, ANNOVAR (81)), or within a
limited splicing region (for example, Variant Effect Predictor looks as far as 8
nucleotides from the natural site (104)). The Automated Splice Site and Exon Definition
Analyses (ASSEDA) (105), and the Shannon Human Splicing Pipeline (Shannon
Pipeline) (86) software programs, however, employ information theory to extend the
analysis to entire coding and non-coding regions of a gene. The application of
information theory to DNA sequences was first proposed by Thomas D. Schneider in
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Figure 1.5 Aberrant splicing patterns resulting from DNA variants. Wildtype (A) and
aberrantly spliced (B-D) transcripts are displayed to portray examples of the potential affect a
mutation can have on mRNA splicing. Exons are indicated by the blue boxes, white filled in exons
represents regions not maintained in the final transcript, and the black lines correspond to the
sequences joined after splicing has occurred. Red arrows represent splice site-inactivating
mutations, and green arrows represent activating mutations. A mutation can decrease the
strength of a splice site, which can lead to intron retention in the final transcript (B), the affected
exon being skipped and not retained in the final transcript, or a now-stronger neighbouring cryptic
splice site to be used (resulting in part of the middle exon included in the final transcript).
Alternatively, Exonic (E-top) or intronic (E-bottom) cryptic splices can be activated, resulting in the
extension or truncation of the exon.
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Table 1.4 Splicing mutation and splice site analysis software.

Genome wide
capability?

Analyzes
mutations?

Analyzes
sequences?

ANNOVAR81

yes

yes

no

Variant Effect Predictor104

yes

yes

no

ASSEDA105

no

yes

yes

Shannon Pipeline86

yes

yes

no

yes

no

yes

no

yes

yes (max 2500 nts)

ESEfinder108

no

no

yes (max 5000 nts)

MaxEntScan109

no

no

yes (9 nt sequences)

Splice Site Prediction by Neural
Network, NNSplice110

no

no

yes

NetGene2111,112

no

no

yes

SpliceView113

no

no

yes (max 31000 nts)

Splice Predictor114

no

no

yes

GenScan115

no

no

yes

no

no

yes

Program

GeneSplicer107
Human Splice Finder

Spliceman

116

87
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1997 (106). The information theory-based approach is based on the formal relationship
between information theory and the second law of thermodynamics. Each splice site is
made up of information (measured in bits), which reflects the thermodynamic entropy
and free energy of binding. The change in total information of the site is used to
determine whether a mutation will strengthen or weaken the splice site.
The limited genome-wide capabilities and regions analyzed by most splicing software
programs has led to an underrepresentation of splicing mutations in genome-wide studies.
In the 5 major breast cancer sequencing studies (12-16), splicing mutations accounted for
only 1.78-2.18% of all of the mutations reported (Table 1.5). This is likely due to the
rudimentary approaches used to identify splicing mutations, which were limited to
mutations located at the canonical dinucleotides at donor or acceptor sites. In addition,
there are also currently limited efforts to attempt to validate the effect of splicing
mutations on the mRNA transcript and protein product in large scale sequencing studies
due to the large number of variants found, and efforts required for a single variant.

1.4 Gene expression signatures in breast cancer
The idea of personalized medicine is not new, however, clinical decision-making based
on molecular profiling of individual tumours is still evolving. Early indications of
personalized medicine date back to 1957, when 2 different papers suggested that genetic
variation in enzymes may be linked to adverse drug response (117). Enzymes, such as
cytochrome P450, can differ between individuals, which can determine how long and
how much of the drug will remain active in the body. Characterizing an individual’s
metabolizing enzymes can dictate the dose required for effective response, therefore
tailoring the treatment strategy for each patient. Personalized medicine has now extended
well beyond analyzing drug metabolizing enzymes. Breast cancer, even more so than
most cancers, is a mixture of several diseases, so it is intuitive that it would be ideal to
tailor treatment and therapy selection on an individualized basis. Although it has been
proposed for many years, it is now becoming feasible to determine the molecular
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Table 1.5 Splicing mutation analyses performed in previous sequencing studies.

Paper

No. Splicing Splicing mutation analysis
Mutations
(Percent of all
mutations)

Validation approach to
confirm affect on mRNA
splicing.

Banerji12

97
(1.95%)

Oncotator – Used gene
annotations to identify
mutations at splice sites.

None

Ellis13

69
(2.15%)

Used gene structure to
annotate "splice site"
mutations.

None

Shah15

43
(1.78%)

Mutations were called using
RNA sequencing - de novo
splice sites were
determined with
HMMSplicer.

4 mutations were
correlated to alternative
splice junction usage in
RNA sequencing data.

Stephens16

158
(2.18%)

Mutations mapped to
essential splice sites.

None

TCGA14

506
(1.79%)

Annotated at "splice site"
with gene annotation file.

None
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profile of each tumour, and personalize each clinical decision based on certain
characteristics. Consequently, there have been many studies applying gene expression
analyses to individualize breast cancer management, including predicting prognosis, the
benefit of adjuvant chemotherapy, tumour response to treatment, and development of
new therapies.

1.4.1 Predicting prognosis and patient outcome
Research groups have been successful identifying and analyzing gene expression
signatures in breast cancer that outperform conventional clinicopathologic criteria in
predicting prognosis. These tests are effective in aiding to predict which patients are most
likely to benefit from chemotherapy. The most common tests used today include
Oncotype DX, MammaPrint, and PAM50. Oncotype DX is made up of a 21-gene assay,
and provides a quantitative likelihood of disease recurrence (118). It was developed and
commercialized based off of a study from 2004 that assessed the probability of breast
cancer recurrence at 10 years using 668 Tamoxifen-treated, lymph-node negative, and
estrogen-receptor positive tumours. The assay employs reverse-transcriptase polymerase
chain reaction (RT-PCR), and measures the expression of the 21 selected genes to
calculate a recurrence score (either low, intermediate, or high). Similarly, MammaPrint
uses a 70-gene assay to identify early-stage breast cancer patients that are at risk of
distant recurrence or metastasis following surgery (7). The assay differs in that it was
developed independent of ER status or any prior treatment, contrary to Oncotype DX.
The 70-gene signature was developed using DNA microarray analysis on primary
tumours of 117 young patients, and stratifies patients that have “poor prognosis” and
would likely benefit from adjuvant therapy. PAM50 is a 50-gene test that has been
optimized to stratify tumours based on the intrinsic subtypes of breast cancer, which are
then used to develop a risk of recurrence score (119). It was developed using both
microarray and RT-PCR using 189 protoype samples, and then tested with an additional
761 patients to predict prognosis and 133 patients to predict complete pathological
response to neoadjuvant chemotherapy. It is the only test of the three that directly
leverages the intrinsic subtypes of breast cancer.
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Gene expression signatures have an increased ability to recognize low-risk cases. This
reduces the number of patients who receive adjuvant treatment, leads to a decrease in
unnecessary toxicity, and lowers the cost of patient care (120). Regulatory bodies, such as
the United States Food and Drug Administration (FDA), have recognized value and
added benefit to patients by approving MammaPrint and PAM50 for clinical use, even
though FDA approval is not required for laboratory-developed tests. Oncotype DX,
which is currently the most commonly used test (121), is recommended by Cancer Care
Ontario (122). The American Society of Clinical Oncology and the National
Comprehensive Cancer Network also endorse these multigene assays to assist in
treatment decisions for ER-positive cancer. Although these tests, and others, aid in
deciding whether the patient would benefit from adjuvant therapy, clinicians still lack
robust signatures that could indicate which specific treatments will be effective on a per
patient basis (123,124).

1.4.2 Selecting therapies and predicting treatment response
Chemotherapy is currently recommended in cases where the benefit to the patient
outweighs the risk of treatment. Conventional clinicopathological features indicating
chemotherapy use for early breast cancer include histological grade 3 carcinomas, high
Ki-67 levels, low hormone receptor status, HER2 amplification or triple negative status,
and tumours that have spread to three or more lymph nodes (125). Chemotherapy can be
used in breast cancer treatment either before (neoadjuvant) or after (adjuvant) surgery.
Adjuvant chemotherapy using cyclophosphamide, methotrexate, and fluorouracil (CMF)
for lymph node positive breast cancer was first cited as an effective treatment strategy in
1976 (126), and was used until the substitution of methotrexate with epirubicin (CEF)
(127) and then docetaxel (a taxane) (128) were later reported to be more successful
combinations. Although clinical trials for many different adjuvant chemotherapy
schedules have been conducted, there is ultimately still no consensus on which may be
the most effective (129). Selection of the most effective adjuvant treatment is suggested
to be individualized and should take into account clinical disease characteristics and
patient-related factors (125,130,131). Treatment selection is already somewhat
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personalized, profiling breast cancer tumours based on the intrinsic subtypes can direct
recommendations in regard to endocrine, cytotoxic, and anti-HER2 therapies (Table 1.6).
Numerous studies have attempted to leverage genomic profiling in order to characterize
or predict tumour response or patient outcome when treating with specific therapies
(Table 1.7). Gene expression is most commonly used for this type of analysis, and
signatures or indicators have ranged from including only a few genes to many. The
majority of the studies performed to date are completed with a limited number of samples
and/or patients. The availability of both training and test sets can be limited for specific
therapies, but is increasing with dataset depositories such as the Gene Expression
Omnibus (GEO). For example, in 2003, a 92-gene expression signature was created using
24 tumours, and was able to classify 10/11 sensitive tumours and 11/13 resistant tumours
to neoadjuvant docetaxel in a leave-one-out analysis (132). No test set was used to
validate the molecular profile, which was likely due to the limited availability of samples
and/or the high costs for gene expression analyses at the time of the analysis. In contrast,
a 20-gene signature was developed in 2014 to discriminate between chemoresistant and
chemosensitive tumours to taxane-based therapies that used 160 tumours to develop the
profile, and 659 datasets to test the method (133). Of the common prognostic gene
signatures, the proliferation score from PAM50 is the only one that is able to identify
patients that will benefit from a specific drug (low proliferation score predict weekly
paclitaxel benefit) (134) or drug combinations (HER2-enriched tumours benefit from
CEF over CMF) (135). Although our technological capabilities and access to data sets
have greatly increased over the past decade, there is still no reliable genomic signature
implemented in the clinic to select between chemotherapy agents on an individual basis.

1.5 The Minimal Breast Cancer Genome and its Relevance
to Chemotherapy
Breast cancer studies to date have focused largely on genomic rearrangements, gene
expression changes, and epigenetic alterations leading to the development and
progression of the disease. Genomic regions in breast tumours that show high frequencies
of abnormal rearrangements have been termed “saw-tooth” or “firestorm” regions (140),
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Table 1.6 Treatment recommendations according to tumour subtype and/or receptor
status
Subtype or receptor status

Type of therapy

Luminal A-like

endocrine therapy is the most critical, often used alone

Luminal B-like (HER2 -ve)

endocrine therapy for all, cytotoxic therapy for most

Luminal B-like (HER2 +ve)

cytotoxic therapy + anti-HER2 + endocrine therapy

HER2-positive

cytotoxic therapy + anti-HER2

Triple-negative

cytotoxic therapy

adopted from Schmidt et al. (2014) (129)
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Table 1.7 Gene expression signatures developed to predict therapy response.
Study

Drug

Tumour

No. genes

No. training
samples

No. test
samples

Indication

Chang
132
(2003)

Docetaxel (neoadjuvant)^

Locally
advanced

92

24 pre-operative
core biopsies

N/A

Classifies tumours as sensitive
or resistant (88% accuracy)

Ma
136
(2004)

Tamoxifen (adjuvant)*

Hormone
receptor
positive

2-gene ratio

60

N/A

Predictive of disease-free
survival

Jansen
137
(2005)

Tamoxifen (first line treatment)*

ER-positive,
advanced

44

46

66

Discriminate between patients
with progressive disease and
objective response

Hallet
138
(2012)

Chemotherapy regimens
containing anthracycline and
taxane drugs (neoadjuvant)^

N/A

2-gene
index

488

N/A

Predicts complete pathological
response

He
133
(2014)

Taxane-based therapies^

N/A

20

92 resistant / 68
sensitive

659
datasets

Discriminates between
chemoresistant and
chemosensitive individuals

Schmitt
139
(2015)

Trastuzumab and docetaxel
(first line)*^

HER2positive

8

79 frozen or FFPE

27 GEO
datasets

Predicted response to
treatment (76% accuracy)

* hormone therapy, ^ chemotherapy
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and many genes have now been identified to be frequently mutated (14). However,
studies that focus primarily on unaltered (“stable”) regions in breast cancer have been
limited to date.
Our laboratory has recently proposed that there is a minimal genome required for breast
cancer cell survival (141). This minimal genome was derived by comparing independent
data sets for regions of breast cancer genomes that are stable in copy number (140,142)
with tumour gene expression levels that are similar to matched normal tissues (143,144).
Genomic regions stable in copy number were obtained from two data sets that assessed a
total of 243 (140) and 171 (142) primary breast tumours. The 812 derived “dually” stable
regions (in both copy number and gene expression) contained a subset of 5,804 genes
enriched for cellular metabolism, regulation of gene expression, DNA packaging, and
regulation of apoptotic functions.
A selection of the stable genes identified are targets of existing anti breast-cancer
therapies, including paclitaxel, estradiol, and topotecan. Growth inhibition of the breast
cancer cell lines MCF7, MDA-MB-231, HS578T, and T47D has been demonstrated using
therapeutic agents that target gene products of the stable regions (145). There was not,
however, consistent drug sensitivity across all cell lines. The average GI50 values (drug
concentrations are –log10M units) for paclitaxel, gemcitabine, and topotecan were found
to be 8.07, 6.65, and 6.92 respectively. Cell lines with GI50 values lower than 1 unit from
these averages are considered outliers, as this relates to a 10-fold increase in the
concentration of drug required for 50% growth inhibition.

1.6 Thesis Scope and Objectives
In order to improve patient care through tailoring therapies based on disease
characteristics, the field will require advancements in our ability to effectively interpret
and analyze large genomic data. We hypothesize that improvements in genome-wide
analyses - diagnostic tools and reagents for better detection of genetic abnormalities,
mutation interpretation, and genomic signatures for chemotherapy response - can result in
a more accurate understanding of tumour biology. This thesis introduces improvements in
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both the design and analysis of experiments, and then applies these techniques to breast
cancer. We describe the generation of new data, as well as leveraging existing data sets,
with the same overall goal of validating the proposed methods and interpreting the results
obtained.
Specifically, the main objectives of this thesis are to:
1) Improve the design and analysis of nucleic acid hybridization studies (specifically
FISH and aCGH). We sought to develop a novel method to identify single copy
regions in the genome that contain highly divergent repetitive elements, which we
predicted to act as single copy sequences in optimized experimental conditions.
We aimed to generate small, single copy FISH probes that contained divergent
repetitive elements, to confirm their predicted behavior in metaphase FISH. In
addition, we proposed that oligonucleotide placement throughout the genome (ie.
distance to highly conserved repetitive elements) within these single copy regions
can affect the variation observed in microarray signal intensities. Accordingly, we
sought to develop an aCGH microarray to test this theory and compare the
platform’s reproducibility to a commonly used commercial platform. Both FISH
and aCGH methods were validated on normal samples, as well as samples with
known genomic alterations.
2) The large number of predicted DNA variants arising from genome-wide studies
creates new challenges to validate the effect of any given variant on the mRNA
transcript and protein product. Splicing mutations represent a unique set of
variants that can be validated using mRNA sequences. We aimed to develop a
software tool that can conduct genome-wide, statistically robust validation of
predicted splicing mutations using sample-matched RNA sequencing data.
3) Splicing mutations are currently underpresented in large genomic studies, given
that the majority of experiments only assess the canonical nucleotides at an
intron/exon boundary. We aimed to carry out indepth splicing mutation analyses
on a large set of breast cancer tumours using previously published data from the
TCGA. We hoped to identify new underlying processes of tumour biology not
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previously described by protein-coding dominated studies. Further, we planned to
validate these mutations using the software described in objective 2.
4) Current selection of the specific cytotoxic agents to be used for breast cancer
patient care does not consider analyzing the tumour for genes involved in drug
disposition. In addition to the classical pathological features, these genes may be
informative in identifying which tumours are the most likely to respond to certain
therapies. This thesis aimed to use machine learning to develop predictive models
of breast cancer tumour sensitivity to paclitaxel and gemcitabine. Rather than
completing a genome-wide study, we sought to start with a much smaller set of
biologically-relevant genes based on what is known about paclitaxel and
gemcitabine drug mechanisms of action. In addition, a set of FFPE tumour
samples was obtained from patients that were treated with paclitaxel and
gemcitabine, and whose response to these drugs is known. In addition to
previously published data sets, we planned to validate the predictive gene
signatures on these FFPE samples through nucleic acid extraction and analysis. In
turn, we wanted to determine whether high quality data could be obtained from
FFPE samples, and how suitable their use would be in studies involving
chemosensitivity predictions.
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Chapter 2
2

Expanding

probe

repertoire

and

improving

reproducibility in human genomic hybridization
The work presented in this chapter is reproduced (with permission, Appendix S1) from:
Dorman, S.N., Shirley, B.C., Knoll, J.H.M., Rogan, P.K. (2013) Expanding probe
repertoire and improving reproducibility in human genomic hybridization. Nucleic Acids
Research 41(7): e81.

2.1 Introduction
Genome-derived nucleic acid hybridization probes are routinely used diagnostically to
identify, detect or quantify specific DNA sequences. It has long been recognized that
repetitive sequences in these probes can interfere with the detection of chromosome
abnormalities through cross hybridization to multiple regions of the genome. This is
because repetitive sequences comprise at least 50% of the human genome and consist of a
diverse set of distinct families (1) with variable degrees of divergence, many of which are
conserved throughout mammalian evolution (2,3). Elimination of these sequences is a
key consideration in genomic probe and experimental design. These sequences can be
sequestered away from unique sequences in labelled probes (4,5), ‘blocked’ with
unlabelled Cot-1 DNA (6–8), or eliminated from the probe sequence by masking all
elements related to known repetitive sequence families (9). We present an approach to
improve the genomic resolution and reproducibility of fluorescent in situ hybridization
(FISH) and microarray comparative genomic hybridization (aCGH). Inclusion of
evolutionarily highly divergent repetitive elements increases genomic coverage without
compromising the specificity of FISH and aCGH to the extent that conserved repetitive
sequences would. Contextual effects of proximate, conserved repetitive sequences on
probe design are also investigated.
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FISH is an essential diagnostic tool for detection of contextual chromosome
rearrangements. However, the diversity of relevant chromosomal abnormalities seen in
patients with cancer or congenital diseases far exceeds the catalogue of available
recombinant probes. Commercial FISH probes often include multiple genes, which
reduces their specificity for targeting abnormalities confined to individual genes. The
Cancer Genome Project (10) has identified translocations in 317 cancer genes implicated
in oncogenesis, 177 of which are <100 kb. Single copy FISH (scFISH) involves
sequence-based genomic DNA probes that are 100–500-fold smaller than commercial
FISH probes (11), thus providing the higher resolution necessary for specific detection of
contextual changes within small genes. Nevertheless, repeat-masked probes contain
exclusively unique genomic sequences, which limit access in genomic regions densely
populated with repetitive elements for scFISH.
aCGH determines copy number variation genome wide (12–14). It has been widely
adopted in cancer research, disease gene discovery, prenatal diagnostics and has
improved clinical diagnosis for patients with congenital and acquired diseases (15,16).
aCGH has been recommended by the American and Canadian Colleges of Medical
Genetics as a first-line test for individuals with development disabilities or congenital
anomalies (17,18). Despite the ubiquity of this test, the accuracy and reproducibility of
aCGH has recently been questioned (19–21). A study assessing 11 copy number variant
(CNV) microarray platforms reported <50% similarity in CNV calls between software
and analytical tools and <70% reproducibility in most replicate experiments (21).
Multiple sources of data from different commercial platforms, analysed with the same
software, call inconsistent copy number changes (CNC) (20), implicating the primary
data as a significant contributor to this variability.
In FISH and aCGH, non-specific cross-hybridization to other genomic locations is most
commonly prevented by sequestering repetitive sequences with excess unlabelled Cot-1
DNA (7,22). Addition of Cot-1 reduces consistency and increases variability in genomic
hybridization to homologous targets, regardless of whether repetitive elements are
present in the labelled DNA (23). Cot-1 DNA contains sc sequence impurities that
increase variability in hybridizations. Probe sequences have also been designed to be
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devoid of repetitive elements by synthesis of repeat-masked unique or sc intervals (9).
However, the use of Cot-1 DNA in aCGH is unavoidable in order to prevent crosshybridization between non-allelic repetitive regions in the labelled sample.
The proximity of repetitive elements to sc targets and the extent to which these sequences
are conserved have not been considered in microarray probe design. We find that unique
sequence microarray probes in close proximity to adjacent repetitive sequences,
contribute to poor reproducibility of hybridization intensities, and the degree of repeat
sequence divergence can affect the variability of hybridization intensities of these unique
sequence probes. By mitigating these effects, it is possible to improve the genomic
resolution and reproducibility of FISH and aCGH.

2.2 Materials and methods
2.2.1 scFISH probe design
We deduced a complete set of effectively sc regions using an ab initio divide-andconquer search algorithm (24,25) directly from the reference human genome
(GRCh37/hg19) (Appendix S2.1). This algorithm identified sc intervals without reliance
on a catalogue of existing repetitive elements. The search constraints were tuned to
include sequences containing highly divergent repetitive elements. Divergent copies of
repetitive elements deviate sufficiently from conserved consensus sequences so as to
preclude cross-hybridization to non-allelic genomic locations. A genome-wide set of ab
initio sc intervals was derived and displayed as custom genome browser tracks. From
these intervals, 15 scFISH probes >1.5 kb were designed to detect rearrangements within
10 small cancer-related onco- and tumour-suppressor genes (<50 kb; CCND1, CDKN2A,
CDKN2C, ERBB2, FGFR3, FLCN, KRAS, MYCN, NOTCH1, TP53) designated by the
Sanger Institute Cancer Genome Project (10). Regions of at least 2.5 kb for scFISH were
used for primer design for long polymerase chain reaction (PCR) as previously described
(9). Appendix S2.2 indicates the eight probes that were produced, their genomic
coordinates, length and primer sequences.
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Divergent repetitive elements included in each probe were localized by genome-wide
Basic Local Alignment Search Tool (BLAST) and analysed for degree and extent of
divergence from consensus sequences of the same repeat family or subfamily. To
estimate stability of probe sequences, nick translation products of 300 nucleotides (nt)
were simulated by windowing along the length of a probe. Melting temperatures (Tm) for
each imperfect duplex were estimated (26) and then plotted for higher and lower
stringency, post-hybridization experimental wash conditions (2X SSC, 37°C, 50%
formamide; and 2X SSC, 42°C, 50% formamide). With more stringent post-hybridization
washing conditions, the divergent repetitive elements were not expected to crosshybridize to non-allelic genomic loci. Related, non-allelic sequences in the human
genome were detected by BLAST analysis. All imperfect duplexes were estimated to
exhibit predicted Tm at least 10°C lower than the homologous targets.
The performance of eight probes containing divergent repetitive elements was validated
by scFISH to human metaphase cells with a normal karyotype. Primers for a genomewide set of ab initio scFISH probes were designed using Primer 3 (27). Probe length and
maximum Tm differences were optimized to produce the highest quality probes while
maintaining genomic resolution. Primers were designed for intervals between 1.5–2 and
3.5–4 kb, with maximum Tm differences set at 0.5°C, 1°C and 2°C. scFISH probes
produced with maximum Tm differences did not significantly vary; therefore, 0.5°C was
used to ensure the highest quality PCR amplification. Primer3 parameters used to
generate
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2.2.2 scFISH probe development and hybridization
Ab initio sc products were optimized by gradient thermal cycling, then amplified using
long PCR with Platinum Pfx DNA Polymerase (Invitrogen™, CA). Amplicons were gel
purified, extracted (QIAquick kit, Qiagen CA) and labelled by nick translation with
digoxigenin-11-dUTP (Roche Diagnostics, ON, Can). Probes were hybridized on normal
human lymphocyte metaphase chromosomes, detected with Cy3-conjugated anti-digoxin
antibody (Cedarlane, CA), then washed and stained with 4',6-diamidino-2-phenylindole
(DAPI) (28). At least 20 metaphases from cytogenetic preparations of control individuals
were examined for each probe to confirm the chromosome location and hybridization
efficiency. A probe from CDKN2A, which is abnormal in the preponderance of
melanomas, was also hybridized to metaphase chromosomes of the melanoma cell line
A-375 (29).

2.2.3 Genome-wide aCGH
A pool of suitable oligonucleotide probes from ab initio intervals was designed with
PICKY (30), which matches melting temperatures to avoid complementarity between
probes and stable hairpin formation. Default parameters were modified as follows: left
selection boundary 200, right selection boundary 200, maximum oligonucleotide size 60,
maximum match length 20, minimum match length 17 and probes per gene 5. PICKYsuggested 2 057 653 coordinate-defined probes from 513 689 ab initio sc intervals.
A subset of these probe sequences was selected to populate a custom genome-wide
4x44K array. To minimize cross-hybridization of ab initio probes to repetitive sequences
within the labelled genomic sample, oligonucleotides were chosen complimentary to
genomic targets whose distance to an adjacent conserved repetitive element exceeded the
length of the labelled extension products. Products were <300 nt. Oligonucleotide targets
and adjacent repeat elements were separated by at least 300 nt, for repetitive sequences
with <30% divergence (higher divergence sequences were tolerated). For purposes of
comparison, ab initio oligonucleotide targets were paired with Agilent Technologies
Human Catalog CGH 4 × 44K microarray (Agilent 44K) genomic probe sequences in
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closest genomic proximity to ensure similar distributions. Where possible, gene coverage
was maximized. The Galaxy metaserver (https://main.g2.bx.psu.edu) was used to ‘fetch’
the closest non-overlapping feature for every interval, ‘subtract’ intervals present in the
ab initio and Agilent 44K oligonucleotide sets and determine the base ‘coverage’ of all
intervals. We first determined the distance in nt of the closest repeat masked repetitive
element to each probe. Oligonucleotides within 300 nt of a repeat were subtracted from
the set. The closest ab initio probe to a corresponding sequence on the Agilent 44K array
was fetched. The distance between ab initio probes and adjacent repeat elements was then
maximized on the custom designed microarray by selecting oligonucleotides central to
each ab initio interval. Gene coverage, which was determined from the proximity of
probes to known NCBI RefSeq gene sequences, demonstrated that the paired set of ab
initio probes did not cover all known genes (31). Gene coverage in the custom microarray
was improved by adding 1510 probes within or adjacent to the missing genes.
Ab initio normalization and replicate probes were also selected in close proximity of the
corresponding Agilent probes. Both the custom designed ab initio 44K and commercial
Agilent 44K microarrays were manufactured by Agilent. We hybridized them with
genomic DNA from HapMap family trios (YRI: GM19143/GM19144/GM19415, and
CEU: GM07019/GM07056/GM07022). DNA from the offspring (GM19145/GM07019)
was used as the reference sample and co-hybridized with either the maternal
(GM19143/GM07056) or paternal (GM19144/GM07022) sample on two replicate sectors
of each array. To produce extension products <300 nt, DNA was subjected to heat
fragmentation (98°C for 10′) before labelling and sized by electrophoresis. Pairs of
genomic DNA samples (0.5 µg each) were individually enzymatically labelled using 5′terminally labelled, fluorescent random nonamers (either Cy3 or Cy5 from IDT) with
5′→3′-exo- Klenow DNA polymerase (New England Biolabs), then mixed and cohybridized according to the Agilent Oligonucleotide Array-Based CGH for Genomic
DNA Analysis Protocol (v6.2). Microarrays were scanned and quantified with Agilent
Feature Extraction software (v10.5.1.1). Hybridization intensities of Agilent’s non-human
control sequences were used to correct for background fluorescence. The coefficients of
variation [CV = |(Log2 ratio or signal intensity) standard deviation|/mean] were
calculated from replicate spot intensities of each autosomal probe sequence on the same
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microarray platform. Identical probe sequences were replicated within the same and on
different sectors on the array, enabling comparisons of both inter- and intra-array
reproducibility on each platform.

2.2.4 Locus-specific aCGH
Reusable 12K oligonucleotide microarrays were produced using a microarray DNA
synthesizer in our laboratory (CustomArray, Bothell, WA). Duplicate arrays containing
either ab initio sc probes or the published Agilent 44K array probe sequences were
manufactured. These arrays were designed to contain a higher concentration of probes
mapping within chromosome 15q11.2q13 to fully assess CNCs present in patient samples
with chromosome abnormalities in this region. In all, 125 ab initio sc probes and 84
published Agilent 44K probes were replicated multiple times on each respective array.
The remaining array content had genome-wide distribution which maximized gene
coverage and minimized the distance between the pairs of Agilent and ab initio derived
probe sequences.
Genomic DNA from WJK35, an Angelman syndrome (AS) patient cell line with a
previously mapped chromosome 15 deletion (32) was used to assess reproducibility for
calling copy number differences. DNA was labelled with random Cy5 nonamers as
indicated earlier in the text. Each array was hybridized, washed and scanned, then
stripped and re-hybridized with the same labelled DNA product. One of the microarrays
could not be re-hybridized to a labelled DNA after the initial hybridization study because
it failed a quality control test for intra-array reproducibility. For all of the other arrays,
labelled genomic DNA was removed from the microarrays after the initial hybridization
(Stripping Kit, CustomArray) and then re-imaged. Array performance was assessed for
quality control by re-hybridizing a Cy5-labelled, random nonamer, which verifies probe
integrity and consistency of signal intensity before subsequent re-hybridization. Custom
microarrays were imaged with an Axon GenePix 4000 B microarray scanner (Molecular
Devices US). CNV was analysed with Nexus 6.0 (Biodiscovery US) software.
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2.3 Results
2.3.1 Genome-wide coverage of ab initio sc intervals
The density and coverage of unique sequences for hybridization studies in any genomic
region is finite, and in some instances, underrepresented in regions associated with
disease or relevant to gene regulation and expression. For example, more than one-fifth
of RefSeq genes are covered >50% in gene lengths by repetitive elements (31). We
implemented an ab initio algorithm, which does not require a catalogue of repetitive
elements to locate all genomic intervals devoid of multicopy sequences (Appendix S2.1).
The density and lengths of contiguous DNA sequences used for probe design were
increased by tuning sequence alignment stringency to include divergent repetitive
elements with hybridization kinetics similar to sc sequences, at the same time avoiding
segmentally duplicated and self-chained alignments of close paralogues. Before selecting
scFISH and microarray probes, the distribution of ab initio intervals was characterized
among previously annotated genomic features. Overlapping, adjacent intervals were
merged to generate contiguous sequences of maximal length, then compared with the
complement of the collective set of annotated repetitive features with an exclusive
disjunction (OR) operation (1,33–36). The coverage or sensitivity for the ab initio set of
intervals comprised 87% of the complementing sequences. The specificity was 83%,
indicating 17% contained multicopy sequences. However, alignments to human selfchained, paralogous sequence families comprised >90% of these false positive intervals,
necessitating an additional filtering step to eliminate these potential probes.
The ab initio probe intervals were densely distributed along chromosomes, with >50% of
intervals exceeding 1 kb. Less than 0.2% of all ab initio intervals were separated by >32
kb, with the majority (98%) occurring <8 kb apart. Gaps in the reference sequence
assembly accounted for many of the widely separated ab initio regions. Gene coverage
was assessed for ab initio intervals ≥50 nt to define potential targets for probe design of
oligonucleotides for both aCGH and FISH. Genes with ≥50% coverage by ab initio
intervals ranged from 5% of those on the Y chromosome to 84% of those on chromosome
18. On average, <8% of genes were completely missed by the ab initio algorithm (from
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3% on chromosome 3 to 87% on the Y chromosome). Genes ≤20 kb comprised 90% of
the genes without coverage. Ab initio intervals overlapped other genomic annotations (at
genome.ucsc.edu), including 85% of CpG islands, 99% of Vista enhancers, 98% of
transcribed, ultraconserved intergenic sequences and 97% of intragenic sequences. Ab
initio sequence intervals covered the majority of disease-associated genes in the
Catalogue of Somatic Mutations in Cancer (COSMIC) (84%), Gene Reviews (93%) and
Pathogenic International Standards for Cytogenomic Arrays (ISCA) gene (95%)
databases.
We then designed genome-wide sets of ab initio scFISH probes. PCR primer pairs were
selected for 957 304 scFISH probes >1.5 kb from 194 795 unique genomic intervals
(Supplementary Table 2.1, for all Supplementary Tables see the “Additional Files”
electronic document). Of these, 455 978 of the scFISH probes overlap with known genes.
Gene coverage varied from 48 to 58% for scFISH probes designed to be 1.5–2 kb and
3.5–4 kb, respectively. These two subsets of FISH probes together cover 71% of NCBI
RefSeq genes. The median distance between adjacent scFISH probes is 6140 nt, with
89.5% of scFISH probes occurring within 25 kb of each other.
A set of oligonucleotides was designed for production of genome-wide and regionally
targeted aCGH platforms. A total of 2 057 649 oligonucleotide sequences were derived,
756 235 of which were separated by at least 300 nt from the nearest conserved repetitive
sequence (Supplementary Table 2.2). Oligonucleotide hybridization to these target
sequences should reduce variability in signal intensities by minimizing crosshybridization of labelled DNA to repetitive regions in non-target or Cot-1 DNA (23) and
prevent sequestration of labelled sc sequences linked to cross-hybridizing adjacent
repetitive sequences (37). The full oligonucleotide set covers 84.7% of known genes,
whereas the reduced subset of well-separated sc targets covers 81.5%. The reduced subset
of adjacent sc probes is separated from each other by ≤25 kb, with a median distance of
1.094 kb. Exceptionally long inter-probe intervals (>250 kb; n = 176) either occurred in
centromeric regions, were enriched in multicopy sequences (i.e. paralogous self-chained
alignments or segmental duplications), or were unsequenced.
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2.3.2 Ab initio scFISH probes
Cytogenetic rearrangements involving small cancer genes (<50 kb) have been
documented; however, large commercial FISH probes may not provide adequate
specificity to resolve intragenic CNCs or delineate intragenic juxtaposition of sequences.
Ab initio scFISH probe sequences containing divergent repetitive elements were used to
detect small cancer genes (9,11) for CCND1, CDKN2A, ERBB2, NOTCH1 and TP53. All
scFISH probes hybridized to the correct chromosomal locations with high efficiency and
specificity—17q21.1 (ERBB2), 9p21 (CDKN2A), 17p13.1 (TP53), 11q13 (CCND1) and
9q34.3 (NOTCH1). Representative hybridizations are shown in Figure 2.1. Inclusion of
divergent repetitive elements in these probes did not produce any observed crosshybridization with high stringency washing conditions. In addition, we hybridized
CDKN2A Probe 1 to metaphase cells from a melanoma cell line (A-375). An aberrant
hybridization pattern was observed on one chromosome 9p, with its hybridization signal
telomeric relative to the normal chromosomal position (see Figure 2.1D). Inclusion of
highly divergent repetitive elements significantly expands access to portions of the
genome that were previously avoided by repeat masking sc sequences. A total of 95.6%
(915 279) of these FISH probes overlap at least one divergent repetitive element. Ab
initio scFISH probes consisting exclusively of sc sequences now comprise a minority of
(3.7%; 35 658) of the genomic intervals.

2.3.3 Ab initio aCGH
Inclusion of divergent repetitive elements in genomic probes expands the regions
accessible for probe development and the potential genomic resolution of aCGH. We
have previously suggested that probe placement and, in particular, oligonucleotide targets
in close proximity to conserved repetitive sequences may increase the variability in signal
intensities observed in microarray hybridization (23). To test this idea, we selected
oligonucleotide probes located greater than 300 nt away (the target size of the random
primed DNA sample) from a conserved repetitive element. Hybridization results from our
custom array design were directly compared with those obtained from the Agilent 44K

63

Figure 2.1: FISH validated sc probes.

Normal metaphase chromosomes from three cells

hybridized with probes targeting TP53 on chromosome 17p13.1 (A), ERBB2 on 17q21.1 (B) and
CDKN2A Probe1 on 9p21.3 (C) are shown. Hybridized chromosomes of each cell are enlarged
and presented to the left of their respective metaphases. In panel (D), chromosome 9s from three
different cells from melanoma A-375 cell line, hybridized to CDKN2A Probe 1, are presented. A
complete metaphase is shown on the left and an ideogram of chromosome 9 on the right. One
chromosome 9 in each cell shows hybridization as expected at 9p21.3 (white arrows), whereas
the other homologue shows hybridization at the end of the chromosome (9p24.3-pter, red arrow).
The aberrant location of the hybridization is likely due to a paracentric inversion between 9p21.3
and 9p24.3. Chromosomes are counterstained with DAPI. Note: The aberrant hybridization
pattern is consistently seen on the chromosome 9 with the pale staining heterochromatin
polymorphism in the q arm.
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platform using the same labeled HapMap trio samples (i.e. healthy individuals).
Reproducibilities of the ab initio and Agilent microarrays were compared from the CV of
hybridization intensities of replicate oligonucleotide probes. The custom oligonucleotide
array of genomic targets with this content exhibited lower variability in hybridization
kinetics and increased consistency of signal intensities in aCGH. The median CVs of all
probes in both replicates were lower in the ab initio custom array for both log2 ratio
(17.8%) and proband (green) signal intensities (24.1%; Table 2.1; Mann–Whitney rank
sum test; P < 0.001). Red signal intensities were excluded because they represented two
different individuals (two sectors of each mother/father), which was insufficient to
reliably compute CVs. The subset of probes contributing to higher variability in signal
intensities in the Agilent platform exhibited lower reproducibility as a function of
genomic location. CVs of different subsets of Agilent probes (all probes, probes within
300 nt of a repeat, and probes greater than 300 nt of the closest repeat) were compared
with CVs for the closest ab initio probes. The mean CVs of the intensity log2 ratios of the
ab initio probes were on average 48.3% below that of the corresponding Agilent genomic
targets, when the corresponding Agilent probe was located within 300 nt of a conserved
repetitive element (paired Student’s t-test; P < 0.05; Table 2.2). The mean CVs after
background correction for all probes, regardless of genomic context were 34% lower for
one HapMap family (P < 0.001); however, the difference was not significant for the other
family. For paired sets of ab initio and Agilent probes, CVs were not significantly
different for Agilent probes separated from adjacent repetitive sequences by >300 nt. In
probe pairs where the Agilent oligonucleotide was within 300 nt of a repeat, the CVs of
the ab initio proband signal were lower in all instances, consistent with our previous
analyses (23). We interpret these findings as follows: probes within 300 nt of a repetitive
element have the potential to hybridize to a random-primed DNA extension product that
contains both a sc target sequence as well as adjacent repetitive elements. Conserved
repetitive elements present in hybridized DNA sample are susceptible to crosshybridization with repeats in non-target labelled and Cot-1 DNA. Figure 2.2A illustrates
an example of this for a pair of probe sequences in TP53. Labelled random-primed (or
nick translated) extension products containing a Tigger5 conserved repeat element
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Table 2.1: Comparison of CV of replicate probes by platform: Mann–Whitney rank sum
test
CVs tested
Platforma
YRI DNA Samples
Median CV
Interquartile range
P-value
CEU DNA samples
Median CV
Interquartile range
P-value

Log2 Ratio

Proband

AG

AI

AG

AI

49.37
85.62

37.34
66.51

4.25
3.18

2.26
1.65

<0.001
88.69
155.89

<0.001
78.70
140.67

<0.001

3.51
2.97

3.46
2.72
<0.001

Median CVs of the log2 ratio and proband signal intensities (‘Proband’) were compared for both
HapMap family DNA samples (YRI/CEU). Bolded values indicate CVs that were significantly
lower in the ab initio platform compared with the corresponding Agilent data. Interquartile range
demonstrates the larger range of CVs in the Agilent platform.
a

AG = Agilent; number of probes = 42 492; AI = Ab initio; number of probes = 41 898; YRI =

Yoruban HapMap trio; CEU = Caucasian HapMap trio.
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Table 2.2: Comparison of CV of replicate probes by platform: Paired t-tests
CVs tested
Platforma
YRI DNA Samples
All probes
AG probes <300 nt
AG probes >300 nt
CEU DNA samples
All probes
AG probes <300 nt
AG probes >300 nt

Log2 Ratio
AG

AI

P-value*

328
366
260

216
218
213

0.0019
0.0046
0.0855

869
1025
594

901
449
1695

0.4655
0.0348
0.0975

Paired t-tests were performed for log2 ratio CVs for all probe pairs, probe pairs where the Agilent
oligonucleotide was within 300 nt of a repetitive element (AG probes <300 nt), and for probe pairs
where the Agilent oligonucleotide probe was at least 300 nt from an adjacent repetitive element
(AG probes >300 nt).
a

AG = Agilent; number of probes = 42 492; AI = Ab Initio; number of probes = 41 898; YRI =

Yoruban HapMap trio; CEU = Caucasian HapMap trio.
*Bolded values indicate P < 0.05.
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Figure 2.2: The effect of genomic context on hybridization signal intensity variability. (A)
This panel demonstrates how the subtle differences in genomic location of ab initio and Agilent
probes (dark grey; light grey vertical bars show target on extension products) may explain the
higher CV in the Agilent platform. Simulated 5′ labelled, random-primed DNA extension products
(of 300 nt) are windowed along the TP53 gene with the locations of a pair of Agilent and ab initio
sc oligonucleotide probes. Increasing the distance between microarray probe sequences (in grey)
and repetitive elements (in red) reduces the likelihood of hybridization to a labelled DNA product
containing both the unique target (in black) and repetitive sequence. Extension products
containing an adjacent Tigger5 repetitive element would be expected to hybridize to the Agilent
probe located 179 nt away, but not to the ab initio sc probe situated 462 nt from the repeat, even
though both are sc (black) probes. The average CV of this Agilent probe was 146, compared with
the ab initio probe, which had a CV of 32. (B) Accurate hybridization signal intensity is achieved
with sc target labelled DNA (black), exclusively hybridizing to probe sequence. Panels C and E
depict how the presence of repetitive sequences in labelled target DNA can lead to higher than
expected signal intensities. (C) Signals can be amplified by repeats (red) in close proximity to sc
sequences (black), leading to non-allelic cross-hybridizations between repetitive elements
adjacent to the labelled target DNA and other regions of the genome. (D) Unlabelled C ot-1 DNA is
known to be contaminated with sc sequences (blue), which can serve as microarray probe
targets. These contaminants in Cot-1 can suppress hybridization to desired target sequences by
blocking the target labelled DNA from hybridizing to the probe sequences, reducing the overall
fluorescent signal. (E) The major repetitive fraction in C ot-1 DNA will hybridize to labelled,
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random-primed DNA containing repetitive sequence (e.g. Tigger5 in this instance). This can result
in an undesirable increase in signal intensity through bridging hybridization of labelled DNA target
to other non-allelic repetitive sequences. This can be mediated by cross-hybridization to repetitive
sequences in Cot-1 DNA, which is usually added in stochiometric excess of the labelled sequence
in microarray studies.
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(11.5% divergent from the TcMar-Tigger consensus) cross-hybridized to the published
Agilent probe sequence 179 nt away (CV = 146), but did not hybridize to the ab initio
probe situated 462 nt from this repeat element (CV = 32). Calibration of the lengths of
the labelled genomic DNA used in aCGH has been demonstrated to significantly improve
microarray performance (38). Indeed, the observed CVs of these specific probes confirm
the expected results.

2.3.4 Probe parameters affecting CVs
As the increased variability in microarray signal intensities can be attributed to proximate
repetitive elements, we performed analysis of variance (ANOVA) and principal
component analyses (PCA) to examine the characteristics of the oligonucleotide
sequences that contribute to this source of noise. Genomic features (GC content, probe
length, distance of nearest neighbouring repeat element and divergence) were determined
for each set of paired probes and assessed by ANOVA for association with signal
intensities and CVs. Repeat distance was associated with the log2 ratio CVs in both
Agilent arrays (P < 0.05 and P < 0.001). In the second Agilent hybridization, repeat
divergence (P < 0.05) was also associated with CVs. However, the CVs of log2 ratios
were associated with neither repeat distance nor repeat divergence in either ab initio array
(P > 0.05). PCA of data from both microarray platforms were consistent among replicate
hybridizations for each platform; however, differences between Agilent and ab initio
arrays were evident for two PCA eigenvectors (Table 2.3). The third component of the ab
initio data was comprised of CV alone, with no significant interaction with the other
factors, as expected from ANOVA. Differences in the Agilent data show that both the
distance between probe and adjacent repetitive sequences, specifically within 300 nt, and
the degree to which the repeat sequence is conserved, are not independent of the CVs of
the probe signal intensities.
We then analysed the CVs of signal intensities from both the Agilent and Affymetrix
(Santa Clara, US) microarrays for the same HapMap samples analysed previously. The
CVs of four data sets (two Agilent, two Affymetrix) were compared within the same
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Table 2.3: Principal components analysis of genomic and probe parameters with CV in
HapMap pedigrees

Platform characteristics
Eigenvectors
AB INITIO
CV intensity
GC content
Probe length
Repeat distance
Repeat divergence
% Variance explained
AGILENT
CV intensity
GC content
Probe length
Repeat distance
Repeat divergence
% Variance explained

1

YRI trio
2

3

1

CEU trio
2

3

−0.0087

0.0734

0.9970

0.0038

−0.0723

0.9959

0.4895

−0.4466

0.0201

0.4894

−0.4441

−0.0742

−0.2562

0.6979

−0.0689

−0.2562

0.7002

0.0195

0.6546

0.2000

−0.0061

0.6547

0.1987

0.0268

−0.5159

−0.5178

0.0288

−0.5159

−0.5174

−0.0388

26.9705

21.6464

19.9922

26.9700

21.6461

20.0012

−0.0397

−0.5311

0.8035

0.0065

0.5145

0.8554

−0.6950

0.0436

0.0250

−0.6957

0.0444

−0.0118

0.6976

−0.0016

−0.0149

0.6979

−0.0088

−0.0066

−0.1643

−0.2629

−0.4577

−0.1647

−0.3947

0.1772

−0.0409

0.8043

0.3796

−0.0412

0.7599

−0.4865

36.8101

20.1829

19.9547

36.7845

20.1786

19.9373

Principal component analysis was carried out to assess the relationship between probe CVs, GC
content, probe length, distance of the closest repeat and its divergence from the consensus
family sequence. In the ab initio probe set, the CV eigenvalues showed little or no interaction with
other probe properties (compare eigenvectors 1 or 2 versus 3). In contrast, the corresponding
eigenvalues were related to distance from and divergence of adjacent repetitive sequences in
data from the Agilent platform. Bolded numbers indicate the parameter has a positive or negative
effect of at least 15% overall.
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hybridization. This eliminated the possibility that the observed results were derived from
subtle differences in experimental conditions or labelling of genomic DNA. Probe CVs
were calculated for the Agilent 44K array and the publically available Affymetrix
Genome-Wide

Human

SNP

Array

6.0

Sample

Data

Set

(http://www.affymetrix.com/support/technical/sample_data/genomewide_snp6_data.affx)
. The median CVs were compared using a Mann–Whitney Ranked Sum Test. Probes
were categorized based on the repeat proximity (either within or beyond 300 nt) and level
of divergence (±20% relative to the consensus repeat) of the repetitive element adjacent
to a probe (Table 2.4). For both commercial data sources, probes within 300 nt of a
repetitive element exhibit significantly higher CVs (P < 0.001), though the Affymetrix
probes had lower CVs overall than those on the Agilent array. In the Affymetrix data, the
level of repeat divergence contributes to probe signal intensity variability to a greater
extent than the probe proximity to adjacent repetitive elements. In particular, the
combination of low divergence and close proximity produces the highest probe CVs in
both commercial microarray platforms. As expected, repeat divergence did not contribute
to probe signal intensity CVs for probes at least 300 nt away from adjacent repetitive
elements.

2.3.5 Targeted chromosome 15q11.2q13 aCGH detects AS deletion
Lower variability in signal intensities is desirable in aCGH to achieve more consistent
calling of CNCs and accurate determination of copy number using fewer probes. To
assess the reliability of ab initio probes in CNC detection, we performed aCGH on a
sample with a documented chromosome deletion using custom-synthesized, targeted
microarrays. A set of 12K oligonucleotide microarrays were produced with probes
concentrated in the chromosome 15q11.2q13 region and genome-wide representation at
other chromosomal locations. The arrays were simultaneously hybridized to randomprimed DNA from a lymphoblastoid cell line derived from a patient with AS carrying a
defined deletion of 5.01 Mb (32).
The same labelled sample was used in eight hybridizations: four containing identical
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Table 2.4: Analysis of variation of CVs in Agilent and Affymetrix aCGH probe subsets

Repeat
Repeat
No.
distance
divergence probes
A. Affymetrix-GM07019
<300
>300
All
<300
>300
<300
>300

<20
>20
<20
>20
All
<20
>20
<20
>20

576 831
276 461
840 370
880 374
1 180 744
540 000
576 831
603 913
263 539
276 461

a

Median

P-value

0.0246
0.0235
0.0244
0.0237
0.0242
0.0238
0.0246
0.0238
0.024
0.0235

<0.001

<300
>300
<300
>300

<20
>20
<20
>20
All
<20
>20
<20
>20

<300
>300
All

<0.001
<0.001
<0.001

<300
>300
<300

<0.001

>300

C. Agilent-GM07019
<300
>300
All

Repeat
Repeat
No.
distance
divergence probes
B. Affymetrix-GM19145
<20
>20
<20
>20
All
<20
>20
<20
>20

Median

P-valuea

576 363
276 705
840 369
880 375
1 180 033
540 711
576 363
603 670
264 006
276 705

0.0236
0.0223
0.0235
0.0224
0.023
0.0227
0.0236
0.0224
0.0232
0.0223

<0.001

14 052
6 940
21 866
18 644
25 756
14 754
14 052
11 704
7 814
6 940

0.503
0.433
0.484
0.449
0.482
0.443
0.503
0.457
0.452
0.433

<0.001

<0.001
<0.001
<0.001
<0.001

D. Agilent-GM19145
14 052
6 940
21 866
18 644
25 756
14 754
14 052
11 704
7 814
6 940

0.921
0.861
0.897
0.875
0.901
0.862
0.921
0.884
0.863
0.861

<0.001

<300
>300
All

0.011
<0.001
0.007

<300
>300
<300

0.555

>300

<20
>20
<20
>20
All
<20
>20
<20
>20

<0.001
<0.001
<0.001
0.301

Comparison of probe CVs of Agilent and Affymetrix platforms based on proximity to and divergence level of neighbouring repetitive elements.
Probe CVs were calculated for Affymetrix (panels A and B) and Agilent (panels C and D) data from hybridizations with the HapMap proband
samples (panels A and C: GM07019, panels B and D: GM19145) used in this study. Median CVs of different groups of probes within each platform
were compared using the Mann–Whitney rank sum test. Probe subsets were selected based on the distance to the closest repetitive element in nt
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(either less or greater than 300 nt) and the divergence of the repetitive element from a consensus family sequence (less than or greater than
a

20%). Mann–Whitney rank sum test.
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probe content from the ab initio custom array and four containing published probe
sequences from the Agilent 44K array. One of the arrays containing the Agilent probe
design failed quality control owing to uneven oligonucleotide synthesis and was excluded
from further analyses. The ab initio platform contained 125 probes and the Agilent
platform contained 84 within the common AS deletion-breakpoint interval. Each probe
was replicated on the array three times. The ab initio probes were distributed on average
52.54 kb apart throughout the CNC region, with a median distance between
oligonucleotides of 18.01 kb. The Agilent probes were slightly more dispersed, with an
average distance between oligonucleotides of 77.83 kb and a median distance of 52.11
kb. CNC detection was done by Rank Segmentation (39,40) and required at least five
probes in a segment to assign a CNC.
Results from five of seven genomic microarrays called the AS deletion accurately: all
four replicates of the ab initio probe set and one replicate containing Agilent probe
sequences. Figure 2.3 indicates representative examples of primary signal intensities for
the oligonucleotide probes spanning the deletion interval and flanking sequences for the
ab initio and Agilent-based microarrays. The primary signal intensities of the ab initio
probes displayed lower overall variability in the distributions of intensities in this
genomic region. Ab initio probes within the deletion interval were then matched, based
solely on genomic proximity, to the 76 Agilent probe sequences (excluding the
breakpoint regions). Considering the matched probes alone, all four data sets from the ab
initio platform were able to call the CNC, which was detectable on only a single array
with Agilent probe content.
We tested the limits of sensitivity of the ab initio and Agilent microarrays to call CNCs
by reducing the probe densities in this region by selecting one of two alternating probes
(n = 37). All four replicates of the ab initio array still detected the AS deletion.
Interestingly, one of the Agilent replicate arrays called the deletion, but it was a different
microarray from the one indicated in the previous analysis that involved twice as many
probes. The resolution and consistency of both array platforms of calling deletions was
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Figure 2.3: Primary hybridization signal intensity data from ab initio and Agilent probe
sequences covering Angelman syndrome (AS) chromosome deletion region (chromosome
15q11.2q13.1). Primary signal intensity data are displayed from Nexus Biodiscovery software for
one replicate each of the (A) ab initio and (B) Agilent probe sequences. Red and blue bars
indicate copy number loss or gain, respectively. Details on the CNCs displayed were outputted as
follows: (A) Deletion genome coordinate range called the following: 21 937 154–30 319 444,
length: 8 362 290 nt, probe count: 123, probe signal intensity mean: 53.84, probe signal intensity
median: −13.00. (B) Miscalled duplication coordinate range: 22 866 888–30 322 138, length: 7
455 250 nt, probe count: 73, probe signal intensity mean: 140.16, probe signal intensity median:
13.7. This figure demonstrates the greater variation in Agilent probe sequence signal intensities
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compared with those from the ab initio array. The average standard deviation of the probe signal
intensities between replicates in the ab initio CNC region (chr15: 21 937 154–30 319 444) is
138.08, whereas it is 238.04 (72% higher) for the Agilent probe sequences in the CNC region
(chr15: 22 866 888–30 322 138).
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unreliable when only 12 probes were scored (every third probe from the set of 37). A
defined region within the deletion (ab initio—chr15:22 815 291–24 061 148 (hg19);
Agilent—chr15:22 784 523–23 930 870) that spans the Angelman breakpoint 2 (BP2)
(32) was called as a gain in one ab initio data set and all three Agilent data sets. By
contrast, the region of the deletion distal to BP2 (ab initio—chr15:25 207 252–30 319
444; Agilent—chr15:25 143 144–30 322 138) is inferred as a copy number loss in all
seven data sets. The mean CVs of all probes within BP2 that inconsistently called CNCs
in both platforms were 34.87% (ab initio) and 17.75% (Agilent) higher than the other
probes in the deletion interval. This is likely due to higher noise in the observed signal
intensities. This may be related to interference of segmental duplicons in the
hybridization, which are known to distort aCGH results (32). Segmental duplicons span
47% (ab initio) and 53% (Agilent) of the BP2 region. This is considerably higher
compared with the genomic interval that was consistently called as a deletion and
contains a smaller proportion of segmentally duplicated sequences (14%).

2.4 Discussion
Sequences of synthetic DNA probes used in genomic hybridization have been
traditionally derived from unique sequences, or include repetitive elements that are
sequestered during hybridization (4–9). The contextual effects of the genomic proximity
of these sequences to repetitive elements have generally not been accounted for in
assessing probe performance. Judicious selection of probes distant from adjacent
conserved repetitive sequences can improve reproducibility of human genomic
hybridization. Furthermore, probes incorporating divergent repetitive sequences do not
adversely affect sc probe specificity. Under more stringent hybridization conditions,
cross-hybridization catalysed by repetitive sequences is preventable. The inclusion of
divergent repetitive elements expands genome-wide probe coverage, the outcome of
which are increased lengths of scFISH probes in those regions and higher resolution in
delineating novel genomic rearrangements by hybridization-based methods (such as
genomic microarrays, multiplex ligation-dependent probe amplification (MLPA), PCR
and others).
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There are other established methods for producing short FISH probes. Software has been
used to design smaller (10–100 kb) FISH probes (41), similar to our own scFISH
products (9,11). Pools of labelled oligonucleotides have been used to visualize regions as
small as 6.7 kb (42); however, the efficiency of detection with these pools is currently
insufficient to be recommended for clinical use. Furthermore, both of these methods still
require repeat-free regions for probe design. The ab initio scFISH probes presented here
can reliably target small genes that are known to be commonly rearranged in cancer. By
contrast, conventional, recombinant FISH probes extend well beyond the boundaries of
these genes and often include neighbouring genes. Repeat-masked probes that lack
divergent repetitive elements (9) within these genes are often too short to perform
scFISH.
The coverage and level of specificity achieved by ab initio scFISH can confirm
intragenic rearrangements or define small chromosomal aberrations detected by aCGH.
Abnormalities that can be detected by these probes include small deletions (genes or
exons), gene amplification, translocations and inversions involving the probe’s genomic
location. For example, CCND1 at 11q13.3 is only 13.37 kb. A common translocation
t(11;14)(q13,q32), which over-expresses this gene has been found in 20% of multiple
myeloma cases (43,44) and 94% of mantle cell lymphoma patients (45). We have created
two probes (<4 kb) targeting exons 3 (probe 1) and 5 (probe 2) of CCND1. In patients
carrying this translocation, these probes will hybridize to the derivative chromosome 14.
Commercial and cloned probes in this genomic region are considerably longer and would
not detect rearrangements confined to this gene.
Despite the widespread application of aCGH for genome-wide copy number
determination (46,47), the inter- and intra-platform reproducibility of both expression and
copy number microarray data may be less than satisfactory (19–21,23,37,48–51). These
previous studies have generally assumed that discrepancies resulted from stochastic noise
in signal intensity measurements and have been attributed to algorithms used to call CNC
analyses. Higher CVs of signal intensities have also been linked to probe length and
composition, cross-, self- and perfect match hybridization free energies, melting
temperatures, position within a target sequence, sequence complexity, potential
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secondary structure and sequence information content (52). Nonetheless, these
parameters have been described as insufficient for optimizing probe performance (53).
Our results suggest that the variability in aCGH studies does not originate solely from
stochastic effects, but rather a systematic error introduced during probe design. We
demonstrated that the genomic location of the probe relative to neighbouring conserved
repetitive elements and the level of sequence divergence of the nearest repeat can account
for 40% of the variance observed in the Agilent genomic microarray data. We were
however not able to explain all of the variance in the signal intensity data. It has been
recognized that self–self hybridization in solution may be responsible for variability by
sequestering some of the labelled hybridizable sequences (37). We propose that
formation of these duplexes is frequently catalysed by repeats in labelled DNA
containing the sc target sequence. Repetitive sequences throughout the genome are of
sufficiently high concentration for such events to be commonplace during hybridization.
Other factors such as variation in the quantity of probe on the array and hybridization
kinetics, could also account for the unexplained variance.
When expanding the oligonucleotide set with additional probes, it is important to
consider the probe characteristics that are the most crucial to minimizing CVs. Probes
within 300 nt of adjacent repetitive elements with <20% divergence from eponymic
repeat family members have the poorest performance, with CVs on average 8.41% higher
than those with greater separation from these elements. The variation of signal intensities
is likely due to cross-hybridization to repetitive sequences present in the labelled target
DNA as well as Cot-1 DNA contaminated with the sc sequences detected by the probe
(Figure 2.2). Figure 2.2B illustrates the expected hybridization pattern, when labelled sc
target DNA hybridizes to the probe resulting in an accurate signal intensity. Figure 2.2C
demonstrates the cross-hybridization that can occur when the microarray probe is located
within 300 nt of a conserved repeat element (e.g. Agilent probe in panel 2A), resulting in
an unexpected, higher signal intensity. In Figure 2.2D, reduced signal intensity can result
from cross-hybridization of unlabelled sc sequences present in Cot-1 DNA, which could
block the labelled target sequences from hybridizing to the array. The signal can also be
amplified when labelled DNA is bridged through non-allelic elements in unlabelled Cot-1
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DNA (Figure 2.2E). Increasing the genomic distance between sc target sequences used as
probes on the microarray and conserved repetitive elements in the genome diminishes the
likelihood of cross-hybridization to labelled target DNA products containing non-allelic
repetitive sequences. We demonstrated that signal intensity CVs can be reduced by
avoiding probe placement within 300 nt of a repeat element.
The reliability of calling CNCs is improved with probes that exhibit lower variation in
primary signal intensities. Such probe sequences are of sufficient density in the genome
that the same rearrangements analysed with commercial microarrays can be detected with
greater reliability. The Agilent 44K array did not have sufficient probe density or low
enough CVs to reliably detect a common chromosome 15q11.2q13 deletion, whereas a
CNC based on 36 ab initio-designed probes was consistently called. Lowering CVs in
microarray hybridization studies actually decreases the number of probes required for
accurate CNC detection without significant loss in genomic resolution while still
detecting small chromosome rearrangements. An implication of reliable detection of
chromosome rearrangements with fewer probes is that it would facilitate increased
multiplexing, with additional sectors on the same microarray allowing analysis of larger
numbers of patient samples per array.
To overcome limitations in sensitivity, manufacturers have increased probe densities to
perform copy number analysis by averaging CNC calling using the results of multiple
probes. These probe densities partially compensate for loss of dynamic range that results
from normalization (which statistically reduces noise). We have taken a different
approach by populating the array with probes that have inherently lower susceptibility to
noise. Future studies will determine the minimum number of ab initio probes required to
call well-characterized CNCs for various clinically relevant genomic imbalances.
Optimizing CNV calling algorithms will nevertheless continue to be a crucial factor in
aCGH microarray experiments. Reliable detection of genomic abnormalities is crucial in
diagnostic microarray studies, especially in situations where each patient sample is
analysed with a single hybridization array.
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Chapter 3
3

Validation of predicted mRNA splicing mutations using
high-throughput transcriptome data

The work presented in this chapter is reproduced (with permission, Appendix S1) from:
Viner, C., Dorman, S.N., Shirley, B.C., and Rogan, P.K. (2014) Validation of predicted
mRNA splicing mutations using high-throughput transcriptome data. [v2; ref status:
Indexed, http://f1000r.es/378] F1000Research 3:8. DOI:10.12688/f1000research.3-8.v2

3.1 Introduction
DNA variant analysis of complete genome or exome data has typically relied on filtering
of alleles according to population frequency and alterations in coding of amino acids.
Numerous variants of unknown significance (VUS) in both coding and non-coding gene
regions cannot be categorized with these approaches. To address these limitations, in
silico methods that predict biological impact of individual sequence variants on protein
coding and gene expression have been developed, which exhibit varying degrees of
sensitivity and specificity (1). These approaches have generally not been capable of
objective, efficient variant analysis on a genome-scale.
Splicing variants, in particular, are known to be a significant cause of human disease (25) and indeed have even been hypothesized to be the most frequent cause of hereditary
disease (6). Computational identification of mRNA splicing mutations within DNA
sequencing (DNA-Seq) data has been implemented to varying degrees of sensitivity, with
most software only evaluating conservation solely at the intronic dinucleotides adjacent
to the junction (i.e. (7)). Other approaches are capable of detecting significant mutations
at other positions with constitutive, and in certain instances, cryptic, splice sites (5,8,9)
which can result in aberrations in mRNA splicing. Presently, only information theorybased mRNA splicing mutation analysis has been implemented on a genome scale (10).
Splicing mutations can abrogate recognition of natural, constitutive splice sites
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(inactivating mutation), weaken their binding affinity (leaky mutation), or alter splicing
regulatory protein binding sites that participate in exon definition. The abnormal
molecular phenotypes of these mutations comprise: (a) complete exon skipping, (b)
reduced efficiency of splicing, (c) failure to remove introns (also termed intron retention
or intron inclusion), or (d) cryptic splice site activation, which may define abnormal exon
boundaries in transcripts using non-constitutive, proximate sequences, extending or
truncating the exon. Some mutations may result in combinations of these molecular
phenotypes. Nevertheless, novel or strengthened cryptic sites can be activated
independently of any direct effect on the corresponding natural splice site. The
prevalence of these splicing events has been determined by ourselves and others (5,1113). The diversity of possible molecular phenotypes makes such aberrant splicing
challenging to corroborate at the scale required for complete genome (or exome)
analyses. This has motivated the development of statistically robust algorithms and
software to comprehensively validate the predicted outcomes of splicing mutation
analysis.
Putative splicing variants require empirical confirmation based on expression studies
from appropriate tissues carrying the mutation, compared with control samples lacking
the mutation. In mutations identified from complete genome or exome sequences,
corresponding transcriptome analysis based on RNA sequencing (RNA-Seq) is
performed to corroborate variants predicted to alter splicing. Manually inspecting a large
set of splicing variants of interest with reference to the experimental samples’ RNA-Seq
data in a program like the Integrative Genomics Viewer (IGV) (14), or simply performing
database searches to find existing evidence would be time-consuming for large-scale
analyses. Checking control samples would be required to ensure that the variant is not a
result of alternative splicing, but is actually causally linked to the variant of interest.
Manual inspection of the number of control samples required for statistical power to
verify that each displays normal splicing would be laborious and does not easily lend
itself to statistical analyses. This may lead to either missing contradictory evidence or to
discarding a variant due to the perceived observation of statistically insignificant altered
splicing within control samples. In addition, a list of putative splicing variants returned
by variant prediction software can often be extremely large. The validation of such a
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significant quantity of variants may not be feasible, for example, in certain types of
cancer, in instances where the genomic mutational load is high and only manual
annotation is performed. We have therefore developed Veridical, a software program that
automatically searches all given experimental and control RNA-Seq data to validate
DNA-derived splicing variants. When adequate expression data are available at the locus
carrying the mutation, this approach reveals a comprehensive set of genes exhibiting
mRNA splicing defects in complete genomes and exomes. Veridical and its associated
software programs are available at: https://mutationforecaster.com.

3.2 Methods
The program Veridical was developed to allow high-throughput validation of predicted
splicing mutations using RNA sequencing data. Veridical requires at least three files to
operate: a DNA variant file containing putative mRNA splicing mutations, a file listing of
corresponding transcriptome (RNA-Seq) BAM files, and a file annotating exome
structure (Appendix S3.1-S3.3). A separate file listing RNA-Seq BAM files for control
samples (i.e. normal tissue) can also be provided. Here, we demonstrate the capabilities
of the software for mutations predicted in a set of breast tumours. Veridical compares
RNA-Seq data from the same tumours with RNA-Seq data from control samples lacking
the predicted mutation. However, in principle, potential splicing mutations for any
disease state with available RNA-Seq data can be investigated. In each tumour, every
variant is analyzed by checking the informative sequencing reads from the corresponding
RNA-Seq experiment for non-constitutive splice isoforms, and comparing these results
with the same type of data from all other tumour and normal samples that do not carry the
variant in their exomes.
Veridical concomitantly evaluates control samples, providing for an unbiased assessment
of splicing variants of potentially diverse phenotypic consequences. Note that control
samples include all non-variant containing files (i.e. RNA-Seq files for those tumours
without the variant of interest), as well any normal samples provided. Increasing the
number of the set of control samples, while computationally more expensive, increases
the statistical robustness of the results obtained.
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For each variant, Veridical directly analyzes sequence reads aligned to the exons and
introns that are predicted to be affected by the genomic variant. We elected to avoid
indirect measures of exon skipping, such as loss of heterozygosity in the transcript,
because of the possibility of confusion with other molecular etiologies (i.e. deletion or
gene conversion), unrelated to the splicing mutations. The nearest natural site is found
using the exome annotation file provided, based upon the directionality of the variant, as
defined within Table 3.1. The genomic coordinates of the neighboring exon boundaries
are then found and the program proceeds, iterating over all known transcript variants for
the given gene. A diagram of this procedure is provided in Figure 3.1. The variant
location, C, is specifically referring to the variant itself. JC refers to the variant-induced
location of the predicted mRNA splice site, which is often proximate to, but distinct from
the coordinate of the actual genomic mutation itself.
The program uses the BamTools API (15) to iterate over all of the reads within a given
genomic region across experimental and control samples. Individual reads are then
assessed for their corroborating value towards the analysis of the variant being processed,
as outlined in the flowchart in Figure 3.2. Validating reads are based on whether they
alter either the location of the splice junction (i.e. junction-spanning) or the abundance of
the transcript, particularly in intronic regions (i.e. read-abundance). Junction-spanning
reads contain DNA sequences from two adjacent exons or are reads that extend into the
intron (Equation 1(e)). These reads directly show whether the intronic sequence is
removed or retained by the spliceosome, respectively. Read-abundance validated reads
are based upon sequences predicted to be found in the mutated transcript in comparison
with sequences that are expected to be excised from the mature transcript in the absence
of a mutation (Equation 1(f)). Both types of reads can be used to validate cryptic splicing,
exon skipping, or intron inclusion. A read is said to corroborate cryptic splicing if and
only if the variant under consideration is expected to activate cryptic splicing. Junctionspanning, cryptic splicing reads are those in which a read is exactly split from the cryptic
splice site to the adjacent exon junction (Equation 1(a)). For read-abundance cryptic
splicing, we define the concept of a read fraction, which is the ratio of the number of
reads corroborating the cryptically spliced isoform and the number of reads that do not
support the use of the cryptic splice site (i.e. non-cryptic corroborating) in the same
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Table 3.1 Definitions used within Veridical to determine in which reads are checked. A
and B represent natural site positions, defined in Figure 3.1(B).
α

– 5’ splice site

β

– 3’ splice site

Pertinent Splice Site
A

B

Strand

Direction

Exonic

Donorα

+



Exonic

Donorα

-



Intronic

Acceptorβ

+



Intronic

Acceptorβ

-
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A)

B)

Figure 3.1 Diagram portraying the definitions used within Veridical to specify genic variant
position and read coordinates. We employ the same conventions as IGV (14). Blue lines
denote genes, wherein thick lines represent exons and thin lines represent introns. A) All reads
overlapping or between D or E are extracted from the BAM files. We assume, for clarity of
illustration, that the genome coordinate D < E. The variant, C, is contained somewhere within the
middle exon or within one of its adjacent introns. B) Veridical searches for validating reads
between A and B, the orientation of which is direction dependent. As indicated, the variant, C, is
contained somewhere within the middle exon or within one of its adjacent introns. Depending
upon the location of the variant, and the directionality (as described within Table 3.1), the interval
boundaries may be delimited by either the blue or red set of labels.
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Figure 3.2 The algorithm employed by Veridical to validate variants.

Refer to Table 3.1 for

definitions concerning direction and Figure 3.1 for variable depictions. B is defined as follows: B
(B site left (←) of A ⇒ B := D. B site right (→) of A ⇒ B := E.
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genomic region of a sample. Cryptic corroborating reads are those which occur within the
expected region where cryptic splicing occurs (i.e. spliced-in regions). This region is
bounded by the variant splice site location and the adjacent (direction dependent) splice
junction (Equation 1(a)). Non-cryptic corroborating reads, which we also termed “anticryptic” reads, are those that do not lie within this region, but would still be retained
within the portion that would be excised, had cryptic splicing occurred (Equation 1(b)).
To identify instances of exon skipping, Veridical only employs junction-spanning reads.
A read is considered to corroborate exon skipping if the connecting read segments are
split such that it connects two exon boundaries, skipping an exon in between (Equation
1(c)). A read is considered to corroborate intron inclusion when the read is continuous
and either overlaps with the intron-exon boundary (and is then said to be junctionspanning) or if the read is within an intron (and is then said to be based upon readabundance). We only consider an intron inclusion read to be junction spanning if it spans
the relevant splice junction, A. Equation 1(d) formalizes this concept. We occasionally
use the term “total intron inclusion” to denote that any such count of intron inclusion
reads includes both those containing and not containing the mutation itself. Graphical
examples of some of these validation events, with a defined variant location, are provided
in Figure 3.3.
We proceed to formalize the above descriptions as follows. A given read is denoted by r,
with start and end coordinates (rs, re), if the read is continuous, or otherwise, with start
and end coordinate pairs, (rs1, re1) and (rs2, re2) as diagrammed within Figure 3.3. Let ℓ be
the length of the read. The set ζ denotes the totality of validating reads. The criterion for r
∈ ζ is detailed below. It is important to note that validating reads are necessary but not
sufficient to validate a variant. Sufficiency is achieved only if the number of validating
reads is statistically significant relative to those present in control samples. ζ itself is
partitioned into three sets: ζc, ζe, and ζi for evidence of cryptic splicing, exon skipping,
and intron inclusion, respectively. We allow partitions to be empty. Let JC denote the
adjacent splice junction, and let B denote the downstream natural site, as defined by
Figure 3.3 and Table 3.1. Without loss of generality, we consider only the red (i.e.
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A)

B)

C)

Figure 3.3 Illustrative examples of aberrant splicing detection. Grey lines denote reads,
wherein thick lines denote a read mapping to genomic sequence and thin lines represent
connecting segments of reads split across spliced-in regions (i.e. exons or included introns).
Dotted blue rectangles denote portions of genes which are spliced out in a mutant transcript, but
are otherwise present in a normal transcript. Mutant reads are purple if they are junction-spanning
and green if they are read-abundance based. Start and end coordinates of reads with two
portions are denoted by (r s1, re1) and (rs2, re2), while coordinates of those with only a single
portion are denoted by (rs, re). Refer to the caption of Figure 3.1 for additional graphical element
descriptions. A) An example of a normally spliced transcript, assuming Veridical is validating a
specific variant, C, shown in yellow. The adjacent intron-exon boundary, in this case, corresponds
to both the adjacent splice junction, JC, and the relevant natural site A. B is the downstream
natural site. Veridical would not identify any aberrant splicing. B) An example of the variant
causing the activation of a cryptic splice site. Additionally, there is intron inclusion present within
the analysis region. Veridical would identify and report read counts for reads pertaining to the
(junction-spanning, purple) cryptic splicing event and those pertaining to the observed (junctionspanning and read-abundance, green) intron inclusion. Since this pertains to a cryptic variant, the
adjacent splice junction, JC, is distinct from the relevant natural site A. C) An example of the
variant causing the containing exon to be skipped. Veridical would report read counts for reads
pertaining to the junction-spanning exon skipping event. These discontinuous reads are those,
that like the one shown, span the variant containing exon.
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direction is right) set of labels within Figure 3.1(B), as further typified by Figure 3.3.
Then the (splice consequence) partitions of ζ are given by:
𝑟 ∈ 𝜁𝑐 ⇔ 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑖𝑠 𝑐𝑟𝑦𝑝𝑡𝑖𝑐 ∧ (𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶 ∨ (𝑟𝑆 > 𝐽𝐶 ∧ 𝑟𝑒 < 𝐴))

(1a)

𝑟 ∉ 𝜁𝑐 ∧ 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑖𝑠 𝑐𝑟𝑦𝑝𝑡𝑖𝑐 ∧ ¬(𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶 ) ⇒ 𝑟 ∈ 𝑎𝑛𝑡𝑖 − 𝑐𝑟𝑦𝑝𝑡𝑖𝑐

(1b)

𝑟 ∈ 𝜁𝑒 ⇔ (𝑟𝑒1 = 𝐷 ∧ 𝑟𝑆2 = 𝐸)

(1c)

𝑟 ∈ 𝜁𝑖 ⇔ (𝐴 ∈ [𝑟𝑆 , 𝑟𝑒 ]) ∨ ((𝐴 ∉ [𝑟𝑆 , 𝑟𝑒 ]) ∧ 𝑟𝑆 > 𝐴 − ℓ ∧ 𝑟𝑒 < 𝐵 ∧ ¬(𝐴 ∈ [𝑟𝑆 , 𝑟𝑒 ]))

(1d)

We separately partition ζ by its evidence type, the set of junction-spanning reads, δ and
read-abundance reads, α:
𝑟 ∈ 𝛿 ⇔ (𝐴 ∈ [𝑟𝑆 , 𝑟𝑒 ]) ∨ (𝑟 ∈ 𝜁𝐶 ∧ 𝑟𝑆2 − 𝑟𝑒1 = 𝐵 − 𝐽𝐶 )

(1e)

𝑟 ∈∝⇔𝑟 ∉ 𝛿

(1f)

Once all validating reads are tallied for both the experimental and control samples, a p-v
alue is computed. This is determined by computing a z-score upon Yeo-Johnson (YJ)
(16) transformed data. This transformation, shown in Equation 2, ensures that the data is
sufficiently normally distributed to be amenable to parametric testing.
(𝓍+1)𝜆
𝜆

Ψ(𝓍, 𝜆) =

𝑖𝑓 𝓍 ≥ 0 ∧ 𝜆 ≠ 0

𝑙𝑜𝑔(𝓍 + 1) 𝑖𝑓 𝓍 ≥ 0 ∧ 𝜆 = 0
−

(−𝓍+1)2−𝜆 −1
2−𝜆

𝑖𝑓 𝓍 < 0 ∧ 𝜆 ≠ 2

(2)

{− log(−𝓍 + 1) 𝑖𝑓 𝓍 < 0 ∧ 𝜆 = 2
The transform is similar to the Box-Cox power transformation, but obviates the
requirement of inputting strictly positive values and has more desirable statistical
properties. Furthermore, this transformation allowed us to avoid the use of nonparametric testing, which has its own pitfalls regarding assumptions of the underlying
data distribution (17). We selected λ = 12, because Veridical’s untransformed output is
skewed left, due to their being, in general, less validating reads in control samples and the
fact that there are, by design, vastly more control samples than experimental samples. We
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found that this value for λ generally made the distribution much more normal. A
comparison of the distributions of untransformed and transformed data is provided in
Appendix S3.4. We were not concerned about small departures from normality as a z-test
with a large number of samples is robust to such deviations (18).
Thus, we can compute the p-value of the pairwise unions of the two sets of partitions of ζ,
except the irrelevant ζe ∪ α = Ø. We only provide p-values for these pairwise unions and
do not attempt to provide p-values for the partitions for the different consequences of the
mutations on splicing. While such values would be useful, we do not currently have a
robust means to compute them. Our previous work provides guidance on interpretation of
splicing mutation outcomes (3-5,10). Thus for ζx ∈ {ζc, ζe, ζi}, let ΦZ (z) represent the
cumulative distribution function of the one-sided (right-tailed — i.e. P[X > x]) standard
normal distribution. Let N represent the total number of samples and let V represent the
set of all ζx validations, across all samples. Then:
𝜇=

∑𝑁
𝑗=1 𝑉𝑗
𝑁

1
̅ 2
𝜎 = √𝑁 ∑𝑁
𝑗=1(𝑉𝑗 − 𝑉 )

𝑧=

|𝜁𝑥 |−𝜇
𝜎

1

𝑝 = Φ(Ψ (𝓏, 2))

The program outputs two tables, along with summaries thereof. The first table lists all
validated read counts across all categories for experimental samples, while the second
table does the same for the control samples. P-values are shown in parentheses within the
experimental table, which refer to the column-dependent (i.e. the read type is given in the
column header) p-value for that read type with respect to that same read type in control
samples. The program produces three files: a log file containing all details regarding
validated variants, an output file with the programs progress reports and summaries, and
a filtered validated variant file. The filtered file contains all validated variants of
statistical significance (set as p < 0.05, by default), defined as variants with one or more
validating reads achieving statistical significance in a strongly corroborating read type.
These categories are limited to all junction-spanning based splicing consequences and
read-abundance total intron inclusion. For example, a cryptic variant for which p = 0.04
in the junction-spanning cryptic column would meet this criteria, assuming the default
significance threshold.
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The p-values given by Veridical are more robust when the program is provided with a
large number of samples. The minimum sample size is dependent upon the desired
power, α value, and the effect size (ES). The minimum samples size could be computed
𝜎2 𝓏 2

as follows: 𝑁 = ⌈ 𝐸𝑆2 ⌉. For α = 0.05 and β = 0.2 (for a power of 0.8): z = 2.4865 for the
one-tailed test. Then, 𝑁 = ⌈

𝜎2 2.48652
𝐸𝑆 2

⌉. Ideally, Veridical could be run with a trial number

of samples.
Then, one would compute effect sizes from Veridical’s output. The standard deviation in
the above formula could also be estimated from one’s data, although it should be
transformed using Yeo-Johnson (such as via an appropriate R package) before computing
this estimation.
We elected to use RefSeq (19) genes for the exome annotation, as opposed to, the more
permissive exome annotation sets, UCSC Known Genes (20) or Ensembl (21). The large
number of transcript variants within Ensembl, in particular, caused many spurious intron
inclusion validation events. This occurred because reads were found to be intronic in
many cases, when in actuality they were exonic with respect to the more common
transcript variant. In addition, the inclusion of the large number of rare transcripts in
Ensembl significantly increased program run-time and made validation events much
more challenging to interpret unequivocally. The use of RefSeq, which is a conservative
annotation of the human exome, resolves these issues. It is possible that some subset of
unknown or Ensemble annotated intronic transcripts could be sufficiently prevalent to
merit inclusion in our analysis. We do not attempt to perform the difficult task of
deciding which of these transcripts would be worth using. Indeed, the task of confirming
and annotating of such transcripts is already done by the more conservative annotation
we employ.
We also provide an R program (22) which produces publication quality histograms
displaying embedded Q-Q plots and p-values, to evaluate for normality of the read
distribution and statistical significance, respectively. The R program performs the YJ
transformation as implemented in the car package (23). The histograms generated by the
program use the Freedman-Draconis (24) rule for break determination, and the Q-Q plots
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use algorithm Type 8 for their quantile function, as recommended by Hyndman and Fan
(25). This program is embedded within a Perl script, for better integration into our
workflow. Lastly, a Perl program was implemented to automatically retrieve and
correctly format an exome annotation file from the UCSC database (20) for use in
Veridical. All data use hg19/GRCh37, however when new versions of the genome
become available, this program can be used to update the annotation file.

3.3 Results
Veridical validates predicted mRNA splicing mutations using high-throughput RNA
sequencing data. We demonstrate how Veridical and its associated R program are used to
validate predicted splicing mutations in somatic breast cancer. Each example depicts a
particular variant-induced splicing consequence, analyzed by Veridical, with its
corresponding significance level. The relevant primary RNA-Seq data are displayed in
IGV, along with histograms and Q-Q plots showing the read distributions for each
example. The source data are obtained from controlled-access breast carcinoma data from
The Cancer Genome Atlas (TCGA) (26). Tumour-normal matched DNA sequencing data
from the TCGA consortium was used to predict a set of splicing mutations, and a subset
of corresponding RNA sequencing data was analyzed to confirm these predictions with
Veridical. Overall, 442 tumour samples and 106 normal samples were analyzed. Briefly,
all variants used as examples in this manuscript came from running the matched TCGA
exome files (to which the RNA-Seq data corresponds) through SomaticSniper (27) and
Strelka (28) to call somatic mutations, followed by the Shannon Human Splicing Pipeline
(10) to find splicing mutations, which served as the input to Veridical. Details of the
RNA-Seq data can be found within the supplementary methods of the TCGA paper (26).
Accordingly, the following examples demonstrate the utility of Veridical to identify
potentially pathogenic mutations from a much larger subset of predicted variants.

3.3.1 Leaky Mutations
Mutations that reduce, but not abolish, the spliceosome’s ability to recognize the
intron/exon boundary are termed leaky (3). This can lead to the mis-splicing (intron
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inclusion and/or exon skipping) of many but not all transcripts. An example, provided in
Figure 3.4, displays a predicted leaky mutation (chr5:162905690G>T) in the HMMR
gene in which both junction-spanning exon skipping (p < 0.01) and read-abundancebased intron inclusion (p = 0.04) are observed. We predict this mutation to be leaky
because its final Ri exceeds 1.6 bits — the minimal individual information required to
recognize a splice site and produce correctly spliced mRNA (4). Indeed, the natural site,
while weakened by 2.16 bits, remains strong — 10.67 bits. This prediction is validated by
the variant-containing sample’s RNA-Seq data (Figure 3.4), in which both exon skipping
(5 reads) and intron inclusion (14 reads, 12 of which are shown, versus an average of
4.051 such reads per control sample) are observed, along with 70 reads portraying wildtype splicing. Only a single normally spliced read contains the G→T mutation. These
results are consistent with an imbalance of expression of the two alleles, as expected for a
leaky variant. Figure 3.5 shows that for the distribution of read-abundance-based intron
inclusion is marginally statistically significant (p = 0.04).

3.3.2 Inactivating Mutations
Variants that inactivate splice sites have negative final Ri values (3) with only rare
exceptions (4), indicating that splice site recognition is essentially abolished in these
cases. We present the analysis of two inactivating mutations within the PTEN and
TMTC2 genes from different tumour exomes, namely: chr10:89711873A>G and
chr12:83359523G>A, respectively. The PTEN variant displays junction-spanning exon
skipping events (p < 0.01), while the TMTC2 gene portrays both junction-spanning and
read-abundance-based intron inclusion (both splicing consequences with p < 0.01). In
addition, all intron inclusion reads in the experimental sample contain the mutation itself,
while only one such read exists across all control samples analyzed (p < 0.01). The PTEN
variant contains numerous exon skipping reads (32 versus an average of 2.466 such reads
per control sample). The TMTC2 variant contains many junction-spanning intron
inclusion reads with the G→A mutation (all of its junction-spanning intron inclusion
reads: 22 versus an average of 0.002 such reads per control sample). IGV screenshots for
these variants are provided within Figure 3.6. This figure also shows an example of
junction-spanning cryptic splice site activated by the mutation (chr1:985377C>T) within
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A)

B)

Figure 3.4 IGV images depicting a predicted leaky mutation (chr5:162905690G>T) within the
natural acceptor site of exon 12 (162905689–162905806) of HMMR. This gene has four transcript
variants and the given exon number pertains to isoforms a and b (reference sequences
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NM_001142556 and NM_012484). RNA-Seq reads are shown in the centre panel. The bottom
blue track depicts RefSeq genes, wherein each blue rectangle denotes an exon and blue
connecting lines denote introns. In the middle panel, each rectangle (grey by default) denotes an
aligned read, while thin lines are segments of reads split across exons. Red and blue coloured
rectangles in the middle panel denote aligned reads of inserts that are larger or smaller than
expected, respectively. Reads are highlighted by their splicing consequence, as follows: cryptic
splicing (green), exon skipping (purple), junction-spanning intron inclusion (dark green), and readabundance intron inclusion (cyan). (A) depicts a genomic region of chromosome 5: 162902054–
162909787. The variant occurs in the middle exon. Intron inclusion can be seen in this image,
represented by the reads between the first and middle exon (since the direction is left, as
described within Table 1). These 14 reads are read-abundance-based, since they do not span the
intron-exon junction. (B) depicts a closer view of the region shown in (A) — 162905660–
162905719. The dotted vertical black lines are centred upon the first base of the variantcontaining exon. The thin lines in the middle panel that span the entire exon fragment are
evidence of exon skipping. These 5 reads are split across the exon before and after the variantcontaining exon, as seen in (A).
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Figure 3.5 Histogram of read-abundance-based intron inclusion with embedded Q-Q plots
of the predicted leaky mutation (chr5:162905690G>T) within HMMR, as shown in Figure 4.
The arrowhead denotes the number of reads (14 in this case) in the variant-containing file, which
is more than observed in the control samples (p = 0.04).
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A)

B)
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C)

D)

Figure 3.6 Examples of validated mutations.

(A) depicts an inactivating mutation

(chr10:89711873A>G) within the natural acceptor site of exon 6 (89711874–89712016) of PTEN.

107

The dotted vertical black line denotes the location of the relevant splice site. The region displayed
is 89711004–89712744 on chromosome 10. Many of the 32 exon skipping reads are evident,
typified by the thin lines in the middle panel that span the entire exon. There is also a substantial
amount of read-abundance-based intron inclusion, shown by the reads to the left of the dotted
vertical line. Exon skipping was statistically significant (p < 0.01), while read-abundance-based
intron inclusion was not (p = 0.53). Panels (B) and (C) depict an inactivating mutation
(chr12:83359523G>A) within the natural donor site of exon 6 (83359338–83359523) of TMTC2.
(B) depicts a closer view (83359501–83359544) of the region shown in (C) and only shows exon
6. Some of the 22 junction-spanning intron inclusion reads can be seen. In this case, all of these
reads contain the mutation, shown by the green adenine base in each read, between the two
vertical dotted lines. (C) depicts a genomic region of chromosome 12: 83359221–83360885,
TMTC2 exons 6–7. The variant occurs in the left exon. 65 read-abundance-based intron inclusion
can be seen in this image, represented by the reads between the two exons. Panel (D) depicts a
mutation (chr1:985377C>T) causing a cryptic donor to be activated within exon 27 (the second
from left, 985282–985417) of AGRN. The region displayed is 984876–985876 on chromosome 1
(exons 26–29 are visible). Some of the 34 cryptic (junction-spanning) reads are portrayed. The
dotted black vertical line denotes the cryptic splice site, at which cryptic reads end. The readabundance-based intron inclusion, of which two reads are visible, was not statistically significant
(p = 0.68). Refer to the caption of Figure 4 for IGV graphical element descriptions.
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the AGRN gene. The concordance between the splicing outcomes generated by these
mutations and the Veridical results indicates that the proposed method detects both
mutations that inactivate splice sites and cryptic splice site activation.

3.3.3 Cryptic Mutations
Recurrent genetic mutations in some oncogenes have been reported among tumours
within the same, or different, tissues of origin. Common recurrent mutations present in
multiple abnormal samples are recognized by Veridical. This avoids including a variantcontaining sample among the control group, and outputs the results of all of the variantcontaining samples. A relevant example is shown in Figure 3.7. The mutation
(chr1:46726876G>T) causes activation of a cryptic splice site within RAD54L in
multiple tumours. Upon computation of the p-values for each of the variant-containing
tumours, relative to all non-variant containing tumours and normal controls, not all
variant-containing tumours displayed splicing abnormalities at statistically significant
levels. Of the six variant-containing tumours, two had significant levels of junctionspanning intron inclusion, and one showed statistically significant read-abundance-based
intron inclusion. Details for all of the aforementioned variants, including a summary of
read counts pertaining to each relevant splicing consequence, for experimental versus
control samples, are provided in Table 3.2.

3.3.4 Performance
The performance of the software is affected by the number of predicted splicing
mutations, the number of abnormal samples containing mutations and control samples
and the corresponding RNA-Seq data for each type of sample. Veridical has the ability to
analyze approximately 3000 variants in approximately 4 hours, assuming an input of 100
BAM files of RNA-Seq data. The relationship between time and numbers of BAM files
and variants are plotted in Figure 3.8 for a 2.27 GHz processor. Veridical uses memory in
linear proportion to the number and size of the input BAM files. In our tests, using RNASeq BAM files with an average size of approximately 6 GB, Veridical used
approximately 0.7 GB for ten files to 1 GB for 100 files.
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B)

110

C)

D)

111

Figure 3.7 IGV images and their corresponding histograms with embedded Q-Q plots
depicting all six variant-containing files with a mutation (chr1:46726876G>T) which, in some
cases, causes a cryptic donor to be activated within the intron between exons 7 and 8 of
RAD54L. This results in the extension of the downstream natural donor (the 5′ end of exon 8).
This gene has two transcript variants and the given exon numbers pertain to isoform a (reference
sequence NM_003579). Only samples IV and V have statistically significant intron inclusion
relative to controls. read-abundance-based intron inclusion can be seen in (A), between the two
exons. The region displayed is on chromosome 1: 46726639–46726976. (B) depicts the
corresponding histogram for the 15 read-abundance-based intron inclusion reads (p = 0.05) that
are present in sample IV. The intron-exon boundary on the right is the downstream natural donor.
(C) typifies some of the 13 junction-spanning intron inclusion reads that are a direct result of the
intronic cryptic site’s activation. In these instances, reads extending past the intron-exon
boundary are being spliced at the cryptic site, instead of the natural donor. In particular, samples
IV and V both have a statistically significant numbers of such reads, 7 (p = 0.01) and 5 (p = 0.04),
respectively. This is further typified by the corresponding histogram in (D). (C) focuses upon exon
8 from (A) and displays the genomic positions 46726908–46726957. Refer to the caption of
Figure 4 for IGV graphical element descriptions. In the histograms, arrowheads denote numbers
of reads in the variant-containing files. The bottom of the plots provide p-values for each
respective arrowhead. Statistically significant p-values and their corresponding arrowheads are
denoted in red.
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Table 3.2 Examples of variants validated by Veridical and their selected read types.

Gene

Chr

Cv

Cs

Variant Type

Initial Final
Ri
Ri

ΔRi

HMMR

chr5

162905690

162905689

G/T

12.83

-2.16

Leaky

10.67

#

SC ET

pRE RT
value

RN

Rμ

Figure

ES

JS

<0.01

5

11

0

0.02

3.4,3.5

ES

RA

0.04

14

2133

103

4.051

PTEN

chr10
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cryptic splicing, ES denotes exon skipping, and II denotes intron inclusion. Evidence types: JS denotes junction-spanning and RA denotes readabundance.
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Figure 3.8 Profiling data for Veridical runtime. Tests were conducted upon an Intel Xeon @
2.27 GHz. Visualizations were generated with R (22) using Lattice and Effects. A surface plot of
time vs. numbers of BAM files and variants is provided in (A). Effect plots are given in (B) and
demonstrate the effects of the numbers of BAM files and variants upon runtime. The effect plots
2

were generated using a linear regression model (R = 0.7525).
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3.4 Discussion
We have implemented Veridical, a software program that automates confirmation of
mRNA splicing mutations by comparing sequence read-mapped expression data from
samples containing variants that are predicted to cause defective splicing with control
samples lacking these mutations. The program objectively evaluates each mutation with
statistical tests that determine the likelihood of and exclude normal splicing. To our
knowledge, no other software currently validates splicing mutations with RNA-Seq data
on a genome-wide scale, although many applications can accurately detect conventional
alternative splice isoforms (i.e. (29)). Veridical is intended for use with large data sets
derived from many samples, each containing several hundred variants that have been
previously prioritized as likely splicing mutations, regardless of how the candidate
mutations are selected. It is not practical to analyze all variants present in an exome or
genome, rather only a filtered subset, due to the extensive computations required for
statistical validation. As such, Veridical is a key component of an end-to-end, hypothesisbased, splicing mutation analysis framework that also includes the Shannon splicing
mutation pipeline (10) and the Automated Splice Site Analysis and Exon Definition
server (5). There is a trade-off between lengthy run-times and statistical robustness of
Veridical, especially when there are either a large number of variants or a large number
of RNA-Seq files. As with most statistical methods, those employed here are not
amenable to small sample sets, but become quite powerful when a large number of
controls are employed. In order to ensure that mutations can be validated, we recommend
an excess of control transcriptome data relative to those from samples containing
mutations (> 5 : 1), guided by the power analysis described in Methods. We do not
recommend the use of a single nor a few control samples to corroborate a putative
mutation. Not surprisingly, we have found that junction-spanning reads have the greatest
value for corroborating cryptic splicing and exon skipping. Even a single such read is
almost always sufficient to merit the validation of a variant, provided that sufficient
control samples are used. For intron inclusion, both junction-spanning and readabundance-based reads are useful and a variant can readily be validated with either,
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provided that the variant-containing experimental sample(s) show a statistically
significant increase in the presence of either form of intron inclusion corroborating reads.
Veridical is able to automatically process variants from multiple different experimental
samples, and can group the variant information if any given mutation is present in more
than one sample. The use of a large sample size allows for robust statistical analyses to be
performed, which aid significantly in the interpretation of results. The main utility of
Veridical is to filter through large data sets of predicted splicing mutations to prioritize
the variants. This helps to predict which variants will have a deleterious effect upon the
protein product. Veridical is able to avoid reporting splicing changes that are naturally
occurring through checking all variant-containing and non-containing control samples for
the predicted splicing consequence. In addition, running multiple tumour samples at once
allows for manual inspection to discover samples that contained the alternative splicing
pattern, and consequently, permits the identification of DNA mutations in the same
location which went undetected during genome sequencing.
The statistical power of Veridical is dependent upon the quality of the RNA-Seq data
used to validate putative variants. In particular, a lack of sufficient coverage at a
particular locus will cause Veridical to be unable to report any significant results. A
coverage of at least 20 reads should be sufficient. This estimate is based upon alternative
splicing analyses in which this threshold was found to imply concordance with
microarray and RT-PCR measurements (30-33). There are many potential legitimate
reasons why a mutation may not be validated: (a) A lack of gene expression in the variant
containing tumour sample, (b) nonsense-mediated decay may result in a loss of
expression of the entire transcript, (c) the gene itself may have multiple paralogs and
reads may not be unambiguously mapped, (d) other non-splicing mutations could account
for a loss of expression, and (e) confounding natural alternative splicing isoforms may
result in a loss of statistical significance during read mapping of the control samples. The
prevalence of loci with insufficient data is dependent upon the coverage of the
sequencing technology used. As sequencing technologies improve, the proportion of
validated mutations is expected to increase. Such an increase would mirror that observed
for the prevalence of alternative splicing events (34). In addition, mutated splicing factors
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can disrupt splicing fidelity and exon definition (35). This effect could decrease
Veridical’s ability to validate splicing mutations affected by a disruption of the definition
of the pertinent exon. Veridical does not currently form any equivalence between distinct
variants affecting the same splice site. Such variants will be analyzed independently.
Veridical is intended to be used with RNA-Seq data that not only corresponds to matched
DNA-Seq data, but also only for sets of samples with comparable sequencing protocols,
since the non-normalized comparisons performed rely upon the evening out of batch
effects, due to a substantial number of control samples. It is important to note that
acceptance of the null hypothesis, due to an absence of evidence required to disprove it,
does not imply that the underlying prediction of a mutation at a particular locus is
incorrect, but merely that the current empirical methods employed were insufficient to
corroborate it.
“Validate,” in the present context, refers to the condition where sufficient statistical
evidence has been marshaled in support of a variant. However, the threshold for
significance can vary so these analyses can also be thought of as strongly corroborating
variants. Recent studies in Bayesian statistics have suggested that a p-value threshold of
0.05 does not correspond to strong support of the alternative hypothesis. Accordingly,
Johnson (36) recommends the use of tests at the 0.005 or 0.001 level of significance.
We consider alternative splicing to be a different problem. Veridical does not aim to
identify putatively pathogenic variants, but rather, to confirm existing in silico
predictions thereof. We do infer exon skipping events (i.e. alternative splicing) de novo,
but only to catalog dysregulated splicing “phenotypes” due to genomic sequence variants.
This is not the first study to use a large control dataset. Indeed the Variant Annotation,
Analysis & Search Tool (VAAST) (37) does this to search for disease-causing (nonsplicing) variants and the Multivariate Analysis of Transcript Splicing (MATS) (29) tool
(among others) can be used for the discovery of alternative splicing events. However, in
our case, in most instances the distribution of reads in a single sample is compared to the
distributions of reads in the control set, as opposed to a likelihood framework-based
approach. We are suggesting that our approach be coupled to existing approaches to act
as an a posteriori, hypothesis-driven, check on the veridicality of specific variants.
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While there is considerable prior evidence for splicing mutations that alter natural and
cryptic splice site recognition, we were somewhat surprised at the apparent high
frequency of statistically significant intron inclusion revealed by Veridical. In fact,
evidence indicates that a significant portion of the genome is transcribed (34), and it is
estimated that 95% of known genes are alternatively spliced (30). Defective mRNA
splicing can lead to multiple alternative transcripts including those with retained introns,
cassette exons, alternate promoters/terminators, extended or truncated exons, and reduced
exons (38). In breast cancer, exon skipping and intron retention were observed to be the
most common form of alternative splicing in triple negative, non-triple negative, and
HER2 positive breast cancer (39). In normal tissue, intron retention and exon skipping
has been predicted to affect 2572 exons in 2127 genes and 50 633 exons in 12 797 genes,
respectively (40). In addition, previous studies suggest that the order of intron removal
can influence the final mRNA transcript composition of exons and introns (41). Intron
inclusion observed in normal tissue may result from those introns that are removed from
the transcript at the end of mRNA splicing. Given that these splicing events are relatively
common in normal tissues, it becomes all the more important to distinguish expression
patterns that are clearly due to the effects of splicing mutations — one of the guiding
principles of the Veridical method.
Veridical is an important analytical resource for unsupervised, thorough validation of
splicing mutations through the use of companion RNA-Seq data from the same samples.
The approach will be broadly applicable for many types of genetic abnormalities, and
should reveal numerous, previously unrecognized, mRNA splicing mutations in exome
and complete genome sequences.
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Chapter 4
4

Splicing

mutation

analysis

reveals

previously

unrecognized pathways in lymph node-invasive breast
cancer
The work presented in this chapter is reproduced (with permission, Appendix S1) from:
Dorman, S.N., Viner, C., Rogan, P.K. (2014) Splicing mutation analysis reveals
previously unrecognized pathways in lymph node-invasive breast cancer. Scientific
Reports 4:7063. DOI: 10.1038/srep07063

4.1 Introduction
Large-scale DNA sequencing studies have attempted to elucidate the genomic landscapes
of breast cancer tumours to identify mutated genes and genomic variation that contribute
to tumour development and progression (1-5). Typically, somatic mutations within gene
coding regions are identified and then filtered for rare or novel variants predicted to affect
protein structure or function (6-9). Frequently mutated genes are cataloged, with the goal
of inferring defective genes that are more likely to contribute to tumour phenotypes.
However, there does not appear to be a consistent set of somatic driver mutations in most
breast cancer cases. For instance, in 100 cases, 73 different combinations of abnormal
gene sequences were reported (4).
Some established cancer genes are enriched for mutations (i.e. TP53, PIK3CA, PTEN,
MAP3K1, AKT1, CDH1, GATA3, MLL3 and RB1), in addition to genes that were not
previously associated with breast cancer (including CBFB, RUNX1, TBX3, NF1 and
SF3B1) (1-5). At least 49 genes (including known breast cancer genes) have been found
to be significantly mutated, 16 of these reproducibly across multiple studies, and the
majority were mutated in <10% of tumours.
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Inconsistencies in mutation composition among different tumours present significant
challenges to understanding the underlying etiology of tumour phenotypes. As a result of
epistasis, mutations in genes with linked biochemical functions would be expected to
reveal dysfunctional pathways in tumours (10). Focusing analyses to one molecular
subtype of breast cancer can also be useful in delineating dysregulated pathways that
define the basis of tumour phenotypes (3). Significant insight into tumour biology has
come from selecting tumours with specific clinical identifiers, for example, by limiting
mutation catalogs in metastatic tumours (10,11).
Somatic mutation analyses of tumour exomes have focused on alteration of amino acid
sequences, or highly conserved dinucleotides adjacent to exons, which usually impact
mRNA splicing. Since these variants most likely comprise only a fraction of the total
mutational load, the pathways inferred to be dysregulated in these tumours may be
incomplete. For example, in familial breast cancer, variants of unknown significance
have been explained by both experimental validation and in silico predictions of defects
in BRCA 1/2 mRNA splicing (12,13). Typically, genomic studies have used tools that
predict splicing mutations based on the highly conserved dinucleotide sequences at
mRNA 5′ donor and 3′ acceptor sites (8,14). There are other well established methods
that can identify splicing mutations beyond those directly at natural sites (15-17), but
these approaches have not been applied to genome-scale cancer studies, until recently
(18). Published studies have revealed only a small fraction of reported somatic mutations
in cancer to be splicing mutations, accounting for only 2% of those reported (1-5). The
present study considers the possibility that many somatic splicing mutations may be
overlooked or are undetected by the conservative approaches currently used in analyses
of tumour genomes.
Splicing mutations frequently lead to changes in the sequence and structure of the
encoded protein, which are usually distinguishable from those generated by normal
alternative splice isoforms. Constitutive splicing mutations are frequently deleterious and
are a major cause of inherited and acquired diseases (19). In cancer, aberrant splicing
(including alternative isoforms that are not a result of cis mutation) is known to cause or
promote tumour propagation (20), and has been described as an additional hallmark of
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the disease (21). RNA analyses can detect the effect of many splicing mutations directly
(22,23). In this paper, we comprehensively analyze predicted splicing mutations in breast
cancer tumours using DNA sequencing data from The Cancer Genome Atlas (TCGA)
(5). We then use tumour-matched RNA sequencing data to statistically validate aberrant
splicing patterns of expressed genes in these tumours that result from these mutations
(24). We extended our splicing mutation analyses beyond molecular breast cancer
subtypes and identified other clinical parameters associated with specific mutation
pathways. We suggest that DNA sequencing analyses that incorporate in-depth splicing
mutation studies reveal additional mutant genes and biochemical pathways, which may
contribute to breast cancer etiology.

4.2 Methods
This study involved a reanalysis of controlled-access data from The Cancer Genome
Atlas Project (NCBI dbGaP Project #988: Predicting common genetic variants that alter
the splicing of human gene transcripts, PI: PK Rogan). DNA and RNA breast cancer
sequencing data were obtained for 445 tumours from 442 patients (Supplementary Table
4.1; July, 2012 DNA-Seq download; July, 2013 RNA-Seq Download) (5). The tumournormal pairs used mirrored those published by the TCGA in the Level 2 mutation data.
Duplicate mutations in the same patient from two different tumour-normal pairs are
reported, but were treated as one tumour for the mutation summaries reported by tumour.
Somatic mutations were predicted from the same DNA sequencing data using two
different algorithms: Strelka (v1.0.10) (6) and SomaticSniper (v1.0.2) (44) (See
Appendix S4.1). Realignment was not necessary before running Strelka because of the
program's internal realignment capabilities, so Strelka was run on the raw BAM files
downloaded from TCGA. Default parameters were used with the provided BurrowsWheeler Aligner (BWA) configuration file, since BWA was used in the initial exome
alignments. Additionally, the isSkipDepthFilters configuration option was changed to
true, since such depth filters are designed for use on whole-genome data and would
erroneously filter out most data when used with exome sequencing data. Strelka's BWA
quality control script was run to remove variants considered low quality. Variants that
were found to be common SNPs, defined by those that were annotated with dbSNP135 in
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over 1% of the population, were filtered out from the variant set before any subsequent
analyses.
Somatic mutations, including single-nucleotide variants (SNVs) and insertion/deletions
(indels) were used to predict the coding and non-coding genic effects of the variants.
Annovar (August 23, 2013 release) (8) was used with default parameters to predict which
variants are likely to affect amino acid sequence and splicing at the natural splice sites.
The Shannon Human Splicing Pipeline Version 2.0 (Shannon Pipeline) (18) was used to
complete a more in-depth analysis of splicing mutations, which predicts variants that will
alter the binding affinity of the natural site or cause cryptic splicing (i.e. extension or
truncation of an exon). The Shannon Pipeline results were subsequently filtered to
prioritize which variants are most likely to have the greatest effect on mRNA splicing,
using the filtering criteria outlined in Appendix S4.2.
Multiple factor analyses used the R package FactoMineR (version 1.25) (45). Clinical
parameters were obtained from the TCGA including AJCC tumour staging (metastasis
stage code, neoplasm disease lymph node stage, and neoplasm disease stage), receptor
statuses (estrogen, progesterone, and HER2/neu immunohistochemistry receptor statuses)
as well as patient status (neoplasm cancer status and vital status). These clinical
parameters were input into FactoMineR as qualitative groups, as listed above, along with
the number of NCAM1 pathway mutations. Within the program, options were set to
perform clustering after MFA, and to automatically determine the choice of the number
of clusters. A second MFA was performed based on the number of NCAM1 pathway
mutations per tumour in genes present only in the NCAM1 related pathways that were
also not present in the collagen or extracellular matrix pathways.
Word Clouds were generated to portray the overrepresentation analysis of mutated
pathway results generated with Reactome (29,30) and, in particular, the differences
between lymph node-positive and -negative tumour samples. The primary input data for
these graphics was the overrepresented pathways from Reactome, partitioned according
to subtype and lymph status. Additional sets were composed of all subtypes and all
subtypes with only pathways not found within both lymph status partitions. However, this
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direct data was not suitable for plotting, as many pathways were vastly too specific and
varied to portray any broader trends. Pathway abstraction was undertaken to mitigate
these difficulties and allow for visual perception of trends in the data. The full Reactome
human pathway hierarchy was downloaded, using the provided RESTful API (46). A
query to abstract pathways was performed using the BaseX XML database engine (47).
The abstraction was designed to generalize the pathways, while still maintaining
sufficient specificity to confer biological meaning in this context. To accomplish this,
corresponding pathways of specific depths were retrieved and abstracted by taking
instead higher-order pathways in the hierarchy. Reactions or black box events that were
four or five levels deep, as well as pathways that were four levels deep, were abstracted
by taking the corresponding element of depth three (i.e. their parent or grandparent).
Pathways one level higher in the hierarchy (i.e. the parent pathway) of all other pathways,
reactions, or black box events (i.e. those not at the aforementioned depths) were
retrieved. The resulting abstracted pathways were then used as input for the word clouds.
They were generated using R (v3.0.2) with the RColorBrewer (v1.0.5 tm, and wordcloud
packages (v2.4) (48). Parameters used to generate the word clouds were as follows: scale
= c(wordFit,0.3), min.freq = 2, random.order = F, colors = brewer.pal(6, “Dark2”)[−1])),
vfont = c(“serif”,“plain”).
The Mutational Significance in Cancer (v0.4) (MuSiC) (25) suite of tools was employed
to identify genes significantly mutated in the breast cancer samples analyzed with the
variant set derived in this study. Three tools from genome MuSiC were used with all
default parameters: bmr calc-bmr, bmr calc-covg, and smg. NCBI Reference Sequence
Genes release 62 (RefSeq) (49) were used as the regions of interest (ROI) file with the
Human Feb. 2009 (GRCh37/hg19) assembly reference sequence for bmr calc-bmr and
bmr calc-covg. All FDRs that we report pertaining to the MuSiC analysis used the
Fisher's combined P-value (FCPT), convolution (CT) and likelihood ratio (LRT)
statistical tests.
The software program Veridical (24) was used for in silico validation of all predicted
splicing mutations using its default settings. At the time the program was run, Veridical
rounded p-values to 2 decimal places. Validated results reported were filtered for cryptic
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variants using reads demonstrating junction-spanning cryptic sites, junction-spanning
exon skipping, or read-abundance intron inclusion, whereas reads for predicted natural
splice site variants were filtered for all of the above evidence types, except for cryptic
splice site-activating, junction-spanning reads. Variants were considered validated if at
least one of the above categories for the indicated variant type were excluded from
normal controls, but present in the transcriptome containing the predicted mutation (p ≤
0.05, after transformation of both sample and control read counts to a normal distribution
and use of a parametric Z test). Validation was not always possible in instances where
predicted mutations occurred in genes or exons with minimal cDNA coverage, resulting
from either low expression in the breast tumours carrying the mutation (50), tissuespecificity of gene expression, or transcript instability from nonsense-mediated decay.
Although Veridical provided experimental validation of predicted splicing mutations, the
impact of these and protein coding mutations on tumour progression and biology could
not be determined from the present analyses. Further laboratory studies with the original
tumour tissues (which were not available), cell line or model organism studies would be
required to prove biological significance.
RSeQC's (v2.3.7) ReadDist (51) script was used to generate the genome-wide intron
inclusion data with the RefSeq gene annotation file to determine intronic genomic
sequences. We ran BedTools multicov (v2.17.0) (52) upon the RefSeq (49) exome
annotation BED file retrieved from the UCSC table browser (53) with a minimum map
quality of 1. The returned coverage values were multiplied by the read length, and
divided by the number of exonic bases. In cases of genes with more than one transcript,
the shortest transcript was used such that the coverage values per exonic base were
maximized, which is the most conservative assumption to adopt when excluding variants
due to low coverage. The heat map, provided in Appendix S4.3, was generated by breast
cancer subtype for this data using the R packages Hmisc (v3.14.3) and gplots (v2.12.1).
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4.3 Results
4.3.1 Derivation of mutations
Somatic mutations in 472 breast cancer tumours from 445 breast cancer patients were
called using matched tumour-normal DNA exome sequencing data from TCGA (5)
(Supplementary Table 4.1). There were 149,959 single-nucleotide variants (SNVs) and
10,000 insertion/deletions (indels) detected using the variant caller, Strelka (6) (see
Appendix S4.1 for results from an alternative variant caller and reasons for our selection
of Strelka). Protein coding mutations were annotated by ANNOVAR (8) and splicing
mutations with the Shannon Human Splicing Pipeline (18) (Table 4.1, see Supplementary
Tables 4.2–4.4 for a list of all mutations). The Shannon Pipeline predicted significantly
more splicing mutations than reported by TCGA, because the information-theoretic
method employed enables analyses of variants beyond exon boundaries that alter mRNA
splicing. 948 variants were found to affect both protein coding and splicing in 747 genes,
among 319 tumours. DYNC2H1, TP53 and PASD were the most commonly mutated of
this group, containing 21, 11, and 9 exonic variants, respectively. Alteration of mRNA
splicing was predicted as a result of 213 substitutions at synonymous codons among 139
tumours. Reanalysis of coding changes confirmed high concordance with the validated
TCGA SNVs, however indels were less reproducible (Appendix S4.4). Overall, 82.1% (n
= 21,041) of protein coding mutations, and 86.5% (n = 371) of splicing mutations
reported by TCGA were confirmed. A small subset of protein coding TCGA substitutions
that were missed occurred within genes commonly mutated in breast cancer (35 TP53, 13
MLL3, 22 GATA3, 25 MAP3K1, 11 CDH1 and 10 PIK3CA; see Appendix S4.5), however
all splicing-associated SNVs found by TCGA in cancer-related genes were detected.

4.3.2 Significantly mutated genes
Significantly mutated genes were identified with the Mutational Significance in Cancer
(MuSiC) software suite (25). There were 225 genes with false discovery rates (FDR) of
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Table 4.1: Single nucleotide variant summaries by mutation type

Type

Mutation Count

Protein Coding
Synonymous

14,717

Nonsynonymous

40,649

Stop gain or loss

2,587

Total protein coding variants

57,953

Splicing
Cryptic

1,130

Inactivating

1,355

Leaky

2,721

Total splicing variants

5,206

Protein coding mutations also predicted to affect splicing
Synonymous

213

Nonsynonymous

664

Stop gain or loss

71

Total

948

Synonymous also splicing

1.4473%

Nonsynonymous also splicing

1.6335%

Stop gain or loss also splicing

2.7445%
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<0.05, based on the Fisher's combined P-value (FCPT), convolution (CT) and likelihood
ratio (LRT) tests. These results were compared with the 49 genes previously identified as
significantly mutated (1-5) (Appendix S4.6). Among the previous genes reported by
TCGA, TP53, CDH1, MAP3K1, and MLL3 were significantly mutated in this study by all
tests, and AFF2, SF3B1, and CBFB were significant for the CT and LRT tests only. We
additionally identified ARID1A as significantly mutated, concordant with an independent,
large-scale, breast cancer genomics study (4).

4.3.3 Validating predicted splicing mutations
Changes in mRNA splicing from the predicted mutations were validated with Veridical
(24), which corroborates predicted, aberrant splice isoforms by assessing mutationderived sequence reads in tumour RNA relative to their abundance in controls lacking the
mutation. Controls comprised tumours lacking a particular mutation (usually, n = 414)
plus additional normal samples (n = 106). Of all variants analyzed from the 415 tumours
with RNA-Seq data (n = 4,952), 988 variants (~20%) in 819 genes caused one or more
splicing aberrations at significantly higher levels than in controls (p ≤ 0.05; i.e. intron
inclusion, exon skipping, or cryptic splicing). Predicted natural splice site mutations (822
of 3,863, or 21.3%), were validated by abnormal mRNA isoforms more often than cryptic
splice site mutations (166 of 1,089 or 15.2% variants). A total of 309 mutations were
found to cause exon skipping, of which 163 (53%) led to expected frameshift mutations.
Sufficient expression levels for each gene, based on RNA-Seq coverage, were required
for validation of mutations. An expression heat map, clustered by BC subtype, is shown
in Appendix S4.3. Variants occurring within significantly expressed genes (defined as an
average of ≥20 reads per base) were statistically validated for 862 (27%) of 3,156
variants (p ≤ 0.05). Of 263 variants reported by TCGA in genes with at least this level of
expression, 156 (59%) were validated by exon skipping (26 variants), by intron inclusion
(80 variants), and by the combination of both types of evidence (50 variants, p ≤ 0.05).
Predicted cryptic splicing mutations were confirmed based on the presence of unique
junction-spanning reads corresponding the ectopically spliced isoforms in GATA3,
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PALB2, CBFB, ABL1, C2CD2L, ENSA, NASP, NOP9, and TFE3 (Appendix S4.7.1).
Four of these genes have been linked to tumourigenesis: ABL1, an oncogene, GATA3 and
PALB2, which are associated with familial breast cancer (26,27), and CBFB has been
recently implicated in breast cancer by TCGA (5) and others (1,2). These cryptic splicing
mutations lead to short exonic deletions that alter the reading frame, and likely affect the
activity of the gene products (Figure 4.1). The GATA3 cryptic isoform is the only
detectable transcript in the majority of controls, although it is substantially more
abundant in the tumour sample (Appendix S4.7.2).
The most commonly mutated genes with splicing mutations were also found by MuSiC to
be significantly mutated in these tumours (n = 13, FDR < 0.05), and at least one third of
the mutations were validated with RNA-Seq data (Table 4.2). In TP53, which exhibited
the highest density of splicing mutations (Figure 4.2), 18 of 23 (78%) predicted variants
were validated to cause aberrant splicing (p ≤ 0.05). All of the validated mutations
exhibited statistically significant intron inclusion above normal controls, which was not
observed genome wide (Appendix S4.8). In three instances, the variants also resulted in
exon skipping.

4.3.4 Copy number analysis of mutated genes
The validated mutations are organized and segregated by tumour subtype on a Circos plot
(28) (Figure 4.3). Copy number changes portray the genomic locations of deletions or
amplifications that coincide with these variants. Validated splicing mutations exhibit a
relatively uniform genomic distribution, except for significantly mutated genes, such as
TP53 on chromosome 17 and HMCN1 on chromosome 1. We investigated variants in
regions showing copy number losses, which may constitute the “second hit” in
oncogenesis. Of the 49 genes found to be significantly mutated in breast cancer (1-5),
five contained splicing mutations (BRCA1 (2 tumours), PTEN (2 tumours), MAP2K4 (4
tumours), MAP3K1 (4 tumours) and KMT2C (7 tumours; also known as MLL3)) and also
recurred within commonly deleted intervals. Of all genes with validated mutations in
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Figure 4.1 mRNA of ABL1, CBFB, GATA3 and PALB2, which each have validated cryptic
splicing mutations confirmed using tumour-matched RNA-Seq data. Full gene lengths are
displayed with vertical black bars outlining exon boundaries. The location of the cryptic variant is
denoted by the red V, and the variant consequence is highlighted by white (wild type), dark grey
(exonic deletion), and red (frameshift mutation). Conserved domains and protein interactions are
labeled by the yellow and blue horizontal bars, respectively. In ABL1, the catalytic and C-terminal
F-actin binding domains are disrupted. In PALB2, the region that interacts with BRCA2 is
truncated. In the GATA3 aberrant transcript, the second zinc finger domain and a conserved motif
crucial for DNA binding and protein function are affected by the altered reading frame.
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Table 4.2: Genes most commonly mutated with splicing mutations

Gene Symbol*
TP53

# Splicing
Mutations
24

# Validated

% Validated

18

75

HMCN1

19

9

47

KMT2C (MLL3)

19

7

37

FHAD1

12

4

33

RAB3GAP1

11

4

36

BCLAF1

11

3

27

ANKEF1

10

6

60

RRM1

8

4

50

RPRD1A

7

2

29

SCAMP5

7

2

29

CDH1

6

4

67

ACTR3

6

2

33

*FDR < 0.05 for all genes from MuSiC (Fisher's combined P-value, convolution and likelihood
ratio tests).
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Figure 4.2: Splicing mutations in TP53, KMT2C and CDH1. TP53, KMT2C and CDH1 gene lengths are displayed with both exons (thick
lines/boxes) and introns (thin horizontal lines), along with the location of all splicing mutations. Diamond markers denote cryptic mutations, natural
splice site mutations are indicated by a circle and the colour of the marker corresponds with breast cancer tumour subtype. Mutations validated by
Veridical are found above the gene, and those mutations not assessed or not validated are below.
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Figure 4.3: Circos plot of validated splicing mutations by tumour subtype. From the
outermost ring in, chromosomes are labeled clockwise with copy number data inside them that
displays deletions in red and amplifications in blue, mutations validated by Veridical (indicated by
black ticks) are then plotted by subtype with basal-like in the outer white ring, HER2-enriched in
the outer grey ring, then luminal A (inner white) and luminal B (inner grey).
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deleted regions, 9 harbored more than 2 variants: 1 had three, 4 had four, and only
KMT2C possessed more than 4 variants.

4.3.5 Analysis of pathways enriched in mutant genes
Mutated genes were clustered by pathway overrepresentation analysis (29) for protein
coding (Supplementary Table 4.5, n = 202) and splicing mutations (Supplementary Table
4.6, n = 452). There were 100 pathways common to both mutation sets (Appendix
S4.9.1). Pathways associated with all types of mRNA splicing mutations include those
that affect collagen structural genes and enzymes that modify or metabolize collagen (n =
14, Appendix S4.9.2 #1–14), and several that involve the extracellular matrix (ECM, n =
4, Appendix S4.9.2 #15–18). Many of these pathways (n = 17, Appendix S4.9.2 #1–
13,15–18) are also overrepresented by pathway analysis of protein coding mutations.

4.3.6 Relationship of mutation spectra to clinical findings
Segregating splicing mutations by patient lymph node status revealed significant
differences in mutated pathways between the two groups. Biochemical pathways with
overrepresented mutant genes in lymph node-negative (LN−) vs. lymph node-positive
(LN+) tumours are indicated in Supplementary Tables 4.7 and 4.8, and compared in
Supplementary Table 4.9. There are 94 pathways overrepresented in both LN+ and LN−
(Supplementary Table 4.9 #421–514), including 17 collagen (Supplementary Table 4.9
#421–437), and 3 ECM (Supplementary Table 4.9 #438–440) pathways. Ontologicallyrelated pathways (29,30) were grouped (Appendix S4.9.3) and visualized as Word Clouds
(Figure 4.4). Pathway groups overrepresented (p < 0.05) in both tumour subsets included
17 pathways involving collagen-ECM protein phosphorylation pathways, metabolism,
cell cycle, DNA repair, and cellular response to stress. However, 13 pathways involving
collagen (Supplementary Table 4.9 #1–13), and 9 pathways involving NCAM1
(Supplementary Table 4.9 #17–25) were overrepresented uniquely in LN+ tumors, but
not in LN− tumours.
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Figure 4.4: Word Clouds demonstrating differences between overrepresented mutated pathways in lymph node-positive (a) and lymph
node-negative (b) tumours. The abstracted pathways (see methods) were plotted if present two or more times. The size of the words as well as
the corresponding colours of the pathway names indicates the frequency of that abstracted pathway, and can be compared within and between
the word clouds of each tumour subset.
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NCAM1, or the neural cell adhesion molecule, is a member of the immunoglobulin super
family with a role in cell-cell and cell-matrix interactions during development and
cellular differentiation. Mutations in NCAM1 signaling genes for neurite outgrowth
(Supplementary Table 4.10 #1) were still overrepresented in tumours with lymph node
invasiveness, even after genes common to both tumour subsets were masked from the
analysis, i.e. primarily collagen and ECM genes (Supplementary Tables 4.10 and 4.11).
These include defects in NCAM1 interactions with FYN and GRB2, a ternary complex
that participates in the conversion of RAS:GDP to RAS:GTP, which subsequently
initiates the RAF/MAP kinase cascade.
We then reanalyzed these data after conservatively limiting the set of mutant genes to
those containing the most deleterious mutations (Appendix S4.9.4; stop-gain, stop-loss,
frameshift/indel mutations, and validated splicing mutations). Four of the 8 sub-pathways
of NCAM1 signaling for neurite outgrowth were overrepresented solely in LN+ tumours.
Autophosphorylation/dephosphorylation of NCAM1- bound Fyn, as well as NCAM1interactions with collagens were overrepresented. The most commonly mutated genes
within these pathways are SPTA1, CACNA1D, COL6A5, NCAM1, and COL6A6
(Appendix S4.10). CACNA1D is a voltage-dependent Ca2+ channel (VDCC) that
associates with NCAM1 in growth cones at the sites of NCAM1 clustering (29,30). In
addition, 6 other channel genes that are expressed in breast tissue (31) were found to be
frequently mutated (CACNA1C, CACNA1D, CACNA1G, CACNA1H, CACNB1,
CACNB3). Mutations interrupting these VDCC interactions may alter the NCAMdependent Ca2+ influx. Collagen VI is expressed as supramolecular aggregates of
composite structures of different chains and is among the most abundant components of
the ECM (32). Knockdown of NCAM significantly reduces expression of ECM
components (33), including collagen, weakening the ECM. Mutations in these ECM
components may also diminish matrix integrity, possibly resulting in more porous
structures (34).
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4.3.7 Elevation of NCAM1-related gene pathway mutations in lymph
node-positive tumours
NCAM1, collagen, and ECM pathway mutations were assessed in tumours, stratifying by
lymph node status and tumour stage (Figure 4.5). The percentage of tumours with
NCAM1-related pathway splicing mutations was increased in N0 (110 localized tumours)
and N1 (84 tumours with lymph node involvement), as well as Stage I (37) and II
tumours (140). Advanced lymph node involvement and tumour stage were not associated
with increased numbers of collagen and ECM pathway splicing mutations, but rather a
decrease in the percent of tumours with these pathway mutations in advanced stages was
observed. A multiple factor analysis (MFA; Table 4.3) was performed to assess
contributions of the number of NCAM1-related pathway mutations per tumour (both
protein coding and splicing), clinical parameters including stage (AJCC tumour stage,
lymph node status and metastasis stage), receptor status (HER2, PR, and ER positivity),
and patient outcome (relapsed, living/deceased). NCAM1-related pathway mutations
were either absent (n = 213), harbored a single mutation (n = 117), or two or more
mutations (n = 112) per tumour. The MFA components containing NCAM1-related
pathway mutations were moderately correlated with both tumour stage and receptor
status, and accounted for 11% of the variance.

4.3.8 Analysis of tumour subtypes
Splicing mutation analysis in different tumour subtypes revealed between 9–15 mutations
per tumour, which generally accounted for 8–9% of all mutations detected (Appendix
S4.11.1) and are similar levels to those previously reported (18). Pathway analyses for
each subtype, stratified by lymph node status, indicated higher enrichment of NCAM1related gene mutations in basal-like and HER2/ERBB2-enriched LN+ tumours (Appendix
S4.11.2 & S4.11.3: see word clouds). LN+ basal-like and HER2-enriched tumours were
the only tumours found to have significant enrichment in “NCAM signaling for neurite
out-growth”, identifying those tumour subtypes and pathways that may play a role in
tumour migration. No single gene was significantly mutated within the NCAM1
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Figure 4.5: Percent of tumours with mutations by pathway group and clinical factors. The
percent of tumours with NCAM1 (red square), collagen (blue diamond), and ECM (green triangle)
pathway mutations were plotted by lymph node status and tumour stage for all mutations (solid
lines), and splicing mutations alone (dashed line).
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Table 4.3: Multiple factor analysis of NCAM1 related pathway mutations and clinical
parameters per tumour

Dim.1

Dim.2

Dim.3

Dim.4

Dim.5

A. No. Mutations in NCAM
Pathways*

0.103

0.892

0.910

0.367

0.321

Stages

0.804

0.459

0.381

0.833

0.725

Receptor status

0.379

0.356

0.406

0.471

0.641

Patient status

0.868

0.159

0.050

0.106

0.159

% Variance explained

7.618

5.699

5.635

4.944

4.694

B. No. Mutations Unique to
NCAM Pathways∧

0.264

0.899

0.894

0.304

0.300

Stage

0.791

0.413

0.380

0.877

0.752

Receptor status

0.389

0.427

0.411

0.429

0.610

Patient status

0.851

0.083

0.158

0.168

0.221

% Variance explained

7.716

5.816

5.534

4.941

4.743

*mutation count for all genes in NCAM pathways.
∧ mutation count for genes unique to NCAM pathways, and not in collagen or ECM pathways.
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pathways that were overrepresented in LN+ tumours. This suggests that a general defect
in NCAM1-pathway signaling may be associated with lymph node metastasis in breast
cancer.

4.4 Discussion
Breast carcinoma tumour exomes contain more deleterious mutations than previously
recognized. Using Shannon information theory, we have predicted an expanded set of
mutations that affect post-transcriptional mRNA processing that either reside in noncoding regions, or overlap known codons. We then employed Veridical (24), a highthroughput, genome-scale method, to statistically validate mRNA splicing consequences
that result from the predicted variants. This study complements the analyses performed
by TCGA (5), which comprehensively reported protein-coding mutations, along with
gene expression, epigenetic, and copy number changes. Together with known deleterious
coding sequence variants, the identification of such splicing mutations can refine and
impact our understanding as to which biochemical pathways are dysregulated in these
tumours.
Pathway overrepresentation analyses reproduced many of the same pathways identified
by TCGA. In our analysis, a number of these attained or increased significance when
genes with previously unrecognized splicing mutations were included. Both splicing
mutations alone and the complete variant set from all tumours were enriched for genes in
pathways known to play a role in tumour development and progression including
signaling by growth factors, cell cycle, ECM organization, and cell-to-cell
communication. Stratifying the tumours by lymph node status revealed that splicing
mutations were enriched for genes within NCAM1 pathways in LN+ tumours,
exclusively. Splicing mutations in these pathways were much rarer and sparsely
distributed in LN− tumours, with 11 mutations in 92 LN− tumours and 25 mutations in
118 LN+ tumours. Interestingly, this enrichment was not observed when all protein
coding substitutions were analyzed, but was significant when assessing all variants that
were likely to be deleterious (i.e. validated splicing mutations, stop codon gain or losses
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and frameshift substitutions). We did not attempt to differentiate loss versus gain of
function, however splicing mutations and nonsense codons usually result in loss of
function. The percent of tumours with NCAM1-related pathway mutations increased by
6% from lymph node stage N0 to N1 and N3 and by 7% from stage I to III. The lower
fraction of tumours with collagen pathway mutations at higher lymph node stages (N3,
N4), and with ECM-related mutations in tumour stages III and IV could be related to
clonal selection of distinct metastatic phenotypes (35), however it is also possible that the
decreases may not be significant due to the lower numbers of tumours in these categories.
Our results indicate that NCAM1 pathways are more likely to be dysregulated in tumours
that have migrated to lymph nodes. We found the enrichment of NCAM1-related
pathway splicing mutations in LN+ tumours was specifically present in HER2-enriched
and basal-like tumours. Basal-like, specifically triple-negative, tumours have been
associated with poor prognosis and survival (36). Early and metastatic HER2 positive
tumours were associated with poor prognoses (37) until the more recent introduction of
HER2-targeted therapies (38). In these tumour subtypes, the presence of NCAM1-related
pathway mutations may indicate a propensity to migrate and/or form distant metastases.
Dysregulated expression of NCAM1 has been suggested to contribute to tumour
migration in other cancers: (i) gene silencing and localization studies have suggested that
“NCAM is both necessary and sufficient to promote a migratory and invasive phenotype
in EOC cells, with no major effect on cell proliferation” (34), (ii) overexpression of
NCAM1 has been linked to high ovarian carcinoma tumour grade (34) and greater
metastatic potential in melanoma cells (39); (iii) preserved NCAM1 expression in
differentiated thyroid carcinoma has been cited as an indicator for tumours with as
increased risk of forming distant metastases (40) and (iv) blocking NCAM1 function in
murine lung tumour cells led to cell vulnerability to apoptosis. More generally, NCAM1
is known to play a role in apoptotic evasion and matrix degradation, and has potential
roles in directional cell migration, cell polarity, extravasation and immunological escape
(41). NCAM1-mediated stimulation of FGFR activity is causally linked to tumour
malignancy, suggesting that this NCAM1-FGFR interaction may be an effective
therapeutic target. It is notable that we find mutations in breast tumours that affect the
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NCAM1-FGFR interaction occur in pathways that are overrepresented in LN+, but not
LN− tumour genomes.
NCAM1 homophilic clusters form within lipid rafts on the cell membrane. Spectrin, an
NCAM1-binding cytoskeletal protein, colocalizes with NCAM1 and is codistributed
within lipid rafts (42). Frequent mutations in spectrin (SPTA1) may prevent its
association with RPTPα, thereby impeding its subsequent association with the
cytoplasmic NCAM1 domain, redistribution of NCAM1 and cluster formation. This
could abrogate downstream interactions with FYN and GRB2, ultimately affecting
activation of RAS. These findings merit further investigation into how dysregulation in
these different partners (i.e. NCAM1, FGFR and the other interacting proteins), acting as
an ensemble, may promote tumour metastasis.
The number of aberrant mRNA splicing mutations reported by TCGA (5) is <10% of
those reported here, and the variants were not functionally validated in the previous
study. We predict that 8% of all cis-activating point mutations detected in these tumours
will significantly reduce the strength of the corresponding natural splice sites. The 5,206
splicing mutations reported here nearly double the number of mutations that lead to stopgains or losses (2,587 variants in 1,907 genes), and the number of insertions/deletions
leading to frameshift substitutions (2,707 variants in 1,848 genes) in this set of tumours.
It is not surprising that these analyses revealed previously unrecognized pathways that
may be dysregulated, in addition to those already known in these tumours.
Our analysis of significantly mutated genes based on the protein coding and splicing
mutations reproduced many of the genes reported by TCGA, and revealed one additional
gene, ARID1A. ARID1A has been implicated in breast cancer in a large-scale genomic
study (4) and has also been mutated in 57% of ovarian clear-cell carcinoma tumours (43).
Thirteen genes identified as significantly mutated in breast cancer by the TCGA did not
reach statistical significance within our study (Supplementary Table 4.4). This can be
explained by a number of different factors: differences in variant callers, variant
annotation, the number of tumours analyzed and differences in the filtering of variants,
once the gene set was derived. In addition, TCGA initially analyzed all variants (SNVs
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and indels) by tumour subtype, unlike our study, which considered mutations in all
tumours, then reanalyzed overrepresented pathways with mutations by subtype.
Mutations that lead to a significant level of aberrant splicing can alter or improve
genomic signatures, which are important when assessing potential biomarkers, diagnosis
and prognosis, and metastatic or treatment-resistant tumour phenotypes.
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Chapter 5
5

Genomic signatures for paclitaxel and gemcitabine
resistance in breast cancer derived by machine learning

The work presented in this chapter is reproduced (with permission, Appendix S1) from:
Dorman, S.N., Baranova, K., Knoll, J.H.M., Urquhart, B.L., Mariani, G., Carcangiu,
M.L., Rogan, P.K. (2015) Genomic signatures for paclitaxel and gemcitabine resistance
in
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cancer derived by machine learning.
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10.1016/j.molonc.2015.07.006.

5.1 Introduction
Chemotherapeutic agents, such as paclitaxel and gemcitabine, are recommended to
patients with developed metastases, basal-like breast cancer, and high-risk indications
(premenopausal, ER/PR-negative, HER2-status, large tumours, or node-positive) (1,2).
There is currently no gold standard chemotherapy regimen (1,2). Treatment selection is
suggested to be individualized and should take into account clinical disease
characteristics, treatment history, patient-related factors, and patient preference.
However, resistance is one of the major barriers to successful therapy. In a recent study,
breast cancer patient response rates to paclitaxel and gemcitabine after 6 cycles of
chemotherapy were found to be only 50.0% and 78.6% respectively (3). This has
motivated a number of groups to develop gene signatures aimed at predicting therapeutic
response to these drugs in breast cancer patients (4-6).
As in breast cancer patients, breast cancer cell lines show variable responses to growth
inhibition by paclitaxel and gemcitabine (7,8). Cell lines mirror many of the pathological
features of breast tumours, such as the intrinsic subtypes of breast cancer (9,10), and can
be useful for testing anticancer therapy responses (11). Daemen et al. (2013) employed
random forest machine learning to assess genomic information from 70 breast cancer cell
lines (including DNA sequence, gene copy number, gene expression, promoter

155

methylation, protein expression, and the corresponding cell line response to 90 anticancer compounds) with the objective of establishing pretreatment signatures that predict
response. The gene expression profile of the tumor subtype was found to be the most
effective way to model response to therapy. However, many molecular signatures derived
using genome-wide approaches are inconsistent between different data sets (12,13). This
is partly due to the fact that deriving predictive gene models using thousands of genes
risks overtraining, that is, fitting the noise rather than the actual gene signature in the data
(12).
We recently defined a set of genes that are stable in gene expression and copy number in
the majority (>90%) of breast cancer tumours (14). The stable gene set is composed of
genes that are unmutated in the majority of tumours. Interestingly, many stable gene
products were found to be targets of paclitaxel and gemcitabine. We examine the
possibility that genomic differences in expression, copy number or mutation in these
genes may be related to GI50. Rather than a genome-wide approach to predict sensitivity
to paclitaxel and gemcitabine (eg. employed by Daemen et al. (2013)), we analyze stable
and linked unstable genes in pathways that determine their disposition (Figure 5.1).
Gene panels were established based on biological and experimental studies of paclitaxel
and gemcitabine metabolism. Paclitaxel binds to the β subunit of tubulin (TUBB1),
inhibiting microtubule formation during mitosis (15). It also binds BCL2, which induces
programmed cell death (16). Paclitaxel is now also recognized to target microtubuleassociated proteins 2 (MAP2), 4 (MAP4) and Tau (MAPT) (17), as well as the xenobiotic
receptor (NRI12, or PXR) (18). SLCO1B3 transports paclitaxel into cells, and it is
exported by ABCB1 (P-glycoprotein), multidrug resistance-associated proteins ABCC1
(19) and ABCC10 (20), and the bile salt export pump ABCB11 (21). Other genes
previously implicated as contributing to paclitaxel resistance include TMEM243 (22),
BCAP29 (23), GBP1 (24), TLR6 (25), NFKB2 (26), FGF2 (27), BIRC5 (28), TWIST1
(29), FN1 (30), OPRK1 (31), CSAG2 (32), and CNGA3 (31). Additionally, genes
expressed in breast tissue involved in paclitaxel metabolism were included: CYP2C8 and
CYP3A4 (33), as well as stable genes in pathways of known direct targets (14): BAD,
BBC3, BCL2L1, BMF, TUBB4A (34), and TUBB4B (34).
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Gemcitabine, a deoxycytidine analog, is transported into the cell by SLC29A1 (35),
SLC29A2, SLC28A1 (36), and SLC28A3 (37).The prodrug is then phosphorylated by
DCK, CMPK1, and NME1 to gemcitabine diphosphate and triphosphate (38). These
active forms are incorporated into DNA, which halts replication and cell growth (39).
Gemcitabine di- and triphosphate target ribonucleotide reductase (RRM1, RRM2, and
RRM2B),

and

inhibit

DNA

synthesis

(40).

An

alternative

metabolite,

difluorodeoxyuridine monophosphate, which is derived by cytidine deaminase (CDA) or
dCMP deaminase (DCTD), inhibits thymidylate synthetase (TYMS), resulting in
apoptosis (38).
We examine the hypothesis that genomic differences in genotypes, expression and copy
number of these genes explain concentration-dependent growth inhibition by gemcitabine
and paclitaxel. We then use machine learning to stratify the relative contributions of
different genes to chemoresistance, by identifying corresponding genomic signatures at
the transcriptional and genomic level in both cell line and patient data.

5.2 Materials and Methods
5.2.1 Data Acquisition
Growth inhibition (GI50), copy number, gene expression, and exome sequencing data
were obtained from the supplementary data of Daemen et al. (2013). GI50s (-log10M,
where M is the drug concentration required to inhibit cell line growth by 50%) for
paclitaxel were available for 49 cell lines and GI50s for gemcitabine were available for
47 cell lines. Appendix S5.1 indicates the cell lines used and Appendix S5.2 indicates the
gene, gene product names and their respective drug disposition functions. Appendix S5.3
& S5.4 describe copy number and variant calling, results of which are shown in
Supplementary Tables 5.1 and 5.2. Log2 normalized gene expression data were derived
from Affymetrix Gene Chip Human Exon 1.0 ST arrays. Replication studies performed to
re-measure and confirm GI50s, verify copy number and mutation data for a subset of the
cell lines are outlined in Appendix S5.5. Figure 5.1 is an overview of the complete
workflow used.
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Figure 5.1 Workflow to derive gene signatures. Gene sets were derived for paclitaxel and
gemcitabine based on known drug pathways, metabolism, and genes previously implicated in
resistance. A multiple factor analysis was completed for each gene to determine which data types
(gene expression, copy number, and mutation data) were correlated with the growth inhibitory
values for paclitaxel and gemcitabine. Gene expression values were used to derive the paclitaxel
SVM classifier, and both gene expression and copy number were used for the gemcitabine SVM.
Cell lines were then clustered on optimized gene sets to visualize stratification of tumour subtype
and sensitivity. The SVM classifiers were validated using random gene iterations to determine the
significance of the classification accuracy, and patient data sets to ensure robustness of the
models derived.
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5.2.2 Cell Lines
Cell lines were composed of 10 basal, 9 claudin-low, 25 luminal, and 5 normal-like
subtypes. Cell lines were designated resistant, if their GI50 was <8.0 for paclitaxel and
<7.0 for gemcitabine, respectively. The threshold values for distinguishing sensitive from
resistant cell lines were based on median GI50s for each particular drug (7.99 and 7.13,
for paclitaxel and gemcitabine). Daemen et al. (2013) classified cell lines by comparing
mean GI50s. We used median GI50, which is not impacted to the same extent by outlier
cell lines.

5.2.3 Multiple Factor Analysis (MFA)
MFA was used to relate each cell line GI50 according to sets of genomic variables (41).
The 44 (gemcitabine) or 45 (paclitaxel) breast cancer cell lines (Appendix S5.1) were
treated as separate individuals. MFA was carried out with the R library “FactoMineR”
(42), with GI50s, gene expression, copy number, mutation status (if the gene contained 1
or more mutations), and 31 and 18 genes associated with paclitaxel and gemcitabine
activity, respectively, as input.

5.2.4 Support Vector Classification
A binary support vector machine (SVM) was trained with the Statistics Toolbox in
MATLAB (Natick, MA) using fitcsvm (linear kernel function) and then
tested with a leave-one-out cross-validation (using ‘crossval’ and ‘leaveout’
options). The SVM was trained on the cell lines and explanatory gene variables deemed
relevant from the MFA: expression data for the paclitaxel SVM, and copy number and
expression data for the gemcitabine SVM. The input data consisted of measurements
from all genes used in the MFA. Sequential backward feature selection was performed
for feature optimization (43) to minimize the percentage of misclassified cell lines
(classification error) returned from the leave-one-out cross validation (Appendix S5.6).
Genes that did not reduce or change the classification error were removed from the SVM
(one at a time). This procedure was iterated until further gene removal lead to a higher
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classification error (stopping criterion). By contrast with the SVM, a partial-least squares
regression was not effective in relating genomic findings to paclitaxel response
(Appendix S5.7).
The hinge loss was also determined for the subset of genes included in the final SVMs.
Hinge loss applies a linear penalty for misclassified data according to their distance from
the hyperplane. The loss function is represented by Equation 1 where yj = {-1,1} and
f(Xj) is the score, i.e. hyperplane distance, for cell line j:
𝐿 = max (0,1 − 𝑦𝑗 𝑓(𝑋𝑗 ))

(1)

5.2.5 Applying the cell line SVM to patient data
Formalin fixed, paraffin embedded (FFPE) tumour samples were obtained from the
Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy), from leftover material
available after diagnostic procedures in consented patients (44). Samples obtained were
from patients that were first treated with paclitaxel (or in a small number of cases
docetaxel) and carboplatin, and then subsequently gemcitabine, upon development of
resistance. Clinical information was available as to whether the patients responded to
each of the drugs (paclitaxel and gemcitabine). Tumour and control normal tissues were
analyzed for expression and copy number of SVM genes, respectively, by real-time
reverse-transcriptase polymerase chain reaction (qRT-PCR) and real time PCR (qPCR,
methods described in Appendix S5.8). The cell line-based SVM models were used to
predict patient sample drug responses in a blinded manner. Two SVM models were
trained for paclitaxel and gemcitabine: one using the normalized gene expression values,
and the other using expression values binned into 10 categories, using the Matlab
function: quantile(X,10). Binning was performed because amplifiable RNA template
concentration in FFPE blocks is not known precisely, because it is subject to long term
degradation and reactivity (45,46). Expression measurements were obtained for 11 genes
from the paclitaxel SVM, and 6 genes for the gemcitabine SVM. The SVM was trained
on the cell line data with these reduced gene sets. Predicted and actual responses were
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compared, and odds risk ratios (contingency analysis) were calculated (GraphPad Prism,
San Diego, California).
Patient data were also obtained from GEO Accession GSE25066, in which expression
levels of tumours that were treated with taxane and anthracycline chemotherapy were
reported (5). Expression levels for the paclitaxel SVM genes (except BMF and CSAG2,
which were not measured) were extracted for those patients treated with paclitaxel (n =
319). In cases with multiple probe sets per gene, expression levels were averaged. The
SVM predictions were then related to response to therapy and residual cancer burden
class for each patient.

5.2.6 Clustering cell lines and patients using expression values of the
SVM gene subsets
The unsupervised, hierarchical clustering function ‘clustergram’ in Matlab was used
to cluster cell lines and patient data (described in 2.5) according to gene expression
values included in the optimized SVM. Expression values were normalized by row so the
mean expression of each gene across individuals was 0, and the standard deviation was 1.
Clustering was performed by individuals and genes, and dendrograms are displayed for
each dimension that indicate relatedness based on their lengths and hierarchical
branching.

5.3 Results
5.3.1 Multiple Factor Analysis
MFAs were performed using GI50s of 49 cell lines, and genomic measurements of 31
and 18 genes related to paclitaxel and gemcitabine activity from an existing data set (7).
We re-confirmed measurements for a subset of the cell lines to ensure consistency
between cell line sources (see Appendix S5.9).

MFAs were assessed by statistics

generated by the program, FactoMineR (42). Relationships were stratified by the
correlation between the variable and GI50, the RV coefficient (a multivariate
generalization of the squared Pearson correlation coefficient), the position of variables on
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the correlation circle, and the representation quality of each variable group in the first two
dimensions (cos2 values). These criteria were used to classify each gene as having a
“strong relationship”, “relationship”, “possible relationship” or “no relationship” to GI50
(see Appendix S5.10 for the thresholds for each class). Examples of correlation circles
and individual factor maps for MAPT (paclitaxel) and DCTD (gemcitabine) are illustrated
in Appendix S5.11.
MFA revealed “strong relationships” between paclitaxel GI50 and copy number and/or
gene expression for 11 genes, consisting of both negative relationships (diminished copy
number and gene expression [-] for CYP2C8, CYP3A4, NR1I2 (previously known as
PXR), TLR6, and TUBB1) and positive relationships (increased copy number and gene
expression [+] for BBC3, BCL2L1, BMF, CNGA3, MAPT, and TUBB4B) with increased
chemoresistance (Appendix S5.12 lists all MFA measurements). The gemcitabine set
revealed strong associations between resistance and ABCB1 (+), DCTD (-), and SLC28A1
(+) gene expression as well as strong relationships for ABCC10 (+) and CDA (+) copy
number (Appendix S5.13). The MFA results for paclitaxel (gene expression results only)
and gemcitabine treatment (copy number and gene expression), in the respective pathway
contexts, are summarized in Figure 5.2.
Point mutation status was based on 74 deleterious coding mutations (Supplementary
Table 5.2) that were predicted to be damaging (47) or to affect mRNA splicing (48,49).
Point mutations predicted to be damaging demonstrated strong relationships in ABCB1 (n
= 4, in 2 cell lines) to paclitaxel resistance and in SLC28A3 (n = 3, in 2 cell lines) to
increased sensitivity to gemcitabine. The limited number of cell lines with mutations in
these genes cannot be effectively incorporated into machine learning models, and point
mutation results were not included in these analyses.

5.3.2 Support Vector Machine (SVM) Learning
A binary SVM was employed to develop a predictive multigene classification of genomic
signatures for resistance to these drugs (50). Based on MFA results, data types orthogonal
to GI50 were excluded from the SVM (see section 2.5 for details). The classification
error of the SVM model was minimized by removing genes, i.e. features, which did not
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Figure 5.2 Genes associated with paclitaxel (A) and gemcitabine (B) mechanism of action
(direct targets, metabolizing enzymes), genes previously associated with resistance, and
stable genes in the biological pathways targets. Genes with an asterisk (*) are stable genes
(Park et al., 2012). Genes highlighted in red showed a positive correlation (within dimension 1
and/or dimension 2) between gene expression or copy number, and resistance in the MFA,
whereas genes highlighted in blue demonstrated a negative correlation. Genes outlined in dark
grey are those included in the final predictive model that was derived using the SVM. Red Tshaped bars indicate the genes that paclitaxel directly binds/inhibits. Genes outlined in light grey
(ie. BAX/BAK) were not included in the analysis because they were not stable genes in the BCL2
pathway.
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improve accuracy by leave-one-out cross-validation (see section 2.5 for details). This
feature selection process is illustrated in Figure 5.3-I. The optimized SVM was then
trained, respectively, on 15 gene variables for paclitaxel (49 cell lines) and 10 variables
for gemcitabine (44 cell lines). Gene expression values from ABCC10, BCL2, BCL2L1,
BIRC5, BMF, FGF2, FN1, MAP4, MAPT, NFKB2, SLCO1B3, TLR6, TMEM243,
TWIST1, and CSAG2 comprised the final set of features used to train the SVM for
classification of paclitaxel sensitivity. For gemcitabine, both gene expression values
(from ABCB1, ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B) and copy number data
(from ABCC10, NT5C, TYMS) were used in the final SVM. The distance of each cell line
value from the SVM hyperplane that distinguishes the degree of sensitivity or resistance
was plotted against the corresponding GI50 (Appendix S5.14). The trained SVMs
misclassified 9 of 49 (18%) cell lines for paclitaxel and 7 of 44 (16%) for gemcitabine,
which is comparable to, or more accurate than other approaches (51). Partitioning by
histological subtype did not improve the classification accuracy; a single variable SVM
model based on subtype misclassified 30% of cell lines for paclitaxel and 45% for
gemcitabine (Appendix S5.15). The feature-optimized SVM outperformed the signature
derived from the initial set of genes, which misclassified resistance/sensitivity of 36% of
cell lines for paclitaxel and 64% for gemcitabine treatments. In addition, multi-gene MFA
analyses of the final SVM gene sets demonstrate that the individual factor maps of the
resistant and sensitive cell lines segregate to a greater degree than MFAs based on the
initial gene sets, which were indistinguishable (Appendix S5.16). These differences were
larger for gemcitabine than paclitaxel.
To assess the individual impacts of a gene on SVM accuracy, each gene remaining in the
optimized SVM was removed, and the misclassification rate was redetermined (Figure
5.3A-II). BCL2L1 and MAPT had the highest predictive value for paclitaxel sensitivity,
with misclassification rates of 36% and 34%, respectively, when eliminated (compared to
21-30% for the other genes). It is notable that the MFA also showed strong associations
with decreasing MAPT or BLC2L1 expression and increasing paclitaxel sensitivity.
BCL2L1 is a member of the Bcl-2 family and is involved in regulation of apoptosis (16).
Additional apoptotic regulators, such as BMF and BCL2, also appear in our SVM results,
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Figure 5.3 Effect of the removal of each gene on the percent of cell lines misclassified
during the SVM feature selection process to determine the most predictive gene set (left
panels AI and BI). The right panels (AII and BII) demonstrate the increase in the percent of cell
lines misclassified when the expression of genes in the inferred, optimal gene set are
subsequently eliminated from the SVM.
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as paclitaxel is known to trigger apoptosis through these pathways (52). The loss of
MAPT in breast cancer cells has been shown to sensitize those cells to the action of
paclitaxel (53), which is supported by our analysis.
For gemcitabine, removing NT5C copy number, NME1 gene expression, ABCC10 gene
expression, and RRM2B gene expression had the largest effects, by respectively
increasing misclassification rates to 34%, 32%, 32%, and 30% (Figure 5.3B-II). NT5C is
located on 17q25.1 a region associated with cancer (54). Allelic imbalances in TYMS
have previously been hypothesized to be involved in drug resistance in renal cell
carcinoma (55) and ABCC10 has been associated with drug resistance (56). NME1 is a
known metastasis suppressor gene which may have great prognostic value (57). RRM2B
and RRM1 have been suggested to be associated with gemcitabine resistance (58) and
have been shown to be overexpressed in a gemcitabine-resistant pancreatic cancer cell
line (59).

5.3.3 Applying the cell line-trained SVM to patient data
Formalin fixed paraffin embedded (FFPE) tissue blocks were obtained from patients that
were treated with paclitaxel and gemcitabine, and whose responses to both drugs are
known. Gene expression measurements for 11 genes from the paclitaxel SVM, and gene
expression (6 genes) and copy number (CN; 3 genes) from the gemcitabine SVM were
obtained using qRT-PCR and qPCR (Supplementary Tables 5.3 and 5.4). Gene
expression measurements were not obtained for BMF, CSAG2, SLCO1B3, TWIST1
(paclitaxel), and ABCB1 (gemcitabine), as no amplification was observed in these
samples by 40 cycles. The absence of amplification in these genes was related to their
low levels of expression in breast cancer tissue (Appendix S5.17.1). In cases where qRTPCR showed no amplification for a specific sample out of the genes measured, the
highest cycle run was used as the Ct value for that gene. Older samples, on average, had
lower numbers of genes with successful measurements (Appendix S5.17.2).
An SVM was trained using the cell line data with a reduced set of 11 (paclitaxel –
ABCC10, BCL2, BCL2L1, BIRC5, FGF2, FN1, MAP4, MAPT, NFKB2, TLR6, and
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TMEM243) and 9 (gemcitabine – ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B,
ABCC10-CN, NT5C-CN, and TYSM-CN) gene values, which corresponded to the
measurements obtained from the FFPE tissue block studies. These SVMs were then
applied to the FFPE tissue sample data to predict their sensitivity to paclitaxel and
gemcitabine (see Supplementary Table 5.5 for full FFPE sample predictions). The
paclitaxel SVM predicted drug sensitivity with 71% accuracy (Table 5.1), which was
similar to a leave-one-out analysis on the cell line data, which classified cell lines with
70.2% accuracy (using the reduced 11-gene subset). Patients who were treated with
docetaxel were excluded from this summary because the trained SVM only predicted cell
line response to docetaxel with 57% accuracy (misclassified 19/44, based on GI50s).
Docetaxel and paclitaxel GI50s for all cell lines were correlated only to a limited extent
(R2 = 0.722), consistent with the possibility that there might potentially be differences in
mechanisms of drug metabolism and resistance between these drugs. The gemcitabine
SVM did not perform as well on the patient sample data as it did on the cell line leaveone-out analysis, which was 79.6% accurate (using the reduced 9-gene subset). The
gemcitabine SVM derived using binned expression values predicted patient response with
62% accuracy, however, 72% accuracy was achieved for samples with gene expression
measurements available for at least 4 of the 6 genes.
Although DNA variants were not incorporated into the SVM models, we sequenced a
subset of the FFPE samples to determine whether any potentially damaging mutations
were present in paclitaxel/gemcitabine genes of interest, especially for genes that showed
relationships between mutations and drug sensitivity in the MFA (Appendix S5.12 &
S5.13). Native DNA from 8 samples (all tumours) and whole genome amplified (WGA)
DNA from 16 samples (9 tumour and 7 matched normal tissue) were used for next
generation sequencing that enriched for the genes of interest. WGA was required for 16
samples, because the amount of DNA extracted from the samples was not a sufficient
starting quantity for the sequencing protocols used. Despite the fact that the samples had
been qualified by PCR amplification from exons of several genes (including BRCA1 and
BRCA2), attempts to prepare NGS libraries for 2 of the original DNA samples were
unsuccessful, presumably due to accumulated DNA damage during formaldehyde
treatment and storage of the sample. Since spectrophotometric measurements indicated
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Table 5.1 Using the SVM to predict patient response from archived FFPE tissue
Paclitaxel

Gemcitabine

NORM

10 bins

No. of accurate predictions

12

Total

17*

Percent accurate
Odds Ratio
P-value^

NORM

10 bins

12

9

13

17

21

21

71%

71%

43%

62%

5.83

6.00

3.00

3.33

0.1534

0.1534

0.5333

0.3615

*4 patients were treated with docetaxel instead of paclitaxel, and were not included in this
summary. ^Fisher's exact test. Gene expression values were either normalized (NORM) or
binned into 10 categories (10 bins), as described in the methods. Please refer to Supplementary
Table 5.5 for all FFPE clinical response/prediction data and the values used for binning.
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that DNA was present in nearly all samples, WGA was used to recover the fraction of
intact DNA present in the isolates that did not yield libraries by conventional procedures.
The full methods used are described in Appendix S5.5.3, and the RNA sequences used
for targeted DNA gene capture are listed in Supplementary Table 5.6.
DNA sequencing coverage was variable beween samples, ranging from 7-31 reads per
base pair for the original DNA, and between 0-139 for the WGA DNA. DNA variants
were detected in five of the original DNA samples (each with 6, 32, 46, 8, and 32
variants) and three of the WGA DNA samples (each with one variant). Of the variants
residing in paclitaxel and gemcitabine genes of interest, 12 were predicted to be
damaging (47) (two were novel with average heterozygosity <1% and 10 were known
SNPs), and the remainder were predicted to be “tolerated” (4 novel, 108 known SNPs,
see Supplementary Table 5.7 for full mutation list). There were very few (ie. 1 or none)
variants detected in the WGA samples because these samples did not have uniform
coverage throughout targeted genes. There was significant bias in the WGA DNA
sequencing, where there were few regions with very high coverage (ie. as high as 4000
reads per bp), and the majority of regions with no coverage (Figure 5.4 – B/C). This was
not the case with the original DNA samples that were sequenced, as coverage was more
uniformly distributed among the genes of interest. This mirrors what we found in the
gene expression experiments, where measurements were not obtained for every sample in
every gene, suggesting that there are regions of the FFPE template DNA that are more
difficult to amplify than others. In total, 5 (22%) out of 22 samples had acceptable,
uniform coverage, which is in line with a previous study that found ~18% of FFPE
samples pass quality control for subsequent next generation sequencing (81).
Ultimately, only 4 samples harbored potentially damaging mutations (47), including
samples from patients 2 (in SLC28A1, two in MAP4, and RRM2B), 6 (in NFKB2), 8
(ABCC1, SLC28A1, and RRM2B), and 24 (three in MAPT and BAD). Of these genes,
ABCC1 mutations were associated with increased sensitivity to paclitaxel in the MFA
(Appendix S5.12), and RRM2B mutations were associated with resistance (Appendix
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[0-116]

A) OR.

B) WGA1

[0-36]

C) WGA2

[0-4317]

Figure 5.4 Coverage and reads from sequencing of three FFPE tumour samples using
originally extracted (A) and whole genome amplified (B/C) DNA.

An IGV screen shot

covering a 25 kb portion of FN1 (gene displayed at the bottom in blue shows exons [thick bars]
and introns [thin bars]) on chromosome 2 (specific band is indicated by the red bar in the top
chromosome diagram). Coverage values for A-C are indicted in the top panel by the grey peaks,
with the scale in square brackets on the right hand side. DNA sequencing reads are individually
displayed as grey (and other colour) bars in the bottom panels of A-C.
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S5.13). This corresponds with our patient response data: sample 2B was a gemcitabine
non-responder and sample 8C initially responded to paclitaxel (and then subsequently
developed resistance), and was resistant to gemcitabine. Although mutation data are a
sparse data source that is not easily modeled by SVMs, it appears that mutations on an
individual basis may provide insight into tumour response to paclitaxel or gemcitabine.
Gene expression measurements and clinical data were also obtained for 319 patient
samples who were treated with paclitaxel and anthracycline chemotherapy (5). Gene
expression data were not available for two genes from the paclitaxel SVM (BMF and
CSAG2), which were two of the 4 genes that could not be measured in the FFPE samples.
Consequently, the same 11-gene SVM used for the FFPE samples was applied to the data
from Hatzis et al. (2011). SVM predictions were compared with the clinical outcome whether the patient had recurrent disease (RD) or complete pathological response (pCR,
see Table 5.2 for a summary, and Supplementary Table 5.8 for all predictions). The SVM
predicted sensitivity in 52 of the 63 patients (84%) that showed pCR. All patients that
showed complete pathological response exhibited no or minimal residual disease
(residual cancer burden [RCB] class 0/1 (60), although some patients within this subset
did not respond to therapy. This group of patients (RCB 0/1) may derive the greatest
benefit from the paclitaxel SVM analysis. The SVM did not perform as well in predicting
resistance, miscategorizing 135 patients of the 257 with RD (52.5%) as sensitive.
However, performance of the SVM exceeded that of the 512-gene signature described in
Hatzis et al. (2011) for both sensitive and resistant patients. The odds ratio of the 11-gene
SVM was 4.484 (Fisher’s exact test, p<0.0001), compared to the odds ratio of 3.181 of
the predictive signature described in that study (Fisher’s exact test, p<0.0001).

5.3.4 Clustering cell line and patient data based on SVM gene
subsets
Two distinct groups emerge from unsupervised clustering using the SVM gene set for
paclitaxel in the cell line data (Figure 5.5A). The left cluster (highlighted in light grey)
corresponds with the luminal subtype, and the right corresponds to a mix of basal,
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Table 5.2 SVM predictions on 319 patients treated with paclitaxel from Hatzis et al. (2011)

Cell Line 11-gene SVM
RD
pCR
ALL RCB Classes
Predicted Insensitive
Predicted Sensitive
Odds Ratio
P-value^
RCB Class 0/1 Only
Predicted Insensitive
Predicted Sensitive
Odds Ratio
P-value^

119
138

10
52

Hatzis "Rx" Prediction
RD
pCR
186
71

4.484
<0.0001

28
34
3.181
<0.0001

11
19
3.011
0.0359

10
52

10
20

28
34
0.6071
0.3673

RD = recurrent disease (designated "insensitive" patient response), pCR = pathological complete
response (designated as "sensitive" patient response), RCB = residual class burden (as
described in Symmans et al. 2007). ^ p-values were determined using a Fisher's exact test.
Please refer to Supplementary Table 5.8 for all predictions and patient information.
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Figure 5.5 Expression heatmap of the paclitaxel and gemcitabine SVM derived genes for
the tested cell lines. Each row represents a gene and each column a cell line. Red indicates
higher expression and blue represents lower expression, as shown by the colour bar on the left.
‘Resistant’ cell lines are coloured grey and ‘sensitive’ cell lines are coloured white in the row
labeled ‘response’. Cell lines are labeled by subtype and copy number according to the legends.
Clustering was done based on the similarity of each cell line’s expression profile in the 1st
(column) dimension and each gene's expression profile in the 2nd (row) dimension. The
dendrograms on the top and left indicate the relatedness of each cell line and gene by the length
and subdivision of the branches, with deeper branches indicating a stronger relationship and
branches in the same 'tree' being more closely related to each other than data in other 'trees‘. A)
A section of the dendrogram for paclitaxel is shaded grey to indicate a cluster composed entirely
of luminal cell lines and a higher proportion of resistant cell lines. The other section is white to
indicate a cluster with very few luminal cell lines and a higher proportion of sensitive cell lines. B)
A section of the dendrogram for gemcitabine is shaded grey to indicate a cluster composed of a
higher proportion of resistant cell lines. The other section is white to indicate a cluster with a
higher proportion of sensitive cell lines.
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claudin-low, and normal-like subtypes. The proportions of resistant (71% of the left
cluster) vs. sensitive (58% of the right cluster) cell lines are not statistically significant
(2 = 3.67, 1 degree of freedom, p = 0.056). Cell lines clustered using the gemcitabine
SVM gene expression values display at least two distinct clusters that do not correspond
to any subtype(s), but, stratify according to gemcitabine sensitivity (73%; left) or
resistance (69%; right) (Figure 5.5B, chi-statistic = 10.75, p = 0.001, d.f. =1). Clustering
of the FFPE derived samples was not as strong as a consequence of limited sample
numbers and lack of expression measurements for every gene in every sample (Appendix
S5.18.1). Nevertheless, clustering of expression in these samples mirrored the cell line
data based on results for MAPT and BCL2 (for paclitaxel) and DCTD (for gemcitabine).
Unsupervised clustering of expression data from Hatzis et al. (2011), using the paclitaxel
SVM distinguished patients according to the proportions of those free of distant relapse
(Figure 5.6 and Appendix S5.18.2). These clusters are partially distinguished by MAPT
and BCL2 expression (Figure 5.6A, the “low MAPT” cluster is indicated in purple, “high
MAPT” in green). MAPT and BCL2 are both components of the PAM50 Breast Cancer
Intrinsic Classifier. Their expression patterns segregate into luminal and basal subtypes to
a large extent. Low MAPT expressing luminal subtypes were observed to have
significantly worse prognoses than higher MAPT expressing luminal tumours in the
patient dataset (p<0.05, Appendix S5.19). The gene signature described by Hatzis et al.
(2011) predicted treatment “sensitivity” and “insensitivity” accurately within the low
MAPT cluster, where “sensitive” patients exhibit significantly longer times to distant
relapse (Figure 5.6C, p = 0.0013, log rank test). However, this was not the case for the
high MAPT cluster, as the proportion free of distant relapse between two predicted groups
did not differ significantly (p = 0.10, log-rank test).

5.3.5 Significance of SVM classification accuracy
To assess the significance of the derived SVM, we selected 100,000 random sets of 15
genes from a set of expression values (to compare to the paclitaxel SVM) and 10 genes
from a set of copy number and expression values (gemcitabine SVM) for 23,030 genes.
Only 0.14% of paclitaxel and 0.01% of gemcitabine random gene combinations exceeded
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Figure 5.6 A) Expression heatmap of the paclitaxel SVM derived genes for 319 tumour
samples (Hatzis et al. 2011). See Figure 5.5 for heat map labeling and diagram details. A
section of the dendrogram on the top is shaded purple to indicate a cluster of tumours (83%
luminal) with a significantly worse outcome assessed by the proportion free of distant relapse
curves (shown in B). Another section is shaded green (63% basal) with significantly better
outcomes. The cluster shaded gray (22% basal, 53% luminal) can be clustered independently
with similar stratification by subtype and outcome (Supplemental Information VI). C) The Hatzis et
al. (2011) gene signature performs very well in the purple cluster and poorly in the green, based
on the Kaplan-Meier curves constructed on each subset using their published labels ("insensitive"
and "sensitive").
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Figure 5.7 The proportion of misclassified cell lines (A/C) and hinge loss scores (B/D) were
measured on SVMs derived using randomly selected gene sets. 15-gene (to compare to the
paclitaxel SVM, A/B) or 10-gene (to compare to the gemcitabine SVM, C/D) values were
randomly selected from an initial set of 23,030 genes and used to derive SVMs. The performance
of 100,000 iterations of the random signatures are plotted in the above histograms. The hinge
loss scores for the paclitaxel and gemcitabine final SVM gene subsets lie in the lowest 2nd
(paclitaxel, z-score -2.0, p < 0.05 one-sided) and 1st percentiles (gemcitabine, z = -2.16, p <
0.05) of the data. Expression alone was used for the 15-gene sets (A/B). Copy number and
expression were used for the 10-gene sets (C/D). The red arrow-heads indicate where the
optimized paclitaxel and gemcitabine SVM gene signatures are found in the distribution.
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the classification accuracy of the derived SVMs. (Figure 5.7 – A/C). The hinge loss,
which increases based on the misclassified object’s distance to the hyperplane, was 0.64
for the paclitaxel SVM and 0.66 for the gemcitabine SVM (optimal is close to zero).
Among the random gene combinations, the likelihood of deriving SVMs with equal or
lower scores was 1.45% and 0.83% for paclitaxel and gemcitabine, respectively (Figure
5.7 – B/D). Thus, the accuracy of the SVMs achieved for both drugs were not likely due
to random chance (p<0.05 in all cases, Table 5.3).
Nearly all of the high performance random gene set combinations appear to be statistical
artifacts. Analysis of 10,000 random gene selections found 18 combinations with lower
paclitaxel misclassification response rates. All 18 signatures were unique (2 transcripts
occurred twice) and transcript combinations were dominated (24%) by alternative splice
variants and expressed pseudogenes. None of the random gene combinations were
significantly associated with known biological pathways. Six of the random signatures
contained ≥ 10 gene expression values in the patient data. None of these signatures
predicted paclitaxel sensitivity, except one set containing WWP1, which has previously
been suggested to be a prognostic indicator in breast cancer (61). This signature (and one
based on WWP1 expression alone) predicted more patients (5) to be sensitive to
paclitaxel than our derived SVM. Similar numbers of patients predicted to be sensitive by
both SVM models exhibited complete remission (52 vs. 55), however the WWP1-based
SVM predicted sensitivity in a greater number of non-responders (n = 178) than our
derived SVM (n= 138) and misclassified 41% of the cell lines. For the gemcitabine
response, the SVM of a single random gene set had a lower misclassification rate than
our derived SVM. The genes in this set were unrelated to gemcitabine metabolism, with 9
of 10 SVM variables exhibiting copy number changes, two of which involved non-coding
RNA genes.

5.3.6 Translation of signature to other cancer types
To mitigate tissue-specific effects, we rederived SVM models specific to lung cancer
(lung) and hematopoietic and lymphoid tissue cancer (hematopoietic) cell lines using
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Table 5.3 SVM performance using randomly selected genes based off 100,000 iterations

minimum maximum average

standard
deviation

drug
SVM

z-score

p-value

No. random SVMs
≤ drug SVMs1

percent misclassification of cell lines in leave-one-out analysis
15-gene2

12.2%

83.7%

42.7%

8.8%

18.4%

-2.78

0.0027

141

10-gene3

12.2%

90.2%

48.0%

10.5%

15.9%

-3.06

0.0011

10

hinge loss score
15-gene

0.39

1.66

0.93

0.14

0.64

-2.04

0.0207

1,453

10-gene

0.30

2.02

1.05

0.18

0.66

-2.16

0.0153

826

Misclassification rates and hinge loss scores were determined from SVMs derived using 100,000 random combinations of gene expression and
copy number values from 23,0303 genes. The minimum, maximum, average, and standard deviations of each 100,000 iterations were determined,
1

and compared to the paclitaxel and gemcitabine SVMs ("drug SVM"). the number of random gene combinations with equal or lower
2

misclassification rates or hinge loss scores compared to the drug SVMs, random selection of 15 gene expression values were compared to the
3

paclitaxel SVM, random selection of 10 gene expression or copy number values were compared to the gemcitabine SVM.
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expression

data

from

the

broad

institute

“CCLE_Expression_2012-09-29.res”

(www.broadinstitute.org/ccle/home;
and

“CCLE_NP24.2009_profiling_2012.02.20.csv”). Lung and hematopoietic tissue types
were chosen because they contained the highest number of cell lines with expression and
paclitaxel GI50s. The final lung SVM contained 14 genes, and classified cell lines with
72% accuracy (Appendix S5.20.1). The final hematopoietic SVM was composed of 8
genes, and classified cell lines with 75% accuracy (Appendix S5.20.2). Four genes were
present in all three (breast, lung and hematopoietic) cancer cell line SVMs (BMF, FGF2,
TMEM243, and TWIST1), and 8 genes were eliminated from all of the SVMs (ABCB11,
BBC3, CNGA3, CYP2C8, CYP3A4, NR1I2, TUBB4A, and TUBB4B; Appendix S5.20.3).
MFAs using the Lung and Hematopoietic SVM gene sets do not show the same degree of
segregation between resistant and sensitive cell lines as the breast SVM (Appendix
S5.20.4 & S5.20.5).

5.4 Discussion
This paper describes the development of genomic signatures using support vector
machines that can predict breast cancer tumour response to paclitaxel and gemcitabine.
We used a biologically-driven approach to identify a meaningful group of genes whose
expression levels and copy number may be useful in guiding selection of specific
chemotherapy agents during patient treatment. Previous studies have derived associations
between the genomic status of one or more genes and tumour response to certain
therapies (5,51,62-65). Correlations between single gene expression and tumour
resistance (32,62) do not take into account multiple mechanisms of resistance or assess
interactions between multiple genes. ABC transporter overexpression has long been
shown to confer resistance, but enzymatic or functional inhibition has not substantially
improved patient response to chemotherapy (66).
Multi-gene analytical approaches have previously been successful in deriving prognostic
gene signatures for metastatic risk stratification (Oncotype DXTM, MammaPrint®),
subtypes (PAM50), and efforts to predict chemotherapy resistance (67). Given the
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complexity of genomic changes and the fundamental biological differences among the
intrinsic subtypes of breast cancer (68,69), this approach has advantages over analysis of
isolated genes. Reasonable gene signatures associated with breast cancer outcome can be
obtained by chance alone (70), however our results show that such signatures are
especially rare. Gene signatures derived without reference to the underlying mechanisms
of chemotherapy response do not capture meaningful biological results (71).
Our approach started with a focused biologically-relevant initial gene set, rather than
taking a genome-wide approach. The derived signatures were demonstrated to
significantly outperform random selected combinations of genes in prediction of
sensitivity and resistance. The random gene sets may be statistical artifacts, as they were
not enriched for any biological relevant pathways, and included expressed pseudogenes.
The compositions of these other gene sets were distinct from the set used to derive the
SVM and another 20-gene signature for taxane sensitivity (6).
Our analysis highlights the importance of the expression of genes encoding microtubuleassociated proteins and apoptotic regulators in paclitaxel resistance (17,72,73). MAPT
expression was significantly correlated with drug resistance, and both MAPT and MAP4
were components of the optimized paclitaxel SVM gene set. In clustering analysis of both
cell lines and patients, MAPT was differentially expressed between tumour clusters
stratified by subtype and outcome (Figures 5.5 and 5.6). Our results confirm that
apoptosis-related proteins, particularly BCL2L1, but also BCL2, BMF, and BIRC5,
contribute to paclitaxel sensitivity (74). BCL2L1, BCL2 and BMF were found to be stable
in breast cancer tumours, reinforcing the notion that alterations in stable genes contribute
to drug resistance (14). Supplementary Table 5.9 describes genes analyzed in the context
of their biological pathways and relevant literature.
The gemcitabine metabolic pathway has been well characterized (75), however the
critical genes have not been treated as an ensemble in conferring resistance (see
Supplementary Table 5.10 for interpretation of the MFA results for all genes). The MFA
analyses indicated gemcitabine genes predominately contribute to drug resistance through
overexpression. For DCTD, however, underexpression is associated with increased
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resistance in the MFA analysis. DCTD deficiency causes an imbalance in the dNTP pool
(76), which affects control of DNA replication. DCTD is inhibited by dFdCTP (a
gemcitabine metabolite) through a mechanism by which gemcitabine exhibits selfpotentiation (the reduction of competing natural metabolites) (77). Lower DCTD
expression and as a consequence, activity would reduce gemcitabine self-potentiation by
altering the dNTP pool. This state is related to drug resistance, which was noticeably
lower in 4 cell lines with increased resistance (HCC1187, HCC1428, HCC202, and
MDAMB134VI). Like DCTD, CDA also catalyzes the conversion of gemcitabine
monophosphate to difluorodeoxyuridine monophosphate (Figure 5.2B), and accounts for
90% of this conversion in the cell (37). However, drug resistance was associated with
CDA overexpression. Likewise, the ribonucleotide reductase subunits RRM1 and RRM2B
make significant contributions to the gemcitabine SVM. The RRM1-RRM2B complex is
associated with mitochondrial genomic integrity (78) and RRM2B is necessary for
nucleotide synthesis in DNA repair (79). Changes in RRM2B expression could be
associated with mitochondrial dysfunction, or may result from loss of p53 expression,
which usually induces RRM2B expression (80).
The 11-gene paclitaxel SVM was able to classify FFPE patient samples we obtained and
measured in our lab with similar accuracy to that of the cell lines. In addition, the same
SVM model was able to predict complete pathological response on a second patient data
set, with greater accuracy than the originally reported gene signature (5). The SVM
performed particularly well for predicting drug-sensitive tumours with low or no minimal
residual disease (Table 5.2). The SVM gene signature proved to be resilient as a
diagnostic marker, as the performance was not compromised by the lack of expression
data for 4 genes.
Unlike paclitaxel, gemcitabine was not used to treat patients in the study by Hatzis et al.
(2011) or other publically available data sets. The SVM analysis on RNA expression and
DNA copy number from the FFPE-derived tumour punches appeared to predict response
more accurately when expression values were obtained for most of the genes in the SVM.
Obtaining high quality gene expression measurements from FFPE samples was especially
difficult from older tissue blocks (Appendix S5.17.2) as previously noted (81).
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Consequently, the SVM analysis may be better suited for fresh-frozen tumour tissue or
more sensitive gene expression analyses (such as mRNA sequencing). Missing data
appeared to impact the gemcitabine SVM to a greater extent than the paclitaxel SVM,
which may be due to the smaller number of gene measurements required for this SVM.
Including gene expression subtype in the SVM did not improve the classification
accuracy even though subtype is known to contribute to tumour biology (11). However,
the two paclitaxel PAM50 genes (MAPT and BCL2) partially stratify the cell lines by
subtype during unsupervised clustering (Figure 5.6). This is not the case in the
gemcitabine gene set. In patient data, clustering by expression of the SVM genes also
revealed statistically significant deterioration in outcome for low MAPT expressing
luminal tumours (Appendix S5.19).
Machine learning may be a fruitful approach in the selection of other chemotherapy
agents. Translating our results to the assessment of human tumour samples (4) confirmed
our gene signature's relevance to predicting chemoresistance by SVM. A limitation of our
work is that both SVMs were not integrated because cell lines were only treated with
individual drugs, so predicting whether patient response to these drug interactions will be
synergistic or antagonistic is not currently possible. In addition, while point mutations are
well known contributors to chemoresistance of other drugs, this approach – for either
SVM training or testing - is not conducive for prediction of chemosensitivity given the
sparse number of observations for these types of mutations.
In cases without residual disease, the paclitaxel SVM was particularly effective in
predicting which tumours would show complete pathological response. Docetaxel is
prescribed somewhat interchangeably (5,82,83) and both paclitaxel and docetaxel act
through similar biological pathways (84). However the performance of the paclitaxel
SVM on patients treated with docetaxel was reduced. This SVM contains 8 paclitaxel
resistance genes. Predictions of docetaxel sensitivity might be improved by rederiving a
specific SVM using taxane pathway genes (84), and those known to be associated with
resistance to doclitaxel (such as CYP1B1 (85,56), miR-141 or EIF4E (87), DKK3 (88),
ABCB1 (89,90), BIRC5 (91), ABCC10 (92), miR-452 (93), and PAWR (94)). The
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approach that we have introduced could aid in rational selection of other therapeutic
regimens that evade or at least minimize the effects of chemoresistance.
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Chapter 6
6

Contextual Insights of Findings in this Dissertation

It is estimated that in Canada, almost 24,000 deaths due to female breast cancer have
been avoided since the mortality rate peaked in 1986 (1). Since then, the age-standardized
mortality rate has fallen 43%, due to an increase in breast cancer screening and
advancements in breast cancer treatment (1). The discoveries of the intrinsic subtypes of
breast cancer and prognostic transcript profiles using gene expression microarrays have
been instrumental in making breast cancer patient management to be more individualized.
The ongoing advancements and reduction in cost of genomic technologies now provide
even further opportunity to personalize breast cancer care. However, there are still gaps
in genomic experiments, both in experimental design and interpretation of the data. In
addition, there are currently no personalized genomic indicators for managing
chemotherapy regimes that take into account drug resistance for breast cancer patients.
The field has, and will, benefit from methods to improve upon current genomic analyses
that detect cardinal abnormalities in driver genes, and predict metastatic progression and
chemotherapy response. This thesis describes improvements for data quality and analysis
for existing genomic technologies, with the aim of detecting and interpreting genomic
abnormalities relevant to breast cancer metastasis and chemotherapy resistance.

6.1 Current limitations of genomic technology
Genome-wide assays, such as microarrays and next generation sequencing, have greatly
improved our understanding of both normal and tumour genomes. The large amount of
data generated from these experiments, however, creates new sets of challenges to ensure
reproducible measurements, robust analyses, and meaningful interpretations.
The issue of low reproducibility, both between and within technology platforms, has not
been fully resolved in genome-wide analyses (2-5) (Section 2.1 describes the variability
observed in aCGH experiments in further detail). This is not surprising, because FISH,
microarrays, and next generation sequencing all rely on the same stochastic events:
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nucleic acid extraction, fragmentation, labeling, and hybridization. A recent study
assessing replicate next generation sequencing experiments demonstrated concordant
rates in single nucleotide variant calling ranged between 54-76% (4). In addition, batch
effects occurring from laboratory-specific conditions can create major problems if the
batch effect results in incorrect conclusions (6). Improving the reproducibility of these
technologies has usually involved increasing the number of measurements obtained in a
given experiment, whether through expanding the number of probes on a single
microarray slide, or increasing the number of reads obtained from a sequencing
experiment. However, genomic experiments are subject to both technical (i.e.
experimental procedure) and biological (i.e. genetic) variation (7). Tumour heterogeneity
makes the analysis of breast cancer particularly complicated (8). For this reason, singlecell genomic analyses (9) have been applied to cancer research (10,11). This thesis did
not address biological variation to the same extent as technical variation, although it is
nevertheless an extremely important aspect of tumour biology research.
With the abundance of different technology platforms, generated data, and computer
software programs available, establishing robust genomic analysis pipelines remains
challenging. This is true for both microarray and next generation sequencing analyses of
DNA or RNA. For clinical applications, working groups, such as the American College
of Medical Genetics (ACMG), have developed thorough guidelines for such analyses
(12-14). For example, recommendations involving next generation sequencing for
primary (production of sequence reads and assignment of base quality scores (12,15)),
and secondary/tertiary (variant calling and interpretation (14,16)) analyses have been well
documented. However, the main objective for clinical analysis (and the guidelines
created) is to accurately report genomic variants that are likely relevant to a patient’s
diagnosis or health. This differs from research groups, who can tolerate greater difficulty
interpreting the data and variants of unknown significance in exchange for more
comprehensive results. There are numerous programs that can be used to discover and
interpret data (Table 1.3), and this list is steadily increasing. Regardless, there is still an
underrepresentation of non-coding variants in published genomic studies, such as indepth splicing mutation analyses outlined in this thesis (Chapters 3 and 4). The
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emergence of new software to predict or interpret non-coding variants (17-19) indicates
the field is still working towards filling these gaps in current genomic analyses.
Interpreting DNA variants, how they affect cellular functions, and whether they are
causing a certain phenoytype is still extremely difficult. Recent evidence presented in this
thesis (Chapter 4) and others (20-24) show there is no single cause or set of abnormalities
that account for these phenotypes. It is well thought that the interpretation of sequencing
data from a full genome is now a much larger task than generating the data itself (25).
Large data repositories, such as the International HapMap Project (26) and dbSNP (27),
begin to allow us to understand which DNA variants are common among the population,
and which variants are rare and potentially pathogenic. However, given the size of the
human genome, the majority of variants observed in a given sample will be novel.
Programs like SIFT (28) and PolyPhen (29) are able to provide some indication as to
whether a mutation will be damaging to the protein’s function, but have extremely low
specificity (30). The genomic field will still greatly benefit from new programs to
validate the predicted effects of a mutation on a genome-wide scale.

6.2 Advances in genomic technology described in this
thesis
6.2.1 Fluorescence in-situ hybridization
FISH probes typically span a large genomic region along the chromosome, well beyond
the length of a single gene. They have been very useful in delineating large pathogenic
chromosomal aberrations, and have played an instrumental role in early gene and disease
discovery. With the introduction of chromosomal microarrays, however, our ability to
detect much smaller rearrangements has improved. In many cases, clinically significant
findings from these high-resolution microarrays will require assays to confirm the
suspected copy number change. Using ab initio-derived single copy intervals from the
human genome sequence, high-resolution FISH probes were designed and validated for
probes of small cancer genes. These FISH probes are small, usually less than 4 kb, and
the exact genomic location of the probes is known. Further, we have automated the
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design process, and have developed >450,000 primer pairs covering regions overlapping
genes that could be developed into single copy probes. The advantages of this technology
are that it can assess parts of genes and at small single copy regions that are embedded in
highly repetitive regions. As with most methods involving nucleic acid hybridization,
developing scFISH probes directly in highly conserved repetitive regions is not possible.
However, scFISH probes have been used to delineate breakpoints within segmental
duplicons (31) and telomeric regions (32). Although the scFISH probes are reproducible,
the fluorescent signal is not as intense as traditional BAC probes, which recognize a
much larger target on the chromosome. Developing probes with increased signal
intensities could allow for easier analysis of interphase cells, as the ab initio probes
developed in this thesis were only validated on metaphase chromosomes.
Although there are cases where genome-wide analysis is more suitable, FISH is a reliable
and inexpensive method to assess specific genomic regions. Future work could include
validating probes for specific actionable or clinically significant genomic alterations in
oncology (Table 6.1), which would require the development of scFISH on solid tumour
FFPE samples. scFISH probes are especially useful for cancer types in which
chromosomal microarrays are not routinely used or effective (i.e. balanced translocations
(32)). For example, it is now evident that tumours with HER2 amplification, in addition
to breast cancer for which it was originally developed, benefit from HER2 targeted
therapies (such as trastuzumab) (33). The ERBB2/HER2 scFISH probe could be used as
an inexpensive method to determine whether amplification is present in a tumour.

6.2.2 Chromosomal Microarrays
Chromosomal microarrays have been instrumental in advancing the evaluation of patients
with constitutional abnormalities, and are now accepted as a first tier diagnostic test for
patients with developmental delay, intellectual disability, congenital anomalies, and
autism (34). However, using genome-wide approaches to detect copy number changes
raises new limitations and regulatory challenges for clinical testing. There are still
difficulties associated with accurately measuring copy number gains or losses, and the
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Table 6.1 Examples of clinically significant genomic alterations in cancer testable by FISH.
Gene

Cancer type

Aberration

Clinical significance

APC

gastric

Decreased copy

Significantly associated with lymph node

number/deletion

invasion and metastasis

Gene amplification

Higher chance of success for treatment

HER2

breast, gastric
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with HER2 monoclonal antibody (ie.
trastuzumab)
EGFR

colorectal

Increased copy number

33,36

Higher chance of success for treatment
with antiEGFR monocolonal antibody (ie.
cetuximab and panitumumab)

EGFR

non-small-cell

Increased copy number

lung
MET

squamous

Higher chance of success for treatment
with gefitinib

cell

37

38

Increased copy number

Poor prognosis (shorter survival)

Increased copy number

Higher frequency in metastasis

Treatment with crizotinib

39

carcinoma
(lung)
E2F3

Urothelial
carcinoma

ROS1

non-small-cell

rearrangement/gene

or ALK

lung

fusion
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41,42

40

subsequent interpretation of the pathogenicity of any findings. The ACMG has approved
a set of Standards and Guidelines for genomic copy number testing using microarrays
(13,43,44). Microarray probes are suggested to be placed throughout the genome at
regular intervals, to enable the detection of copy number changes of 400 kb or larger with
99% sensitivity. It is also recommended that there be an emphasis on probes targeting
haploinsufficient genes with known phenotypic abnormalities (43), or regions known to
be associated with unbalanced genomic alterations in cancer (44). In addition, it is
desirable to be able to detect small rearrangements with high confidence and low false
positive rates, to improve diagnosis of small clinically significant copy number variants
(45).
Ab initio single copy intervals were used to design a genomic oligonucleotide microarray
that demonstrated reduced noise in signal intensities compared to a common commercial
platform. We suggest that genomic placement of oligonucleotides relative to repetitive
elements can alter their susceptibility to cross hybridization, which increases variability
in probe signal intensity. Historically, improved accuracy and resolution of commercial
microarray platforms has been achieved by increasing the density of probes on the array
(46). This thesis describes an alternative solution to overcoming noise: including a
reduced set of oligonucleotides that demonstrate high reproducibility in signal intensity.
This may offer a cost-effective solution for high throughput microarray testing by
increasing the number of samples that can be processed per slide (through increased
multiplexing with the same number of total probes).
These findings are not limited to microarray analysis, but rather apply to any nucleic acid
hybridization experiment using genomic DNA. In next generation sequencing analysis,
solution hybrid selection is becoming a useful method to enrich for targeted genomic
sequences (47). This approach uses biotinylated RNA ‘bait’ that is hybridized to a
sheared DNA sample, and then purified using streptavidin-coated beads to enrich for the
target sequence. This thesis describes the application of ab initio sequences to design the
RNA sequences (bait) used for DNA capture and subsequent sequencing (Appendix
S5.5.3). Where possible, sequences were selected to be distant from conserved repetitive
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sequences to minimize cross-hybridization and wasted coverage on unintended
sequences. In addition, capture probes were designed in divergent repetitive elements to
allow for greater coverage in some regions that would be excluded using repeat-masking
(48). Capture probes resulted in enrichment of the targeted 45 gene sequences, with
sufficient coverage to allow for multiplexing of 48 samples per sequencing experiment.
Clinics or research groups with specific gene panels of interest could use this method as a
cost-effective alternative to whole exome sequencing.

6.2.3 Next Generation Sequencing
With decreasing costs and the development of more user-friendly analysis software, next
generation sequencing is becoming mainstream in both research and clinical settings.
During mutation analyses, and especially when clinical decisions rely on the results of a
study, it is important that we leverage the data to the best of our ability to obtain the most
complete and accurate results. In this thesis, the Shannon Human Splicing Pipeline (49)
was used to improve splicing mutation detection in 445 breast cancer tumours. Further, a
software program was developed and described, named Veridical (50), to employ RNA
sequencing data for validation of the predicted mutations’ affect on mRNA splicing.
Veridical was the first published genome-wide tool that is able to directly link DNA
mutations to aberrant mRNA splicing. Before the development of Veridical, validating
splicing mutation could be fairly laborious. RT-PCR is the most common method used to
confirm that a splicing mutation will cause abnormal splicing, either through measuring
patient mRNA or a transfected cell line that expresses the mutation. Although this
method is reliable for individual mutations, it would be difficult and time consuming to
apply this technique to all predicted splicing mutations in a genome. For example, 5,206
splicing mutations were detected in 442 tumours (Chapter 4). Assuming patient mRNA is
attainable, a very conservative estimate of 4-6 hours of hands-on time would be required
to validate each mutation (to develop primers, set up and run the RT-PCR reaction, and
analyze the results). This would amount to at least 2,600 8-hour workdays, or ~6 days per
tumour to validate these results using a traditional approach.
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In addition to its genome-wide capabilities, Veridical can compare the mutated sample to
normal exome sequences or other controls to determine the corresponding frequency of
the aberrant splicing pattern in samples that do not contain the variant of interest.
Veridical is able to achieve high statistical power through comparing hundreds of
controls, the extent of which would not be reasonable for a single-variant wet lab
experiment. One additional benefit is that the RNA-Seq controls do not need to be
generated by the group performing the study, due to the availability of data from online
resources such as TCGA (https://tcga-data.nci.nih.gov/tcga/) and the International Cancer
Genome Consortium (https://icgc.org).
Other software programs with similar objectives to Veridical have also been recently
developed, including PVAAS (51) and SNPlice (52). PVAAS uses “spliced reads” (reads
spanning two exons) from RNA sequencing data, and identifies non-canonical splicing,
defined as splicing where the 5’ and/or 3’ splice site(s) are not known. It works in the
reverse order of Veridical, identifying variants that are associated with the aberrant
splicing after the non-canonical splicing reads are discovered. SNPlice finds RNA
sequencing reads that contain a single nucleotide variant, and span into the intronic
sequence. It highlights variants that preferentially occur in intron-containing molecules
versus reads that are properly spliced, to implicate the variant in abnormal splicing.
The recent development of both PVAAS and SNPlice highlight the importance of
identifying splicing mutations that cause aberrant splicing. They are potentially powerful
tools that are especially useful in the absence of DNA sequencing data. However, they
fail to address some key considerations that were incorporated into Veridical. Both
approaches rely on associations between a variant and a splice form to potentially
implicate the variant in abnormal splicing. There are two major flaws to this approach.
First, the authors did not work with complete gene or genome data, and therefore all
possible splicing variants (especially those deep in an intron) would not be present in the
analysis. Because the true causal variant may not be detected or known, some atypical
splicing transcripts may be miscalled as natural alternative splicing events. Second, a
truly causal variant may be in linkage disequilibrium with the inferred variant, and
therefore the cause of abnormal splicing is not explained correctly. Further, if two
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variants reside in the same region, the programs may have difficulty determining which
variant is affecting splicing. While both of these are serious drawbacks and the first is
more likely a result of the authors’ lack of complete genome or gene data, which means
that their inferences were based on a minor fraction of genome variation (53).
Veridical differs in that it is hypothesis-driven, looking for aberrant splicing at the
specific location of predicted splicing mutations rather than making post-hoc associations
of variants to abnormal splicing, as in PVAAS and SNPlice. In addition, Veridical is able
to perform robust statistical analyses against large sets of controls. This is important
because it avoids mis-identifying naturally occurring abnormal splicing (i.e. the GATA3
cryptic splicing found in all controls in Appendix S2.2.3) or intron retention (i.e. the
abundance of intron-spanning reads in both breast cancer samples and normal controls
demonstrated in Appendix S2.2.4) as abnormal.
Veridical confirmed 19% of all splicing mutation predictions in a large subset of breast
cancer tumours. That leaves the question, however, of why the other 81% of variants
were not confirmed. The parameters outputted from the Shannon Pipeline (i.e. initial,
final, or change in the splice site strength, distance to or strength of the nearest natural
site) showed no obvious indications of whether the variant would be validated by RNASeq. This implies that it is not due to some variable of the algorithm underlying the
Shannon Pipeline (which uses information theory), but rather related to the methods of
validation.
The first of these issues is the fact that genes were not filtered based on breast tissue
expression, so many of the genes harboring splicing mutations may be in genes not that
are not expressed (and show minimal read coverage in the RNA-Seq data). For example,
a donor mutation at a natural site in ACSBG1 with a ΔRi of -18.64 bits (inactivating the
site) was not validated even though there was a dramatic decrease in the strength of the
site. The GTEx (54) expression value, however, suggests this gene has very low
expression in breast (mammary) tissue (Figure 6.1). Second, variants were only called
and grouped within the tumour samples, so there was no information as to whether the
normal breast samples contained the variant. If enough of the normal samples contained

205

Figure 6.1 Screenshot from GTEx Portal – ACSBG1 Gene View. Measured gene expression
values of ACSBG1 for different tissue types are listed along the x-axis. The vertical red bar
indicates the location of the breast (mammary) tissue, which is filled in light blue. The horizontal
red bar indicates the log(expression) value measured from 66 samples. Data Source: GTEx
Analysis Release V4 (dbGaP Accession phs000424.v4.p1).
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the variant, the abnormal splicing would not have enough statistical power to be observed
as significant based on the p-value cutoffs applied. This situation is less likely, because
common variants (in dbSNP present in more than 1% of the population) were filtered out
of the analysis. Third, although from the same tumour, the DNA- and RNA-Seq data may
represent genotypically-different cell populations due to tumour heterogeneity. Finally,
some of the splicing variants may have been false positives (i.e. an artifact of the
sequencing) or there was simply no evidence of aberrant splicing. Standard quality filters
were used during variant calling, although this only reduces and does not fully eliminate
false positives. In addition, predicting splicing mutations using information theory has
been shown to have a sensitivity of 85% (18), so a minority of the predicted variants may
not affect mRNA splicing.
In this thesis, the Shannon Pipeline and Veridical were applied to breast cancer tumours.
Future studies could apply similar analyses (from Chapters 3 and 4) to other types of
cancer using newly generated or previously published data (from groups like the Cancer
Genome Atlas or International Cancer Genome Consortium). This would be particularly
valuable in both heritable and somatic cancers where there has been either a lack of
causal variants identified in a large portion of cases or where mutations in specific genes
lead to clinical decisions. For example, our laboratory is applying splicing (among other
non-coding) mutation detection to families with a strong history of breast and/or ovarian
cancer that have tested negative for BRCA1/2 actionable mutations. BRCA testing
primarily involves Sanger sequencing (55) of exons to assess mutations in coding
regions, and so there are likely protein-damaging splicing mutations that are missed with
standard techniques used in the clinic.
Efforts are currently underway in our laboratory to expand Veridical to incorporate
additional types of analyses. For example, it could be used to detect whether any type of
mutation (splicing or coding) is increasing nonsense-mediated decay (NMD). Transcript
levels of both alleles could be detected, and the proportion of the transcript with versus
without the mutation could indicate whether the mutated mRNA is susceptible to NMD.
A similar type of analysis with different objectives (i.e. not assessing NMD)
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comprehensively mapped genotype relationships with expression of specific transcripts
using expression quantitative trait loci (eQTLs) in over 40 different tissue types (54,56).
In addition to allele-specific expression, the RNA-Seq read coverage in the 5’ end of the
transcript (low) versus the 3’ end of a transcript (high) may also indicate that NMD is
occurring. Exon-exon junction protein complexes (EJC) are thought to be removed by the
ribosome during the first round of protein translation. When there is a premature stop
codon (and the ribosome is released), the 3’ EJCs are not removed, and their presence on
the transcript triggers the NMD process. Consequently, mutations in the last exon are
often missed by NMD because they do not have any remaining EJCs. Veridical could
also be applied to any other read-counting based analysis, such as detecting or
quantifying non-coding or micro-RNAs in a disease sample or tissue type compared to
controls.

6.3 Implications for breast cancer treatment
6.3.1 DNA mutations in metastasis
This thesis demonstrates that there are elevated numbers of NCAM pathway mutations in
lymph node positive tumours. Lymph node involvement compared to tumour size can be
a marker of the metastatic potential of a tumour independent of the tumour subtype (57).
Therefore, NCAM pathway mutations may be an indicator for tumours most likely to
metastasize.
Cancer has long been proposed as a multistage process, both in tumour development
(58,59) and advancement of the disease (60). Interestingly, the percent of tumours with
NCAM pathway mutations drops off in later (stage IV) tumours. It is possible that
NCAM pathway mutations increase metastatic potential in early tumour development,
but are not clonally selected for once the tumour has spread. This would explain why
these mutations are not present at high levels in advanced disease. If the NCAM pathway
mutations were simply passenger mutations in breast cancer, it has been proposed that
these genes would be low expressing (61) and late replicating (62-64), which have been
associated with higher background mutation rates (65). The stage of replication and
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expression levels were compared between NCAM pathway genes and genes significantly
mutated in breast cancer, which were cited to be likely driver genes (20-24). We do not
find any differences in both replication stage and expression levels between NCAM
pathway and other significantly mutated genes (Figure 6.2), which supports excluding the
possibility that NCAM pathway mutations are the result of bystander effects. The
contributions of these defects to tumour metastasis would have to be demonstrated by
functional studies (see below).
A high proportion of the breast cancer tumours assessed harbored extracellular matrix
(ECM) and collagen mutations, although these mutations were found at similar levels in
all tumours, regardless of their lymph node status. Clonal frequency was previously
evaluated in a large set of breast tumours to segregate mutations as either early or later
events, which delineated that mutations appear to be acquired later in tumour
development in genes that play a role in cytoskeletal pathways, such as myosins,
laminins, collagens, and integrins (21). In addition, the differential expression of ECM
components has been used to classify breast cancer tumours into groups related to patient
prognosis and tumour metastatic potential (66,67). These and other stromal signatures
can have higher predictive power when combined with current pathogenic features
(receptor status, tumour grade) (68). The ECM of tumours has been cited as a potential
target for anti-cancer therapy, although it is challenging to identify which specific ECM
component may serve as an effective therapeutic target (69).
Alternative ways to identify tumours that are likely to migrate to other tissues, beyond
prognostic gene expression profiling, would be beneficial for many patients. Further
work could be completed to confirm the hypothesis that NCAM pathway mutations are
indicators for tumour migration. There are now effective, inexpensive ways to test a cell
line’s metastatic potential. For example, chick chorioallantonic membrane (CAM) assays
in conjunction with multiple fluorescent imaging is a useful model to study angiogenesis,
invasion, and metastasis (70-72). The assay involves measuring the level of intravasation
and growth achieved by inoculated xenogenic tumour cells within the CAM of a chick
embryo. Splicing mutations in NCAM pathway genes that were observed in this thesis
(Section 4.3.7) could be introduced into breast cancer cell lines, and the cell line’s ability
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A)

B)

Figure 6.2 Replicating stage and expression of NCAM pathway and significantly mutated
genes. A) Replicating stage was determined using the MCF7 cell line data from the UCSC
Genome Browser track “Replication Timing by Repli-seq from ENCODE/University of
Washington” (73,74). In cases where a gene was replicated during two stages equally, the
earliest stage was used. Gene sets used can be found in Appendix S4.3.3 (significantly mutated
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genes), and Appendix S4.3.8 (NCAM pathway genes). B) RPKM gene expression values were
obtained for each gene (average of 66 normal breast mammary tissue samples) from the GTEx
portal (http://www.gtexportal.org/home/). The log(RPKM) was plotted against replication stage for
each gene, as in described in A.
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to migrate through the CAM could indicate the affect of that mutation on a tumour
metastatic potential. This type of study could also potentially identify specific genes
within NCAM pathways that contribute the greatest to lymph node invasiveness. Other
cell migration and metastatic potential in vitro assays that could be applied to study
NCAM pathway mutations include scratch-wound assays (75) and Boyden chamber
assays (76).
Our laboratory has recently proposed to carry out a prospective trial with basal-like and
HER2-enriched breast cancer patients (Section 4.3.8 and Appendix S2.2.5) that would
involve sequencing NCAM pathway genes at the point of diagnosis, surgery and/or
relapse. Patients could be followed to determine whether those tumours with NCAM
pathway mutations were more invasive than those that lacked mutations. A prospective
trial would be required due to the fact that some patients with early stage tumours that
contain NCAM mutations at initial diagnosis may have longer latency periods to
metastasis. In addition, tumour dormancy (77,78) may significantly increase the time to
distant metastasis, but the cell migration could still be due to NCAM pathway mutations
in the primary tumour. Sequencing tumours that have already metastasized and have
undergone further clonal selection will not necessarily harbor the same set of mutations
as the primary tumour (21). This study would likely require several years, however would
be non-invasive because it would not change the course of treatment for current breast
cancer patients, meaning there would be limited downsides for patients enrolling in the
study.

6.3.2 Predicting tumour sensitivity to paclitaxel and gemcitabine
Chemotherapy is widely used in breast cancer treatment, although selection of which
specific agent to use is qualitative and variable due to patient-related factors. Developing
robust genomic signatures to guide selection of chemotherapy agents would be
particularly useful for triple negative (TNBC) and advanced breast cancer. In the case of
TNBC, there are limited options for therapeutic treatment beyond conventional
chemotherapy (79). TNBC (most commonly basal-like and Claudin-low subtypes) are
usually aggressive and are more likely to become metastatic, however, women with
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TNBC who have a complete pathological response to treatment have excellent outcomes
(79). In advanced breast cancer, chemotherapy is used for palliative care and to improve
quality of life given that the chance of survival and cure are low (80). Usually, a specific
chemotherapy drug, or class of drugs, is only effective until the tumour develops
resistance to the treatment. Therefore, it is advantageous to be able to identify those
patients who would benefit from immediate treatment with cytotoxic therapies, and those
for which surgery and radiation may be sufficient at the time of initial diagnosis. In
addition, selecting the chemotherapy agent that is most likely to be effective early on may
avoid periods of ineffective treatment and the corresponding unnecessary toxicity and
side effects.
This thesis describes a novel approach that used machine learning to generate models that
can predict breast cancer tumour sensitivity to paclitaxel and gemcitabine. Gene selection
was driven by the biological understanding of these drugs, rather than employing a
genome-wide approach that risks identifying un-meaningful signatures correlating to
tumour response by chance (81,82). A reduced 11-gene signature for paclitaxel was able
to predict tumour response in a set of formalin-fixed paraffin-embedded breast cancer
tissue samples with similar accuracy to the cell line data. A reduced 9-gene signature was
able to predict tumour response to gemcitabine in samples where at least 4 of the 6 gene
expression measurements were obtained, however, it performed poorly on those with
limited data. This result highlights the difficulties in working with FFPE tissue samples,
where there can be variable and low preservation of nucleic acids (83,84). Measuring the
FFPE samples using qRT-PCR was unsuccessful for some genes due to low expression
and/or the differences in amplifiable template between samples.
The reduced 11-gene expression signature for paclitaxel was particularly effective in
predicting patients with low residual cancer burden that will be have a complete
pathological response to paclitaxel. It was not as effective at predicting tumours likely to
show resistance, especially in advanced disease. This is not necessarily surprising, as
primary and metastatic breast cancer tumours, both within and between lesions, are made
up of multiple genetically diverse subpopulations of cancer cells (85). Recent data
highlight that differences, in the case of both genomic aberrations and mutation
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frequencies, have been observed between primary tumours and subsequent metastatic
lesions (86,87). In multifocal breast cancer, it was found that the genetic differences of
the lesions in each patient were significantly correlated with the physical differences
between the tumours (88). Therefore, the gene signatures developed may only be relevant
to a limited subset of the tumour populations related to primary breast cancer tumours,
but not those of aggressive clonal isolates. In addition, it is likely that the SVM may only
predict response to the specific lesion measured, and not to genetically differentiated
lesions or metastases.
Recently, a 20-gene signature (“TAXSig”) was developed that predicts chemoresistance
to taxane-based therapies in breast cancer patients (89). This study included, but was not
limited to, paclitaxel. There was no direct overlap in genes included in the TAXSig
signature and the genes included in our SVM model, or randomly generated gene sets
that had low misclassification rates from Figure 5.7. However, a pathway analysis using
Reactome (90) revealed slight overlap in biological pathways between FGFR1 from
TAXSig, and a subset of the paclitaxel SVM genes. The 35 genes from both signatures
are enriched for the innate immune system (p=0.034), as 7 genes (FGF2, BCL2, BCL2L1,
TLR6, NFKB2, FN1 from the SVM and FGFR1 from TAXSig) are part of the 1,031
genes in this pathway. In addition, FGFR1 (from TAXSig) interacts with FGF2 and FN1
in at least 53 and 31 additional specific signaling pathways, respectively. Although there
is some overlap in biological pathways of the TAXSig and paclitaxel SVM gene sets, the
majority of genes are unrelated. The taxane (TAXSig) resistance signature may be
capturing a different mechanism (or mechanisms) of resistance, which may at least
partially explain why chemosensitivity is not predicted with greater accuracy. The
paclitaxel SVM was not predictive of docetaxel GI50s, further supporting the notion that
they are unrelated processes. The paclitaxel SVM derived in this thesis was reliable in
predicting tumours that will respond to the treatment, but nevertheless the phenotypes of
patients or cell lines could not all be accurately predicted. One possible explanation might
be that some of the features sensitizing a tumour to paclitaxel are independent from those
leading to resistance. While we are not aware of any evidence that this occurs, such a
hypothesis could explain why we are unable to predict the phenotypes of all cell lines and
patients accurately.
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Although previous studies have developed gene signatures to predict paclitaxel (or
taxane) sensitivity, there has been limited work in using gene expression signatures to
predict breast cancer sensitivity to gemcitabine. One study found that polymorphisms in
SLC28A3, SLC29A1, and RRM1 can predict metastatic breast cancer sensitivity to
combination therapy with paclitaxel and gemcitabine (91). RRM1 was included in the
paclitaxel SVM, and SLC28A3 mutations and GI50s were strongly related in the set of 44
cell lines assessed using a multiple factor analysis. A study assessing copy number
changes in RRM1 and RRM2B found that copy number aberrations of these genes were
present in breast cancer tumours, but were not related to clinical outcome of patients
treated with gemcitabine (92). During feature selection (used to generate the SVM), we
found that copy number of both RRM1 and RRM2B had no impact on the model’s ability
to predict gemcitabine sensitivity (Figure 5.3). Given that there is a need for models to
predict gemcitabine, further work on large patient sets could be completed to validate or
improve upon the gemcitabine SVM derived in this thesis. Although the SVM did not
perform as well on a small number of FFPE tumour samples as it did in the cell lines,
obtaining reliable gene expression measurements from these tumour blocks was
challenging. Attempting a similar analysis on fresh-frozen tumours may provide further
insight into the utility of the gemcitabine SVM in patient care.
Similar methods may be effective in generating models for other chemotherapy agents for
which the biological mechanism of action is known. For example, pathways involved in
the thiopurine class of drugs (including azathioprine, mercaptopurine, and 6-thioguanine)
mechanisms of action and metabolism are well documented (93). As with gemcitabine,
multiple enzymes (for example, HPRT1, IMPDH1, GMPs, and TPMT) are required to
convert the drugs into their active metabolites before they are incorporated into RNA and
DNA to exert cytotoxicity. Similarly, genes involved in the pathway (i.e. NQO1, NOS3,
XDH, TOP2A, NFKB1) and transport (i.e. ABCC1, ABCB1, RALBP1, SLC22A16) of
doxorubicin have also been previously described (94). These gene sets are strong
candidates for use in the development of SVMs to predict chemosensitivity to the
respective drugs (using their gene expression and/or copy number values), as the genes
playing a role in drug disposition within the tumour itself. Therefore, it is reasonable to
expect that changes in expression or copy number of the genes identified may predict the
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effectiveness of thiopurine, doxorubicin, or other drugs with similar information.
Conversely, tamoxifen metabolism largely takes place in the liver by multiple genes from
the cytochrome P450 (CYP) and the UDP glucuronosyltransferases (UGT) families (95),
and the exact downstream mechanism of action is not well documented. Measuring breast
tumour expression or copy number of the CYP and UGT genes would not be informative,
because this is not where the metabolism occurs for these drugs. We did not find the
cytochrome P450 (CYP) genes to be informative for paclitaxel or gemcitabine, as they
were not included in the final SVMs. Therefore, the approach described in this thesis may
not be suitable for tamoxifen or other drugs with limited knowledge beyond the fact that
their metabolism takes place in the liver. Eight genes were included in the final paclitaxel
SVM that were not implicated in paclitaxel’s disposition, but were previously implicated
in resistance (FGF2, TMEM243, BIRC5, CSAG2, FN1, NFKB2, TLR6, TWIST1). These
genes improved the accuracy of the SVM, indicating ancillary data would be useful in
generating chemosensitivity models for other drugs (Figure 6.3). However, there were no
additional genes in the gemcitabine analysis other than those directly in the drug
pathway, indicating that they are not necessary for developing a successful model.

6.4 Thesis impact on personalized medicine in breast
cancer
There are still a number of challenges that researchers and healthcare providers face
regarding data analysis, management, and interpretation. This thesis describes
improvements upon the techniques that are increasingly used for clinical care. Although
this thesis focuses on leveraging genomic technologies to advance our knowledge in
breast cancer, all of the techniques and methods described could be applied to other
disease types.
There are many cases where point mutations in specific genes are relevant for cancer
patient management in regard to predicting outcome or response to treatment. For
example, Afatinib was found to be active in non-small-cell lung cancer in patients
harboring uncommon EGFR mutations (96). The application of the Shannon Pipeline and
Veridical for splicing mutation prediction and validation in the analysis of any tumour
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type can expand current efforts to detect potentially damaging and relevant mutations. In
breast cancer, this thesis found that a large subset of synonymous mutations identified by
the TCGA to actually affect mRNA splicing. Synonymous mutations are usually not
considered in downstream analyses (beyond variant detection), which would leave some
potentially relevant or crucial mutations unreported due to a misidentification of their true
effect on the protein product.
Machine learning is proving to be a robust tool in interpreting features and making
predictions using large biological datasets (97,98). The biologically-driven machine
learning approach described in this thesis could be employed for additional cancer types
that are treated with generic chemotherapy agents. While there is no single recipe that
will assure successful prediction of chemotherapy response, there are a number of key
considerations that need to be accounted for in applying this approach. Specifically:
1) The quality of the tissues analyzed or data obtained should be verified before their
application to this type of study. The availability of large genomic data sets with drug
response information for a specific type of cancer are crucial for training and testing the
predictive SVMs. Resources such as the Gene Expression Omnibus have greatly
improved access to this type of data, which are usually made available from previous
studies. However, this thesis and other studies (84) have described the level of
degradation of nucleic acids in FFPE samples can be variable between tumours, and
should be considered when conducting any study;
2) The training data needs to be representative of the tumour type as a whole, and contain
roughly equal numbers of sensitive and resistant samples. In this thesis, we demonstrated
that cell lines are both a practical and minimally invasive tool; one that can be used to
generate gene signatures. However, SVMs perform the best when trained on equal (or
close to equal) numbers of data sets in each of the binary classes (i.e. resistant or
sensitive). We found that using 44-49 cell lines was sufficient, but when reducing this set
by half, it was not adequate for the creation of robust models (data not shown). In
addition, the dynamic ranges of GI50 observations did not appear to greatly affect SVM
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performance, as paclitaxel GI50s were between 6.5-8.5, and gemcitabine GI50s were
between 2.5-9.
3) Any SVM model generated (including the ones described in this thesis) would need to
be validated on multiple independent patient data sets before they could be applied to
patient treatment, where the outcome of the SVM may alter the course of therapy. For
any biomarker, the FDA (or Health Canada) requires extensive analytical validation,
clinical validation, and clinical qualification before it is approved to be used in the clinic
(99). This level of validation was beyond the scope of this thesis, although we apply the
paclitaxel derived SVMs to two different patient datasets. Ultimately, how these type of
signatures perform in other patient groups would need to be determined before clinical
adoption (as has been done for commercial diagnostic/prognostic assays (100,101).
4) SVM models would likely need to be derived for each tumour type separately. As
described in Section 5.3.6, the genes distinguishing tissue specific expression classes
dominated those associated with chemotherapy resistance in previous studies employing
machine learning (102), but was not true for regression models (103). For example, tissue
specific expression patterns were dominant when using genome-wide data with the
random forest method (unsupervised machine learning) used by Daemen et al (2013). A
benefit to the biologically-driven approach is that SVMs have a greater likelihood of
success when using a limited number of attributes (i.e. gene parameters).
5) The genes selected should be relevant to chemotherapy response, and play a role in
drug disposition within the tumour itself (as outlined in paragraph 5 of section 6.3.2).
Pathways and genes that contribute to resistance in other less well-studied drugs may not
be known, and the lack of these features in the SVM would lower prediction accuracy.
There may be additional genes or biological functions involved in paclitaxel and/or
gemcitabine mechanism of action that are not yet known, which may explain why the
SVM is not able to predict drug sensitivity in 15-20% of cases. Alternatively, the these
cases may habour point mutations in the present set of genes, or others, that are leading to
chemosensitivity, which are not included in the current SVM models.
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6) Unrelated prognostic indicators do not appear to be synergistic with our derived gene
signatures. In section 5.3.5, this thesis demonstrated that gene signatures using randomly
selected expression values (from 23,030 genes) that are able to predict cell line response
to paclitaxel were not accurate in predicting response in a patient data set. Many of the
genes included in these random signatures were pseudogenes and genes unrelated to the
biology of a tumour or paclitaxel metabolism, which is an indication that the signatures
derived from them could be statistical artifacts.
The only random signature, among the 10,000 that were derived, that was able to predict
patient sensitivity in an external patient data set contained WWP1, which has been
previously identified as a prognostic indicator for breast cancer (104). Adding WWP1 to
the paclitaxel SVM, however, greatly increased the misclassification rate of predicting
cell line response (18% to 26%), and increased the number of patients predicted to be
sensitive that were actually non-responsive. WWP1 has not been previously identified as
having a role in paclitaxel drug disposition, indicating that adding generic patientoutcome related genes that are not pertinent to biologically meaningful signatures of drug
response, may not be an effective strategy to improve SVM accuracy.
7) One strategy worth considering for improving SVM performance is to stratify tumours
by subtype (and/or receptor status) in concert with chemotherapy response. We showed
in Chapter 4 of this thesis that different subtypes have diverse splicing mutation profiles,
specifically that NCAM-related pathway mutations appear to be preferentially enriched in
basal-like and HER2-enriched lymph node positive tumours (section 4.3.8). In our
analysis of SVMs derived using random sets of genes, we found that one signature
containing WWP1 could be related to patient outcome. It has been suggested that WWP1
plays a role in apoptosis in ER positive breast cancer (105), so although it did not
improve the paclitaxel SVM for all tumour types, WWP1 incorporation into an ER
positive-specific SVM may possibly increase the classification accuracy for this subset of
tumours. However, there were insufficient numbers of ER positive cell lines available for
SVM training, and too few patients available with known ER phenotype to test its
accuracy. Incorporating additional subtype-specific genes to the current SVM models
could be one strategy that might increase the accuracies of these gene signatures.
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8) In order to successfully incorporate any genomic signature for clinical application
(whether for breast cancer or other tumour types), the expression and copy number
studies would need to be performed within the clinically relevant time window either
preceding or early on in chemotherapy treatment. For solid tumours, the assay would
need to be completed in the timeframe between surgical removal, or biopsy of the tumour
tissue, and the onset of treatment. Although this time frame will vary on a case-by-case
basis, it would be advantageous and more feasible to accurately measure a small set (1015) of expression and copy number values compared to performing larger scale (complete
genome or exome) determination and analyses.
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Appendix S2:

Supplementary Information for Chapter 2

Appendix S2.1 Supplementary Methods: Ab Initio single copy (sc)
sequence algorithm and implementation
The ab initio method eliminates the requirement to exclude sequences from a catalog of
consensus-like repetitive elements. It exploits a state space search strategy in which a
depth-limited search is run repeatedly, increasing the depth limit with each iteration, until
it reaches the depth of the shallowest level, in order to determine the copy number of seed
subsequences of a larger input sequence (e.g. a complete chromosome). In each iteration,
progressively shorter sequences containing elements present in multiple copies in the
genome are searched in a sequenced genome, at low stringency using BLAT (BLASTlike alignment tool), in parallel (using threaded jobs) on a cluster computer. To define the
boundaries of sc segments, the above steps are recursively run on branched subsequences
of repeat-containing intervals that occur adjacent to sc segments discovered in the
previous step. In addition to finding known repeat sequence families, ab initio eliminates
repeat elements, segmental duplicons, and conserved paralogs that are not filtered out by
catalogue-based approaches. The algorithm is tuned to exclude highly and moderately
conserved multicopy and/or repetitive sequences, but not highly divergent repetitive
elements. The algorithm can be applied to any genome.
A secondary screen using multiprocessor BLAST analysis (54) filtered out any residual
repetitive sequences. Parameters were selected to maximize speed without compromising
sensitivity. The default parameters were modified to return 2 sequence alignments, using
a word size set to 28, the number of best hits kept limited to 2, descriptions of 5
sequences retained, and an expected hit value threshold of 0.1. This threshold produced
significant alignments ≤50 base pairs in length to genomic targets, when present. The
parameters provided a reasonable level of genomic resolution and adequate sensitivity to
detect nearly all conserved or moderately conserved repeat elements, while exhibiting
performance suitable for genome-scale application. The average run time for the
recursive BLAT runs, followed by filtering apparent sc results with mpiBLAST, using a
128 CPU Xeon-based compute cluster was 19 hours 20 minutes for a chromosome length
of~130 Mb.
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We then compared the ab initio genomic regions output with a deduced set of annotated,
non-repetitive intervals to determine the sensitivity and specificity of the algorithm. The
comparison set comprised the genomic complement of the combined set including
segmental duplication, self-chained paralogous intervals, and repeat-masked sequences.
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Appendix S2.2
probes

Coordinates and PCR primers of validated scFISH

Gene
Target

Genomic
Coordinates

Probe
Length
(bp)

ERBB2

chr17: 3786115537863542

2388

CDKN2A
(Probe 1)

chr9: 2199199021995076

3087

CDKN2A
(Probe 2)

chr9: 2198174321985184

3442

CDKN2A
(Probe 3)

chr9: 2198468821987911

3224

TP53

chr17: 75895277592796

3270

CCND1
(Probe 1)

chr11: 6945865869461950

3293

CCND1
(Probe 2)

chr11: 6946546569469037

3573

NOTCH1

chr9: 139435414139438778

3365

Hybridization
Efficiency*

Primers
L GCATTGGGAGAATTAGTGTGTATTTATGTTG

96/68
R GTTAGATGTTAGAAAGGACTTCCTGGTTGAG
L GTAAATGCACCAAGGTAGAAGTAACAAATCA
100/79.8
R GTTTAGTTTAATTTCGCTTGTTTTCCAAATCT
L TAGTTCTACCACCTACTTTGTTACCCTGAAAA
97.7/75.9
R TATATTTCATCAAGAAGTTGATTCCCTTGAGT
L TTTCACTGATAGGTTTAACACTGGTTTAGGAT
91.4/75.4
R AATCTGCATTTTAAATAAACACTTGAAGGAGA
L CAAAGCTAGATAACAGGTAGATTGTTTTTCC
95.7/70.3
R TAGAAGACACAAACTGCTAGATAAAATGTAAGC
L ACGATTTCATTGAACACTTCCTCTCCAAAAT
100/94.1
R CTGATGTAGCCCAACAATTCCAGTGACTT
L ACATGGAGAGGTTAAGTCTGAAAAGGCTGA
100/77.9
R CTCTCGATACACACAACATCCAGGACTTG
L CCCAGCTCTCCTCAAAACAAAGAGAAAAA
100/73.9
R TGACTACAGAACTCTGGGCAGAATGTTGA

scFISH probe primer design: Gene targets, genomic location, probe length and
primers used for each validated probe. *Hybridization efficiencies are indicated as the
percent of cells with both homologues clearly hybridized, preceded by the percent of
cells that had at least one homologue hybridized to the correct chromosome band.
Genomic coordinates are based on NCBI Build 37/hg19. L = left, R = right.
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Appendix S3: Supplementary Information for Chapter 3
Appendix S3.1

Veridical variant input format

This input format most easily accepts formatted output from the Shannon Pipeline. In
particular, all variants of interest should be concatenated into a single file. Once a, tabdelimited, concatenated file has been generated, it can easily be formatted correctly by
using FilterShannonPipelineResults.pl. All file headers must precisely match their
outlined schema. One can also manually ensure the following: the header line has no
quotation marks or special characters, empty columns have been replaced by a period (.)
and each variant line contains only a single gene (comma-delimited gene lists must be
split such that there is only one gene per line). If one wishes Veridical to consider
variants pertaining to more than one experimental sample, a comma-delimited list of
experimental samples, in the form of BAM file names, must be provided as the key
column. The key column must always contain at least one file name that is present as the
base name of one of the files listed in the BAM file list that must be passed to Veridical.
Alternatively, one can prepare the input format as follows. The header must contain at
least the following, case-insensitive, values to which the file’s columns must adhere to:
chromosome,

splice&coordinate,

strand,

type,

gene,

location,

location_type,

heterozygosity, variant, input, key. The column headers need only contain the given text
(i.e. a column labeled gene_name would be sufficient to satisfy the above requirement
for a “gene” column). Column headers with ampersands (&) denote that all words joined
by this symbol must be present for that column (i.e. Splice_site_coordinate satisfies the
“splice&coordinate” requirement). The order of the columns is immaterial. The input
column can contain any identifier for the variant and need not be unique. The location
column specifies if the site is natural or cryptic. For Veridical, all that matters is that
cryptic variants contain the word “cryptic” as part of their value in this column and that
non-cryptic variants do not. The location_type column is only used for cryptic variants
and specifies if the variant is intronic or exonic. It is not currently used by the program.
This column must be present but can always be set to null (i.e).
A few rows from a sample variant file is provided below (text wrapped for readability):
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Chromosome
Splice_site_coordinate
Strand
Ri-initial Rifinal ∆Ri Type Gene_Name Location Location_Type Loc._Rel._to_exon
Dist._from_nearest_nat._site Loc._of_nearest_nat._site
Ri_of_nearest_nat Cryptic_Ri_rel._nat. rsID Average_heterozygosity
Variant_coordinate
Input_variant
Input_ID RNASeqDirectory_ID
RNA_Seq_BAM_ID_KEY
chr10 89711874 + 12.09 -2.62 -14.71 ACCEPTOR PTEN
NATURALSITE . . .
. . . . . 89711873 A/G ID1 dir
file
chr10 89712017 + 5.18
-1.85 -7.03 DONOR PTEN
NATURALSITE . . .
. . . . . 89712018 T/C ID1 dir
file
chrX
9621719 + -4.78 2.25 7.03
DONOR TBL1X
CRYPTICSITE
EXONIC . 11 9621730 2.24 GREATER .
. 9621720 C/T ID1 dir file

Veridical exome annotation input format
This input format can be generated via ConvertToExomeAnnotation.pl. The file must
be tab-delimited, excepting its header, which must be comma-delimited. It must have the
following, case-insensitive, header columns, to which its data must adhere: transcript,
chromosome, exon chr start, exon chr end, exon rank, gene. The column headers need
only contain the given text (i.e. a column labeled gene_name would be sufficient to
satisfy the above requirement for a “gene” column). The order of the columns is
immaterial.
A few rows from a sample exome annotation file is provided below (text wrapped for
readability):
Transcript ID,ID,ID,Chromosome Name,Strand,
Exon Chr Start,Exon Chr
End, Exon Rank in Transcript,Transcript Start, Transcript End,
Associated Gene Name
NM_213590 NM_213590
NM_213590 chr13 + 50571142
50571899 1
50571142
50592603 TRIM13
NM_213590 NM_213590
NM_213590 chr13 + 50586070
50592603 2
50571142
50592603 TRIM13
NM_198318 NM_198318
NM_198318 chr19 + 50180408
50180573 1
50180408
50191707 PRMT1

Appendix S3.2

Veridical output

If a variant contains any validating reads, Veridical outputs the variant in question, along
with some summary information and a table specifying the numbers of each validating
read type detected for both the experimental and control samples. Within the output of
Veridical, the phrase: “Validated (x) variant n times” means that the variant was validated
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mainly for splicing consequence x and has n validating reads. The variant will only
appear within the *.filtered output file if the p-value for either junction-spanning or readabundance-based reads for splicing consequence x was statistically significant (defined,
by default, as: p < 0.05). After the variant being validated is provided, along with its
primary predicted splicing consequence, the output is divided into two sections with
identical contents: one for the experimental sample(s) and another for control samples.
The summary enumerates the number of reads of each splicing consequence, partitioned
by evidence type (junction-spanning or read-abundance-based), and by sample type
(tumour or normal for control samples, and only tumour for experimental samples). A
table describing the number of each read type for every file follows this summary. An
example of this output, for the variant within RAD54L, as shown by Figure 7 and the last
portion of Table 2, is provided. While Veridical outputs this as plain text, with the table
in a tab-delimited format, we provide this output as an Excel document with descriptions
of the meaning of each table heading, to clarify the presentation of the data. All input and
output files for the five variants presented are provided. VeridicalOutExample.xls
contains the output for the variant within RAD54L, along with descriptions of the terms
used

and

the

output

format.

all.vin

contains

the

input

variant

file.

allTumoursBAMFileList.txt and allNormalsBAMFileList.txt are the BAM file lists
for tumour and normal samples, respectively. all.vout contains the Veridical output. The
exome file can be retrieved using ConvertToExomeAnnotation.pl, available with the
other programs at: www.veridical.org. The BAM file lists contain the TCGA file UUID,
followed by a slash, followed by the file name. The RNA-Seq data itself can be
downloaded from TCGA at: https://tcga-data.nci.nih.gov/tcga/.
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Supplementary Figure 1
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Histogram and embedded Q-Q plots portraying the difference between untransformed
and Yeo-Johnson (YJ) transformed data. The plots depict intron inclusion for the
inactivating mutation (chr12:83359523G>A) within TMTC2, as shown in Figures 3.6(B)
and 3.6(C). The arrowheads denote the number of reads in the variant-containing file,
which is, in all cases, more than observed in the control samples (p < 0.01). The figure
legend for all panels is provided in (G), which shows that blue and red plot elements
correspond to untransformed data, while yellow and purple correspond to YJ transformed
elements. Dotted lines in the Q-Q plots are lines passing through the first and third
quantiles for a normal reference distribution. (A), (C), and (E) show junction-spanning
based reads, while (B), (D), and (F) show read-abundance-based reads. (A/B) depict
tumour sample distributions, (B/C) depict normal sample distributions, and (E/F) depict
combined tumour and normal sample distributions.
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SomaticSniper Supplementary Materials

Appendix S4.1.1 Supplementary Methods – Variant Calling Methods
Two independent variant callers, Strelka (1) and SomaticSniper (2), were evaluated. The
main analysis performed using results from Strelka, which has greater sensitivity and
ability to detect subclonal mutations, by minimizing reporting of spurious variants and
germline polymorphisms (3). Additionally, the SomaticSniper methods and results are
reported below.
Before running SomaticSniper, all DNA sequencing BAM files were realigned using the
Genome Analysis Toolkit (GATK) Indel Realigner program (4). In addition to default
parameters, the knownAlleles parameter was used with the well-documented
insertions/deletions

(indels)

Mills_and_1000G_gold_standard.

files:

indels.b37.sites.vcf (5) and 1000G_phase1.indels.b37.vcf (6), available
through the bioinformatic resource Galaxy (7, 8). SomaticSniper data was then postprocessed to only include variants with both mapping and somatic qualities of at least 40
(equivalent to running it with ‐Q 40

‐q 40).

Appendix S4.1.2 Supplementary Results – SomaticSniper Variant
Calling Results
SomaticSniper variant predictions are summarized in Appendix S3.1.3. Notably, there
were 1,208 variants from SomaticSniper that are predicted to affect both protein coding
and splicing 594 genes. In the SomaticSniper data, mutations classified as both protein
coding and splicing variants were found in 383 tumours, with 63 of these variants in
PASD1, 61 in PRSS3, 52 in NF1. The variants in these genes, as well as others that were
highly mutated, are the exact same genomic location and nucleotide change, suggesting
that SomaticSniper reported higher numbers of SNPs (3) that were not annotated with
dbSNP135 in >1% of the population, which was used to filter out common SNPs. There
were 248 variants in 186 tumours from the SomaticSniper set that were classified as
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silent amino acid changes from ANNOVAR, but were revealed to affect splicing from the
Shannon Pipeline predictions.
There was relatively low concordance between the two variant callers, which reported
variant lists with less than 50% similarity. There were 21,112 protein coding and 1,811
splicing variants common to both Strelka and SomaticSniper. The predicted variants were
compared to the previously reported TCGA Level 2 somatic mutations (Appendix
S3.1.4). Strelka showed the highest concordance with TCGA mutations, reporting 82.1%
of protein coding mutations, and 86.5% of the splicing variants. Conversely,
SomaticSniper predicted 73.4% protein coding and 75.3% splicing variants reported by
TCGA.
Both of the somatic variant callers we employed utilize Baysian methods to elucidate
somatic event probabilities. Strelka and SomaticSniper were found to be the two best
variant callers in a comparison by Roberts et al 2013. Additionally, these two are a
valuable combination, in that SomaticSniper is useful to generate “a variety of candidate
SNV sites without any particular drawbacks”, although with a fair amount of false
positives, while Strelka is least prone to returning germ-line polymorphisms. The relative
stringency of Strelka was our main reason for performing most of our analyses with it,
along with the fact that many of its candidates (at probability 0.2) were also returned by
other callers. It is worth mentioning that different callers have been found to have poor
correlations at the same sites; in particular, Strelka and SomaticSniper were found to have
a 0.21 Pearson correlation coefficient in the abovementioned study. Our use of Veridical
to validate splicing variants with functional evidence of the mutation significantly
resolves the inconsistency between somatic variant callers (for this type of mutation).
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Appendix S4.1.3 Variant Summaries by Mutation Type
Somatic Sniper
ANNOVAR protein coding variants
Synonymous
Nonsynonymous
Stop gain or loss
Total protein coding variants
Shannon Pipeline splicing variants
Cryptic
Inactivating
Leaky
Total splicing variants
Synonymous
Nonsynonymous
Stop gain or loss
Total
% Synonymous also splicing
% Nonsynonymous also splicing
% Stop gain or loss also splicing

Appendix S4.1.4 SomaticSniper
Findings

TCGA Protein Coding Variants
SNVs Validated
SNVs Not Validated
Indels Validated
Indels Not Validated
Total
TCGA Splicing Variants
SNVs Validated
SNVs Not Validated

Variants

23,458
52,634
2,127
78,219
6,441
2,685
10,648
19,774
248
905
55
1,208
1.0572%
1.7194%
2.5858%

Compared

to

TCGA

Total TCGA

TCGA predicted by
SomaticSniper

5,557
18,197
125
1,758
25,637

4,365 (77.3%)
13,380 (72.2%)
N/A
N/A
17,745 (73.4%)

87
342

70 (80.5%)
253 (74.0%)

429

323 (75.3%)

Total
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Appendix S4.2
Supplementary

Filtering criteria for splicing mutations

Figure

S6.

Flowchart

indicating procedure for filtering splicing
mutation variants. Shannon pipeline splicing
variants output was filtered using the steps
shown in this flowchart to identify those
variants that are likely to cause aberrant
splicing. Upon identifying variants with
Strelka (or Somatic Sniper), the VCF files
were submitted to the Shannon splicing
mutation pipeline, then categorized as either
mutations affecting natural splice sites (3’
acceptor, or 5’ donor) or cryptic splice site
strengths. In a small number of cases, both
natural and cryptic splice sites were
simultaneously altered. Natural sites that
were predicted to be abolished were further
considered.

Predicted

leaky

splicing

mutations were excluded from the present
analysis, since the validation methods for
such mutations has not yet been assessed.
Aside from standard information theorybased mutation criteria, cryptic splicing
mutation candidates were also filtered for
proximity to the nearest neighboring natural
splice site and population frequency. The
filtered variant subset (n = 5,206) was used
for all subsequent analyses.
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Supplementary Figure 1

RNA-Seq Coverage Heat Map by Subtype. Heatmap depicting coverage per exonic base
of TCGA RNA-Seq tumour and normal data. Expression based on RNA-Seq datasets is
shown along the x-axis, with tumours first, ordered by subtype, followed by matched
normal breast tissues. These categories are demarcated within the heatmap by black
vertical lines, which correspond to the sample types: (A) basal-like; (B) HER2-enriched;
(C) luminal A; (D) luminal B; (E) tumour, subtype not available; (F) normal-like tumor;
and (G) normal control samples. The y-axis consists of all RefSeq genes (with major and
minor tick marks every 5,000 and 1,000 genes, respectively), clustered to form a
dendrogram, which is visible on the left side of the graph. Genes with low nominal
expression levels were below minimum threshold read counts for analysis by Veridical.
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Appendix S4.4
TCGA

Variants compared to those previously published by

TCGA Protein Coding Variants
SNVs Validated
SNVs Not Validated

Total TCGA

No. TCGA mutations
predicted

5557

5085 (91.5%)

18197

15742 (86.5%)

Indels Validated

125

44 (35.2%)

Indels Not Validated

1758

170 (9.7%)

Total

25637

21041 (82.1%)

SNVs Validated

87

80 (92.0%)*

SNVs Not Validated

342

291 (85.1%)^

Total

429

371 (86.5%)

TCGA Splicing Variants

*contains two variants that were filtered out based on our filtering criteria
^contains eight variants filtered out
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Appendix S4.5 Overrepresentation analysis of TCGA mutations
missed by Strelka
A pathway analysis using G:Profiler (Reimand et al. 2011) on the 4,654 TCGA variants,
missed by Strelka, revealed 116 overrepresented pathways including development (20),
morphogenesis (11), cellular processes (16), regulation (10), ion binding (6) and adhesion
(5). Details below.
PATHWAY NAME
cell adhesion
biological adhesion
multicellular organismal
development
homophilic cell adhesion
system development
single-organism cellular process
developmental process
single-multicellular organism
process
anatomical structure development
single-organism process
multicellular organismal process
cellular process
nervous system development
single-organism developmental
process
cell-cell adhesion
calcium ion binding
organ development
anatomical structure morphogenesis
cellular component movement
neurogenesis
cell differentiation
cellular developmental process
cell development
generation of neurons
circulatory system development
cardiovascular system development
ion binding
cation binding
BioGRID interaction data
neuron differentiation
metal ion binding
cell communication
cell projection organization
organ morphogenesis
cellular component morphogenesis

Pathway
Group

Pathway
Depth in
Group

P-VALUE

2
2

3
2

4.52E-15
5.61E-15

# Genes
mutated
in
pathway
200
200

2

4

1.35E-14

626

4561

2
2
2
2

5
5
3
2

4.26E-14
5.93E-14
3.90E-13
7.50E-13

52
552
1325
685

140
3942
11241
5169

2

3

2.51E-12

813

6363

2
2
2
2
2

3
2
2
2
6

3.59E-12
7.29E-12
2.59E-11
6.19E-11
4.51E-10

614
1438
833
1668
296

4568
12461
6605
14918
1939

2

3

6.29E-10

541

4033

2
7
2
2
2
2
2
2
2
2
2
2
7
7
6
2
7
2
2
2
2

4
5
6
3
4
7
4
3
4
8
6
6
2
3
1
9
4
4
2
7
2

8.99E-10
1.10E-09
7.55E-09
5.76E-08
1.07E-07
1.41E-07
2.72E-07
3.58E-07
3.66E-07
7.55E-07
2.25E-06
2.25E-06
5.39E-06
9.74E-06
1.07E-05
1.15E-05
1.74E-05
2.62E-05
2.68E-05
2.72E-05
4.53E-05

99
139
396
337
240
204
428
450
254
192
144
144
813
565
933
176
556
693
167
145
175

459
737
2824
2362
1570
1286
3176
3375
1704
1215
856
856
6765
4489
7657
1128
4424
5695
1069
896
1141
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Total #
Genes in
Pathway
1059
1061

heart development
signaling
single organism signaling
neuron development
Factor: LRF; motif:
VNNRMCCCC; match class: 3
regulation of cellular process
cell morphogenesis
biological regulation
locomotion
calcium-dependent cell-cell
adhesion
biological_process
binding
cell-cell junction
regulation of biological process
cell morphogenesis involved in
differentiation
cytoskeleton
basement membrane
Small cell lung cancer
neuron projection development
localization
tissue development
chordate embryonic development
Factor: LRF; motif:
VNNRMCCCC; match class: 2
cytoskeletal part
system process
cytoskeleton organization
embryo development ending in
birth or egg hatching
anatomical structure formation
involved in morphogenesis
MI:hsa-miR-940
Factor: Sp1; motif:
CCCCGCCCCN; match class: 3
cell morphogenesis involved in
neuron differentiation
cell projection morphogenesis
cell projection
muscle structure development
Factor: LRF; motif:
VNNRMCCCC; match class: 4
cellular response to growth factor
stimulus
plasma membrane part
negative regulation of biological
process
axonogenesis
Muscle contraction
Striated Muscle Contraction
Calcium Binds Troponin-C
Myosin Binds ATP

2
2
2
2

7
2
3
10

4.84E-05
5.57E-05
5.57E-05
6.08E-05

83
677
677
146

438
5571
5571
915

3

2

6.81E-05

1542

12643

2
2
2
2

3
3
2
2

1.02E-04
1.12E-04
1.15E-04
1.87E-04

1040
165
1157
205

9037
1075
10182
1410

2

5

1.92E-04

15

31

2
7
25
2

1
1
1
2

2.11E-04
2.97E-04
5.93E-04
6.62E-04

1812
1488
62
1088

16892
13523
313
9577

2

4

7.48E-04

124

778

15
11
14
2
2
2
4

1
2
1
3
2
4
2

7.98E-04
8.52E-04
9.47E-04
9.98E-04
1.24E-03
1.62E-03
1.62E-03

273
27
25
125
596
226
101

2015
93
98
790
4926
1629
610

3

3

1.63E-03

1374

11197

15
2
16

1
4
1

2.10E-03
2.34E-03
2.38E-03

205
258
141

1457
1911
931

4

1

2.77E-03

101

617

2

3

2.98E-03

144

959

22

1

3.63E-03

105

625

5

2

4.64E-03

779

6025

2

5

6.22E-03

101

628

2
20
2

3
1
4

6.26E-03
6.88E-03
7.08E-03

119
194
89

770
1389
537

3

1

7.75E-03

1600

13333

8

1

7.80E-03

102

639

9

1

8.10E-03

297

2282

2

3

9.91E-03

453

3686

2
13
13
13
13

5
1
2
3
3

1.11E-02
1.11E-02
1.11E-02
1.11E-02
1.11E-02

92
12
12
12
12

566
33
33
33
33
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ATP Hydrolysis By Myosin
Release Of ADP From Myosin
response to growth factor stimulus
neuron projection guidance
axon guidance
MI:hsa-miR-939
Factor: Sp1; motif:
CCCCGCCCCN; match class: 4
regulation of metabolic process
proteinaceous extracellular matrix
Factor: LRF; motif:
VNNRMCCCC; match class: 1
localization of cell
cell motility
cell part morphogenesis
MI:hsa-miR-615-5p
Pathways in cancer
Factor: VDR; motif:
GGGKNARNRRGGWSA; match
class: 3
neuron projection morphogenesis
signal transduction
regulation of nucleobase-containing
compound metabolic process
Factor: AP-2; motif:
SNNNCCNCAGGCN; match class:
3
cell surface receptor signaling
pathway
MI:hsa-miR-423-5p
muscle organ development
negative regulation of cytoskeleton
organization
in utero embryonic development
positive regulation of cellular
process
regulation of nitrogen compound
metabolic process
cytoskeletal protein binding
Factor: VDR; motif:
GGGKNARNRRGGWSA; match
class: 4
Chronic myeloid leukemia
transmission of nerve impulse
blood vessel morphogenesis
cellular component organization
cellular response to stimulus
negative regulation of cellular
process
cellular response to epidermal
growth factor stimulus
MI:hsa-miR-675
Phosphatidylinositol signaling
system

13
13
8
2
2
18

3
3
1
1
2
1

1.11E-02
1.11E-02
1.20E-02
1.30E-02
1.30E-02
1.36E-02

12
12
103
68
68
104

33
33
653
386
386
637

5

1

1.41E-02

881

6940

2
11

3
1

1.51E-02
1.51E-02

660
71

5616
410

3

4

1.56E-02

925

7323

2
2
2
10
21

3
4
3
1
1

1.68E-02
1.68E-02
1.70E-02
1.72E-02
1.80E-02

150
150
119
125
56

1039
1039
786
799
343

12

2

1.86E-02

1140

9204

2
2

4
2

2.15E-02
2.36E-02

100
596

638
5036

2

1

2.42E-02

473

3900

26

1

2.44E-02

753

5869

2

3

2.64E-02

361

2886

23
2

1
7

2.68E-02
2.76E-02

114
69

723
402

16

2

2.80E-02

23

86

4

3

2.87E-02

66

380

2

1

3.32E-02

451

3710

2

4

3.36E-02

484

4013

24

1

3.41E-02

111

733

12

1

3.45E-02

1415

11684

17
2
2
2
2

1
1
4
1
1

3.78E-02
3.87E-02
3.89E-02
4.33E-02
4.44E-02

18
120
77
585
705

75
808
467
4958
6085

2

4

4.76E-02

411

3358

8

1

4.77E-02

8

14

1

1

4.95E-02

101

635

19

1

4.99E-02

19

83
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Appendix S4.6
Gene Name

PIK3CA*
TP53*
GATA3*
RB1*
AKT1*
CBFB*
CDH1*
MAP3K1*
KMT2C
(MLL3)*
PTEN*
RUNX1*
SF3B1*
CDKN1B*
NF1*
STMN2
TBX3*
AFF2*
AGTR2
APC
ARID1A
ARID2
ASXL1
ATR
BAP1

MuSiC Results Compared to Significantly Mutated Genes

#
Studies

Total
Mutations

#Stop
Gain/
Loss

#
Missense

#
Silent

#
Splicing

#
Validated
Splicing

% Splicing
Mutations
Validated

MuSiC
P-Value
LRT

MuSiC
P-Value
CT

MuSiC
FDR LRT

MuSiC
FDR CT

5
5
4
4
3
3
3
3

181
153
10
19
6
12
20
40

0
19
0
5
0
2
5
13

3
2
2
1
1
1
1
5

177
107
7
12
5
7
5
17

1
25
1
1
0
2
9
5

0
18
1
0
0
2
4
4

0%
56%
100%
0%
NA
100%
22%
80%

0.0226
0
0.0075
0.0610
1
0.0011
0
0

0.0493
0
0.0232
0.0471
1
0.0001
0
0

0.4088
0
0.1926
0.7410
1
0.0414
0
0

1
0
0.7132
1
1
0.0122
0
0

72

7

16

30

19

7

37%

0

0

0

0

11
8
19
1
27
1
5
20
0
7
32
11
8
11
6

4
1
1
0
3
0
0
3
0
0
6
2
1
0
1

0
1
6
0
3
0
0
5
0
2
5
3
3
3
3

5
6
11
1
17
1
5
11
0
5
19
5
4
6
2

2
0
1
0
4
0
0
1
0
0
2
1
0
2
0

2
0
0
0
2
0
0
0
0
0
1
0
0
0
0

100%
NA
0%
NA
50%
NA
NA
0%
NA
NA
50%
0%
NA
0%
NA

0.0116
1
0
1
1
1
1
0.0006
1
1
0
0.4970
0.0025
1
0.1206

0.0023
1
0.0006
1
1
1
1
0.0003
1
1
0
0.2598
0.0089
1
0.1182

0.2677
1
0.0009
1
1
1
1
0.0257
1
1
0
1
0.0806
1
1

0.1240
1
0.0418
1
1
1
1
0.0263
1
1
0.0005
1
0.3561
1
1

3
3
3
3
2
2
2
2
1
1
1
1
1
1
1
1
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BRAF
BRCA1
BRCA2
CCND3*
COL6A3
ERBB2
ERBB3
GH1
KRAS
LDLRAP1
MAP2K4
MLL2
MYH9
MYO3A
NRAS
PIK3R1*
PTPN22*
PTPRD*
SETD2
SMAD4
STK11
SYNE1
SYNE2
UBR5
USH2A

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

7
15
15
2
15
16
16
1
3
0
16
24
15
11
0
7
5
25
16
1
1
65
57
29
65

1
2
2
0
1
0
1
0
0
0
2
1
0
0
0
0
0
3
1
0
0
4
0
0
0

0
2
3
0
3
2
2
1
0
0
0
10
2
6
0
1
0
4
3
0
0
14
10
10
12

6
7
9
2
11
13
11
0
3
0
10
13
13
3
0
5
5
18
9
1
1
41
44
18
52

0
4
1
0
0
1
2
0
0
0
4
0
0
2
0
1
0
0
3
0
0
6
3
1
1

0
2
1
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
1
0
0
0
0
1
0

* Identified by TCGA to be significantly mutated
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NA
50%
100%
NA
NA
0%
0%
NA
NA
NA
100%
NA
NA
0%
NA
0%
NA
NA
0%
NA
NA
0%
0%
100%
0%

1
0.1109
0.2360
1
1
0.1453
0.0355
0.0893
1
1
0.0536

1
0.0531
0.2227
1
1
0.3469
0.3206
0.4113
1
1
0.0120

1
0.9945
1
1
1
1
0.5458
0.8910
1
1
0.6904

1
1
1
1
1
1
1
1
1
1
0.4405

0.01427
1
0.0050
1
1
1
0.0335
0.0408
1
1
1
1
0.1179
1

0.02027
1
0.0009
1
1
1
0.0410
0.1420
1
1
1
1
0.0142
1

0.3081
1
0.1390
1
1
1
0.5258
0.5975
1
1
1
1
1
1

0.6498
1
0.0571
1
1
1
1
1
1
1
1
1
0.4993
1

Appendix S4.7

Validated Cryptic Splicing Mutations

Appendix S4.7.1 Cryptic Splicing Mutation Details
Information theory based analysis and corresponding evidence demonstrating abnormal
mRNA splicing in predicted mRNA splicing mutations. (A) Table indicates the TCGA
sample identifier, variant, information analysis and statistical support for the mutation.
(B) Screenshots from the Integrative Genomics Viewer (IGV) displaying junctionspanning reads that demonstrate cryptic splicing for mutations predicted by the Shannon
Pipeline in the genes CBFB, GATA3, PALB2, and ABL1. The normal exonic structure is
indicated by blue, with the thick bars representing exons, and the thin lines introns. RNASeq reads are shown in grey with the vertical dotted black lines demarcate the location of
the cryptic splice site.
(A)
Patient
TCGAA8A08S
TCGAB6A0I5
TCGAB6A0RT
TCGAB6A0RV

Splice Site
Coordinate

Variant
Coordinate

Ref/
Var

Riinitial

Rifinal

Δ
Ri

Cryptic
Site
Use PValue

Exon
Skipping
P-Value

CBFB

chr16:
67070591

chr16:
67070577

G/T

5.6

7.5

1.9

< 0.005

0.12

GATA3

chr10:
8115709

chr10:
8115702

A/C

4.2

5.9

1.7

< 0.005

NA

PALB2

chr16:
23637694

chr16:
23637710

T/A

5.3

7.0

1.7

< 0.005

0.05

ABL1

chr9:
133750256

chr9:
133750254

G/C

0.8

9.6

8.8

< 0.005

NA

Gene
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(B) CBFB

(C) GATA3
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(D) PALB2

(E) ABL1
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Appendix S4.7.2 The rate of GATA3 abnormal splicing in variant
containing tumour and tumour/normal controls
Junction-spanning, cryptic splicing read counts for GATA3 mutation (chr10:
g.8115702A>C). The number of RNA-Seq reads per exonic base were plotted against the
number of reads demonstrating GATA3 cryptic splicing in the variant-containing
tumours and controls. The variant containing tumour is indicated by the number of
cryptic splicing reads (n = 791), tumours that do not contain this variant are in red, and
normal controls are in blue. Cryptic splicing in the control samples likely occurs because
the cryptic splice site (Ri = 4.2 bits) exceeds the strength of the natural splice site (Ri =
0.9 bits). However, the mutation further weakens the natural splice site (final Ri = 0.0
bits), while simultaneously strengthening the cryptic splice site (final Ri = 5.8 bits), which
are consistent with the RNA-Seq analysis.
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Appendix S4.8

Supplementary Figure 4

Intron inclusion in tumour and normal breast genomes, based on RNA-Seq evidence.
Histogram of the density of intronic sequence reads for normal (blue) and tumour (red)
RNA-Seq samples. Purple shading represents overlapping components of the two density
distributions. Intron inclusion was calculated with RSeQC's ReadDist script and RefSeq’s
gene annotation. High levels of unspliced isoforms with intron inclusion were the most
frequent outcome of mutations with significant effects on mRNA splicing. Nevertheless,
when considering non-specific aberrant splicing across the transcriptome, the numbers of
junction-spanning, intron inclusion reads present in normal and tumour samples did not
significantly differ (p > 0.1). In fact, non-junction-spanning, intronic read-abundance
reads of normal controls exceeded those of the tumour samples (p < 0.01). This suggests
that validation events in these tumour samples are not due solely to intron inclusion and
aberrant mRNA splicing known to be present in breast tumours (9). It is notable,
however, that the levels of intronic inclusion for validated mutations significantly

0.10
0.05
0.00

Density

0.15

0.20

exceeded the read counts for all controls that did not contain these variants.

0

5

10

15
Intronic Tags/Kb
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Appendix S4.9

Pathway Analyses

Appendix S4.9.1 Pathways Overrepresented by Protein Coding and
Splicing Mutations
Pathway
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24
25
26
27
28
29
30
31
32

Pathways common to both Strelka splicing
and protein coding mutations
Anchoring fibril formation
Assembly of collagen fibrils and other
multimeric structures
Association of procollagen chains
Collagen biosynthesis and modifying enzymes
Collagen formation
Collagen prolyl 3-hydroxylase converts proline
to 3-hydroxyproline
Collagen prolyl 4-hydroxylase converts proline
to 4-hydroxyproline
Collagen type VII binds laminin-322 and
collagen IV
DDR1 binds collagens
ECM proteoglycans
Extracellular matrix organization
Galactosylation of collagen propeptide
hydroxylysines by PLOD3
Glucosylation of collagen propeptide
hydroxylysines
Interaction of NCAM1 with collagens
Non-integrin membrane-ECM interactions
PDI is a chaperone for collagen peptides
Procollagen lysyl hydrolases convert lysine to 5hydroxylysine
Procollagen triple helix formation
Removal of fibrillar collagen C-propeptides
Removal of fibrillar collagen N-propeptides
Secretion of collagens
Formation of collagen fibres
Formation of collagen fibrils
Galactosylation of collagen propeptide
hydroxylysines by procollagen
galactosyltransferases 1, 2.
PDGF binds to extracellular matrix proteins
Cell Cycle, Mitotic
Cell-Cell communication
CBL, GRB2, FYN and PI3K p85 subunit are
constitutively associated
Signaling by FGFR1 fusion mutants
Indirect recruitment of PI3K to KIT via p(Y)GAB2
Loss of Nlp from mitotic centrosomes
Base Excision Repair
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Present in Pathway
Analysis with both
Protein Coding and
Splicing Mutations?
YES

Col/ECM

YES
YES
YES
YES

Col/ECM
Col/ECM
Col/ECM
Col/ECM

YES

Col/ECM

YES

Col/ECM

YES
YES
YES
YES

Col/ECM
Col/ECM
Col/ECM
Col/ECM

YES

Col/ECM

YES
YES
YES
YES

Col/ECM
Col/ECM
Col/ECM
Col/ECM

YES
YES
YES
YES
YES
NO
NO

Col/ECM
Col/ECM
Col/ECM
Col/ECM
Col/ECM
Col/ECM
Col/ECM

NO
NO
NO
YES

Col/ECM
Col/ECM
Cancer
Cancer

NO
YES

?
Cancer

YES
YES
YES

Cancer
?
Cancer

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76

Mitotic Prometaphase
Signaling by FGFR in disease
PLCG1 events in ERBB2 signaling
Downstream signaling of activated FGFR
Signaling by FGFR1 mutants
Separation of sister chromatids
Kinetochore assembly
Recruitment of mitotic centrosome proteins and
complexes
Centrosome maturation
Mitotic G2-G2/M phases
Signaling by ERBB2
Resolution of AP sites via the single-nucleotide
replacement pathway
G2/M Transition
Transmembrane transport of small molecules
Ion channel transport
Axon guidance
Integrin cell surface interactions
Ion transport by P-type ATPases
Developmental Biology
NICD1 displaces co-repressor complex from
RBPJ (CSL)
NICD1 PEST domain mutants displace corepressor complex from RBPJ (CSL)
L1CAM interactions
Transport of inorganic cations/anions and amino
acids/oligopeptides
SLC-mediated transmembrane transport
cAMP degradation by Phosphodiesterases
CBL is tyrosine phosphorylated
Dystroglycan binds Laminins and Dystrophin
Signalling by NGF
P-type ATPases type IV transport external-facing
APLs to internal side of the plasma membrane
P-type ATPases type IV transport internal-facing
APLs to external side of the plasma membrane
NCAM signaling for neurite out-growth
NRAGE signals death through JNK
p75NTR indirectly activates RAC and Cdc42 via
a guanyl-nucleotide exchange factor
Signaling by Rho GTPases
Rho GTPase cycle
Stimuli-sensing channels
ABC-family proteins mediated transport
GEFs activate RhoA,B,C
Other semaphorin interactions
Signaling by PDGF
Semaphorin interactions
Signaling by Interleukins
Interaction between L1 and Ankyrins
Transmission across Chemical Synapses
261

YES
YES
YES
NO
NO
YES
YES

Cancer
Cancer
Cancer
Cancer
Cancer
?
?

YES
YES
YES
NO

?
?
Cancer
Cancer

YES
YES
YES
YES
YES
YES
YES
YES

Cancer
Cancer
Other
Other
Other
Other
Other
Other

NO

Other

NO
YES

Other
?

YES
YES
YES
YES
YES
YES

Other
Other
Other
Other
Other
Other

YES

Other

YES
YES
YES

Other
Other
?

YES
YES
YES
YES
YES
NO
YES
YES
YES
YES
YES
YES

Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other

77

78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Plk1-mediated phosphorylation of Nlp
Loss of proteins required for interphase
microtubule organizationÃƒâ€šÃ‚ from the
centrosome
Loss of C-Nap-1 from centrosomes
Dissociation of Phospho-Nlp from the
centrosome
Recruitment of Plk1 to centrosomes
Resolution of Abasic Sites (AP sites)
Platelet calcium homeostasis
Recruitment of additional gamma tubulin/
gamma TuRC to the centrosome
Recruitment of CDK11p58 to the centrosomes
Ankyrins link voltage-gated sodium and
potassium channels to spectrin and L1
Translocation of Influenza A virus nonstructural
protein 1 (NS1A) into the nucleus
Synthesis of PIPs at the early endosome
membrane
The ABCC family mediates organic anion
transport
PLC beta mediated events
Downstream signal transduction
Phosphorylation of cohesin by PLK1 at
centromeres
PP2A-B56 dephosphorylates centromeric
cohesin
DAG and IP3 signaling
G-protein mediated events
Kinetochore capture of astral microtubules
ESPL1 (Separase) cleaves centromeric cohesin
Recruitment of Grb2 to pFAK:NCAM1
2GABRA:2GABRB:GABRG:GABA transports
extracellular Cl- to cytosol
GABA A receptor activation
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YES

Other

NO
YES

?
?

YES
YES
YES
YES

?
?
?
Other

YES
YES

?
?

YES

Other

YES

Other

YES

Other

NO
YES
YES

Other
Other
?

YES

?

YES
YES
YES
YES
YES
YES

?
Other
Other
?
Other
Other

YES
YES

Other
Other

Appendix S4.9.2 Pathways Overrepresented by Every Splicing
Mutation Type (inactivating, leaky, cryptic)

1 Association of procollagen chains
Collagen biosynthesis and modifying
2
enzymes
3 Collagen formation
Collagen prolyl 3-hydroxylase converts
4
proline to 3-hydroxyproline
Collagen prolyl 4-hydroxylase converts
5
proline to 4-hydroxyproline
6 DDR1 binds collagens
Galactosylation of collagen propeptide
7
hydroxylysines by PLOD3
Galactosylation of collagen propeptide
8 hydroxylysines by procollagen
galactosyltransferases 1, 2.
Glucosylation of collagen propeptide
9
hydroxylysines
10 PDI is a chaperone for collagen peptides
Procollagen lysyl hydrolases convert lysine
11
to 5-hydroxylysine
12 Procollagen triple helix formation
13 Secretion of collagens
14 Degradation of collagen
15 ECM proteoglycans
16 Extracellular matrix organization
17 Non-integrin membrane-ECM interactions
18 Anchoring fibril formation
19 Axon guidance
20 Cell Cycle, Mitotic
21 Developmental Biology
22 Integrin cell surface interactions
23 L1CAM interactions
Transmembrane transport of small
24
molecules
Activation of Chaperone Genes by
25
XBP1(S)
26 Activation of Chaperones by IRE1alpha
27 Cell Cycle
28 Hemostasis
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Overrepresented by protein
coding mutation set?
YES
YES
YES
YES
YES
YES
Collagen

YES

YES
YES
YES

ECM

Other

YES
YES
YES
NO
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
NO
NO
NO
NO

Appendix S4.9.3 Comparing Grouped Pathways Overrepresented between LN- and LN+ Tumour
Mutations
RED = collagen, BLUE = extracellular matrix, GREEN = NCAM1 pathways, No. = number of pathways in group
Lymph Node Negative Tumours

No.

Lymph Node Positive Tumours

No.

Pathways in Both Lymph Node Positive and
Negative Tumours

No.
LN-

No.
LN+

Signaling by FGFR1 fusion mutants
Cytosolic tRNA aminoacylation

10
9

10
8

Collagen biosynthesis and modifying enzymes
Semaphorin interactions

12
9

12
10

Striated Muscle Contraction

7

8

L1CAM interactions

8

8

PI3K events in ERBB2 signaling
COPI Mediated Transport
Glucose metabolism

6
6
4

Neurotransmitter Release Cycle
Complement cascade
NCAM signaling for neurite outgrowth
SHC1 events in ERBB2 signaling
SHC1 events in ERBB4 signaling
Downregulation of ERBB4 signaling

4
4
3

12
4
4

1
6
4

Synthesis of PIPs at the late endosome membrane

3

Generic Transcription Pathway

3

2

6

STAT6-mediated induction of chemokines

3

3

4

3

Signaling by SCF-KIT

3

5

1

Regulation of signaling by CBL
Regulation of AMPK activity via LKB1
Transport of vitamins, nucleosides, and related
molecules

3
3

3
3

3
3

3
3

2

Signal Transduction

2

4

Synthesis of PIPs at the Golgi membrane

2

2

Fc epsilon receptor (FCERI) signaling

1

5

Signaling by constitutively active EGFR

2

Nuclear signaling by ERBB4
Regulation of Hypoxia-inducible
Factor (HIF) by Oxygen
Signaling by ERBB4
Xenobiotics
Apoptosis induced DNA
fragmentation
Assembly of the pre-replicative
complex
Binding and Uptake of Ligands by
Scavenger Receptors

Signaling by Interleukins
Extracellular matrix organization
GPCR downstream signaling
Regulation of Cholesterol Biosynthesis by
SREBP (SREBF)
Hemostasis
Transport of inorganic cations/anions and amino
acids/oligopeptides
Transmembrane transport of small molecules
Condensation of Prometaphase Chromosomes

2

Recruitment of mitotic centrosome proteins and
complexes

3

2

PIP3 activates AKT signaling

2

Conjugation of carboxylic acids

2

3

2

PI3K events in ERBB4 signaling

2

2

2

3

PI3K Cascade

2

2

Non-integrin membrane-ECM interactions

2

3

Nuclear import of Rev protein

2

DAG and IP3 signaling
Metabolism of amino acids and
derivatives
Mitotic G1-G1/S phases

Factors involved in megakaryocyte development
and platelet production
Synthesis of PIPs at the plasma membrane

2

Ion channel transport

2

3

2
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3

Metabolism of steroid hormones and vitamin D

2

Intrinsic Pathway

2

Nitric oxide stimulates guanylate
cyclase
Opioid Signalling

GPVI-mediated activation cascade

2

PI Metabolism

2

Downstream signal transduction

2

Phospholipid metabolism

2

COPII (Coat Protein 2) Mediated Vesicle
Transport
Cell Cycle
Assembly of collagen fibrils and other
multimeric structures
Muscle contraction

Cross-presentation of particulate exogenous
antigens (phagosomes)

2

Scavenging of Heme from Plasma

2

Costimulation by the CD28 family

2

2

Cell Cycle, Mitotic

2

CD28 dependent PI3K/Akt signaling

2

Vitamin C (ascorbate) metabolism

1

Signaling by ERBB2
Synthesis of IP2, IP, and Ins in the
cytosol
Synthesis of very long-chain fatty
acyl-CoAs
Activated NOTCH1 Transmits Signal
to the Nucleus

VEGF ligand-receptor interactions

1

tRNA Aminoacylation

2

2

3

2

3

1

4

3

1

Membrane Trafficking

3

1

Integrin cell surface interactions
Inactivation, recovery and regulation of the
phototransduction cascade

3

1

3

1

2

Regulation of the Fanconi anemia pathway

2

2

1

Nephrin interactions

2

2

Amino Acid conjugation

1

Loss of proteins required for interphase
microtubule organization√Ç¬†from the
centrosome

2

2

1

Antiviral mechanism by IFNstimulated genes

1

Loss of Nlp from mitotic centrosomes

2

2

Transport of glucose and other sugars, bile salts and
organic acids, metal ions and amine compounds

1

Asparagine N-linked glycosylation

1

Fatty acid, triacylglycerol, and ketone body
metabolism

2

2

Translocation of GLUT4 to the Plasma Membrane

1

1

Developmental Biology

2

2

Tie2 Signaling

1

1

Collagen formation

2

2

TCR signaling

1

1

Stimuli-sensing channels

1

3

1

Ion transport by P-type ATPases

1

3

1
1
1

ECM proteoglycans
DAP12 interactions
Unfolded Protein Response
Synthesis of PIPs at the early endosome
membrane

1
1
2

3
3
1

2

1

Platelet activation, signaling and aggregation

2

1

2

2

1
1
1

CDC6 association with the
ORC:origin complex
CDO in myogenesis
CDT1 association with the
CDC6:ORC:origin complex
CREB phosphorylation through the
activation of Adenylate Cyclase
Calnexin/calreticulin cycle
Chromosome Maintenance
Circadian Clock

S6K1-mediated signalling

1

Conjugation of benzoate with glycine

1

S6K1 signalling

1

Conjugation of phenylacetate with
glutamine

1

STING mediated induction of host immune
responses
Smooth Muscle Contraction
Signaling by Rho GTPases
Signaling by FGFR mutants

1
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RIG-I/MDA5 mediated induction of IFN-alpha/beta
pathways
Rho GTPase cycle

1

DNA Repair

1

1

Disease
E2F-enabled inhibition of prereplication complex formation

1

NGF signalling via TRKA from the plasma
membrane
Cell-Cell communication

1

2

1

2

1

Signalling by NGF

1

2

1

Regulation of Insulin Secretion

1

2

1

p75 NTR receptor-mediated signalling

1

2

1
1
1
1
1
1

G2/M Checkpoints
Effects of PIP2 hydrolysis
Axon guidance
Transmission across Chemical Synapses
Stabilization of p53
SLC-mediated transmembrane transport
Signaling by NOTCH1 PEST Domain Mutants
in Cancer

1
1
1
1
1
1

2
2
2
1
1
1

1

1

Response to elevated platelet cytosolic Ca2+

1

Regulation of mRNA Stability by Proteins that Bind
AU-rich Elements

1

Rap1 signalling

1

Polo-like kinase mediated events
Platelet Adhesion to exposed collagen
PKB-mediated events
Phase 1 - Functionalization of compounds
Organic cation/anion/zwitterion transport
NRAGE signals death through JNK

1
1
1
1
1
1

mTORC1-mediated signalling

1

mTOR signalling

1

N-glycan trimming in the ER and
Calnexin/Calreticulin cycle

1

Signaling by FGFR1 mutants

1

1

Metabolism of water-soluble vitamins and cofactors

1

NGF processing

1

1

1

Metabolism of nucleotides

1

Neuronal System

1

1

1

Metabolism
Ligand-gated ion channel transport
ISG15 antiviral mechanism
Integration of energy metabolism
Inhibition of replication initiation of damaged DNA
by RB1/E2F1

1
1
1
1

PKA activation
Phase II conjugation
Platelet calcium homeostasis
Platelet homeostasis

1
1
1
1

Peroxisomal lipid metabolism
NOTCH1 Intracellular Domain Regulates
Transcription
Metabolism of proteins
Meiosis
M Phase
Interleukin receptor SHC signaling

1
1
1
1

1
1
1
1

1

Platelet sensitization by LDL

1

Inositol phosphate metabolism

1

1

Homologous recombination repair of replicationindependent double-strand breaks

1

Pyruvate metabolism and Citric Acid
(TCA) cycle

1

ER to Golgi Transport

1

1

Golgi to ER Retrograde Transport

1

Signaling by EGFR

1

Depolarization of the Presynaptic Terminal
Triggers the Opening of Calcium Channels

1

1

Gene Expression

1

Signaling by FGFR

1

1

1

Gamma-carboxylation of protein precursors

1

Signaling by NOTCH2

1

1

1

EGFR interacts with phospholipase Cgamma
ER Quality Control Compartment
(ERQC)
Fanconi Anemia pathway
G-protein mediated events
Interferon Signaling
Interleukin-2 signaling
Lipoprotein metabolism
Lysine catabolism
MyD88 cascade initiated on plasma
membrane
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1

Conversion from APC/C:Cdc20 to APC/C:Cdh1
in late anaphase
Collagen degradation

E2F mediated regulation of DNA replication

1

Signaling by PDGF

1

Cytokine Signaling in Immune system

1

1

Cyclin E associated events during G1/S transition

1

Constitutive PI3K/AKT Signaling in Cancer

1

ChREBP activates metabolic gene expression

1

Cell surface interactions at the vascular wall

1

Cell death signalling via NRAGE, NRIF and NADE

1

Signaling by Robo receptor
Signaling by the B Cell Receptor
(BCR)
Syndecan interactions
Synthesis and interconversion of
nucleotide di- and triphosphates
Synthesis of IP3 and IP4 in the cytosol
Transcriptional Regulation of White
Adipocyte Differentiation

CD28 co-stimulation
Biological oxidations
Antigen processing-Cross presentation
AMPK inhibits chREBP transcriptional activation
activity

1
1
1

Activation of the AP-1 family of transcription
factors
Activation of Chaperones by ATF6-alpha
Abacavir transmembrane transport

1
1
1
1
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1
1
1
1
1

ATM mediated phosphorylation of repair
proteins
Activation of Chaperones by IRE1alpha

1

1

1

1

Appendix S4.9.4 Pathway Analysis of Deleterious Mutations in LN- and LN+ Tumours
RED = collagen, BLUE = extracellular matrix, GREEN = NCAM1 pathways

Syndecan-1 binds collagen types I, III, V

FGFR1 fusions bind PLCgamma

Syndecan-1 binds collagen types I, III, V

Hemostasis
Inhibition of integrin activation by sequestering
PIP5KIgamma
Interaction of integrin alphaEbeta7 with Cadherin-1
Interleukin-1 receptor type 1 binds Interleukin 1
Interleukin-2 signaling
Interleukin-7 signaling
Na+-coupled HCO3- cotransport
NrCAM interactions
p-PLCgamma dissociates from FGFR1 fusions

Over Represented by Both Lymph Node
Positive and Negative Tumour Mutations
Assembly of collagen fibrils and other multimeric
structures
Association of procollagen chains
Collagen biosynthesis and modifying enzymes
Collagen formation
Collagen prolyl 3-hydroxylase converts proline to
3-hydroxyproline
Collagen prolyl 4-hydroxylase converts proline to
4-hydroxyproline
Galactosylation of collagen propeptide
hydroxylysines by PLOD3
Galactosylation of collagen propeptide
hydroxylysines by procollagen
galactosyltransferases 1, 2.
Glucosylation of collagen propeptide
hydroxylysines
PDI is a chaperone for collagen peptides
Procollagen lysyl hydrolases convert lysine to 5hydroxylysine
Procollagen triple helix formation
Removal of fibrillar collagen C-propeptides
Secretion of collagens
Extracellular matrix organization
Axon guidance
Cell Cycle
Developmental Biology

Phosphorylation of STAT5 by FGFR1 fusions

Dissociation of Phospho-Nlp from the centrosome

PI is phosphorylated to PI5P by PIKFYVE at the
late endosome membrane

DOCKs bind to RhoGEFs

Lymph Node Positive Tumour Mutations

Lymph Node Negative Tumour Mutations

Autophosphorylation of NCAM1 bound Fyn

Activation of Chaperones by ATF6-alpha

Dephosphorylation of NCAM1 bound pFyn
Interaction of NCAM1 with collagens
NCAM signaling for neurite out-growth

Cargo, Sec31p:Sec13p, and v-SNARE recruitment
Cell-Cell communication
Cleavage of ATF6-alpha by S1P

NCAM1 interactions

COPII (Coat Protein 2) Mediated Vesicle Transport

Formation of collagen fibres

ER to Golgi Transport

Formation of collagen fibrils
Removal of fibrillar collagen N-propeptides

Degradation of the extracellular matrix
ECM proteoglycans
Non-integrin membrane-ECM interactions
PDGF binds to extracellular matrix proteins
Activation of Adenylate Cyclase
Activation of Chaperones by IRE1alpha
Activation of PPARA by Fatty Acid Ligands
AGRN binds Laminins with gamma-1 subunit
Ankyrins link voltage-gated sodium and potassium
channels to spectrin and L1
Antiviral mechanism by IFN-stimulated genes

factor VIII + von Willebrand factor multimer ->
factor VIII:von Willibrand factor multimer
factor VIII:von Willibrand factor multimer ->
factor VIIIa + factor VIIIa B A3 acidic polypeptide
+ von Willibrand factor multimer
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Association of MCM8 with ORC:origin complex
Binding of Beta-TrCP1 to phosphorylated PER
proteins
Binding of IP3 to IP3 receptor
Ca2+ influx through voltage gated Ca2+ channels
Calcium Influx through Voltage-gated Calcium
Channels
Calnexin/calreticulin cycle
Cell Cycle, Mitotic
Cell death signalling via NRAGE, NRIF and
NADE
cGMP effects
Dephosphorylation of CK2-modified condensin I

PI is phosphorylated to PI5P by PIKFYVE at the
late endosome membrane
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at
the early endosome membrane
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at
the Golgi membrane
PI(3,5)P2 is dephosphorylated to PI3P by FIG4 at
the late endosome membrane
PI3P is phosphorylated to PI(3,5)P2 by Pikfyve at
the early endosome membrane
PI3P is phosphorylated to PI(3,5)P2 by Pikfyve at
the early endosome membrane
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE
at the Golgi membrane
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE
at the Golgi membrane
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE
at the late endosome membrane
PI3P is phosphorylated to PI(3,5)P2 by PIKFYVE
at the late endosome membrane

Integrin cell surface interactions
Interaction between L1 and Ankyrins
Loss of C-Nap-1 from centrosomes
Loss of Nlp from mitotic centrosomes
Loss of proteins required for interphase
microtubule organizationÃ‚Â from the centrosome
Meiosis
Phosphorylation of MEK4 by MEKK1
Phosphorylation of p53 at ser-15 by ATM kinase
Plk1-mediated phosphorylation of Nlp
Recruitment of CDK11p58 to the centrosomes

Depolarization of the Presynaptic Terminal
Triggers the Opening of Calcium Channels

PLCgamma is phosphorylated by FGFR1-fusions

Recruitment of Plk1 to centrosomes

Dystroglycan binds Laminins and Dystrophin

Plexin-A1-4 binds NRP1

Transport of inorganic cations/anions and amino
acids/oligopeptides

ER Quality Control Compartment (ERQC)

Recruitment of additional gamma tubulin/ gamma
TuRC to the centrosome

ERBB4:TAB2:NCOR1 complex translocates to the
nucleus
ERBB4:TAB2:NCOR1 complex translocates to the
nucleus
ERBB4s80 binds Tab2:Ncor1 complex
ERBB4s80 binds Tab2:Ncor1 complex
Fanconi Anemia pathway
Formation of the BRCA1-PALB2-BRCA2
complex
Interaction of L1 with Laminin-1
Interaction of nephrin with adherens junction-

Release of platelet cytosolic components
Replication initiation regulation by Rb1/E2F1
Semaphorin interactions
Signaling by FGFR1 fusion mutants
SLC-mediated transmembrane transport
Stabilization of mRNA by HuR
Synthesis of IP3 and IP4 in the cytosol
Transcriptional activation of Acetyl-CoA
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associated proteins
IP3 binds to the IP3 receptor, opening the
endoplasmic reticulum Ca2+ channel
ISG15 antiviral mechanism
L1CAM interactions
Mitotic Prometaphase
N-glycan trimming in the ER and
Calnexin/Calreticulin cycle
NDP + reduced thioredoxin => dNDP + oxidized
thioredoxin + H2O
Neurofascin binds contactin-1:CASPR complex
NICD1 displaces co-repressor complex from RBPJ
(CSL)
NICD1 displaces NCOR co-repressor complex
from CSL
NICD1 PEST domain mutants displace corepressor complex from RBPJ (CSL)
Nitric oxide stimulates guanylate cyclase
NTN4 binds laminins with gamma-1, gamma-3
Opening of ER calcium channels by activated PKA
p75 NTR receptor-mediated signalling
Phosphorylation of FANCD2 by ATR/ATM
Phosphorylation of FANCI by ATM/ATR
Release of calcium from intracellular stores by IP3
receptor activation
Signaling by ERBB4
Signaling by PDGF
Signalling by NGF
Syndecan interactions
Transport of Ca++ from platelet dense tubular
system to cytoplasm
Unfolded Protein Response

carboxylase by ChREBP:MLX
Transmembrane transport of small molecules
Vesicle Budding
Vesicle Uncoating
Vesicular glutamate transport
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Appendix S4.10 Frequency of Mutations in NCAM1 Pathway Genes
Gene Name

All Mutations

Splicing Mutations

Total:
SPTA1
CACNA1D
COL6A5
NCAM1
COL6A6
COL6A3
CACNA1G
CACNA1I
COL4A1
CACNA1C
SPTBN1
COL3A1
SPTBN4
CACNB2
COL4A4
COL4A5
SPTB
CACNA1S
COL4A3
COL5A2
CNTN2
COL5A3
COL9A2
NCAN
SPTAN1
AGRN
COL5A1
COL6A2
PTPRA
CACNA1H
CACNB1
COL9A3
FGFR1
PRNP
SOS1
SPTBN5
COL9A1
CREB1

425
30
22
19
17
16
15
13
13
13
12
12
11
11
10
10
10
10
9
9
9
8
8
8
8
8
6
6
6
6
5
5
5
5
5
5
5
4
4

37
2
3
1
2
1
0
2
1
4
0
2
0
0
1
0
1
0
0
2
2
1
1
4
1
0
0
0
0
0
0
1
1
0
0
0
0
0
0
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Indel Frameshift &
Stop Gain/Loss
Mutations
35
3
7
0
1
1
3
0
0
0
1
1
2
0
1
0
1
2
0
0
1
1
2
0
1
0
0
2
0
0
0
0
0
0
0
1
0
0
0

PTK2
CACNB3
COL4A2
KRAS
MAPK3
RAF1
RPS6KA5
CDK1
COL2A1
FYN
GDNF
GFRA1
GFRA2
GRB2
MAPK1
SPTBN2
SRC
ST8SIA2
HRAS
MAP2K2
YWHAB

4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1

0
0
0
0
0
1
0
0
0
1
0
0
0
1
1
0
0
0
0
0
0
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0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
1
0
0
1

Appendix S4.11 Breast Cancer Mutations by Subtype
Appendix S4.11.1
Subtype*

No.
Tumours

Number of Mutations by Subtype
All Coding

Deleterious
Coding^

Splicing

No.

Av.

No.

Av.

No.

Av.

Basal Like

81

15,383

190

1,350

16.7

1,288

15.9

HER2enriched

51

8,633

169

708

13.9

729

14.3

Luminal A

192

22,634

118

1,889

9.8

1,786

9.3

Luminal B

104

14,501

139

1,166

11.2

1,209

11.6

6

1,105

184

105

17.5

78

13

"Normal
Like"

*subtype not available for 8 tumours, ^ Frameshift indels, stop codon gain or loss, No. =
total number of mutations, Av. = average number of mutations per tumour
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Appendix S4.11.2
Pathway Analysis of Mutations by Subtype
and Lymph Node Status
Basal

Her2

Luminal A
+

Luminal B
+

NormalLike
+

-

+

-

+

# Tumours

50

31

18

32

89

96

43

59

1

5

# Enriched
Pathways Total

115

115

132

120

122

142

185

147

8

7

# NCAM Pathways

0

9

2

7

0

2

1

2

0

0

# Collagen
Pathways

0

26

16

3

11

36

21

15

0

0

# ECM Pathways

0

4

3

0

1

5

4

4

0

0

844

444

300

414

1013

698

548

639

29

49

3

6

3

4

3

7

4

5

0

0

9

11

4

5

13

11

7

8

1

0

# Mutations Total
# NCAM Pathway
Mutations
# Collagen Pathway
Mutations

The “NCAM1 Interactions” and “Interaction of NCAM1 with collagens” pathways, were
overrepresented in luminal B and HER2-enriched LN+ tumours. The NCAM1 interaction
pathways contain a large number (n = 153) of different proteins where NCAM1 acts as a
signal transducing receptor molecule. These functions are tangential to NCAM1’s role in
neurite outgrowth and may explain why they are overrepresented in tumours that have
not invaded the lymph nodes.
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Appendix S4.11.3
subtype.

Word clouds of overrepresented pathways by

Word clouds of generalized overrepresented Reactome pathways for mutations stratified
by lymph node status (positive or negative) and breast cancer subtype (basal-like (A),
HER2-enriched (B), Luminal A (C), or Luminal B (D)). The size of each word is
proportional to its frequency in the abstracted list of overrepresented pathways.
(A)

Basal Like Lymph Node Positive
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Basal Like Lymph Node Negative

276

(B)

HER2-enriched lymph node positive

HER2-enriched lymph node negative

277

(C)

Luminal A lymph node positive

Luminal A lymph node negative

278

(D)

Luminal B lymph node positive

279

Luminal B lymph node negative

280
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Appendix S5: Supplementary Information for Chapter 5
Appendix S5.1
Cell Line

Cell Lines Used

Transcriptional
subtype

Total Count
184A1
184B5
600MPE
AU565
BT474
BT483
BT549
CAMA1
HCC1143
HCC1187
HCC1395
HCC1419
HCC1428
HCC1569
HCC1806
HCC1937
HCC1954
HCC202
HCC2185
HCC3153
HCC38
HCC70
HS578T
LY2
MCF10A
MCF10F
MCF12A
MCF7
MDAMB134VI
MDAMB157
MDAMB175VII
MDAMB231
MDAMB361
MDAMB415
MDAMB436
MDAMB453
MDAMB468
SKBR3
SUM1315MO2

Normal-like
Normal-like
Luminal
Luminal (Her2+)
Luminal (Her2+)
Luminal
Claudin-low
Luminal
Basal
Basal
Claudin-low
Luminal (Her2+)
Luminal
Basal (Her2+)
Basal
Basal
Basal (Her2+)
Luminal (Her2+)
Luminal
Basal
Claudin-low
Basal
Claudin-low
Luminal
Normal-like
Normal-like
Normal-like
Luminal
Luminal
Claudin-low
Luminal
Claudin-low
Luminal (Her2+)
Luminal
Claudin-low
Luminal
Basal
Luminal (Her2+)
Claudin-low

Pac
GI50

Gem
GI50

49
7.35
7.74
7.51
8.14
7.99
7.00
8.16
7.95
7.80
8.05
7.71
7.04
7.58
7.95
8.11
7.81
8.15
8.10
8.22
7.70
8.13
8.03
8.38
7.97
8.03
8.08
7.97
7.79
7.99
8.27
7.74
8.37
7.79
8.18
7.65
7.99
8.06
7.94
8.29

47
6.16
6.14
7.64
7.81
4.88
8.05
8.08
6.79
7.92
5.07
6.47
4.81
3.58
6.76
8.72
5.97
4.51
4.82
7.61
7.19
8.17
4.58
5.66
7.62
7.70
7.08
7.17
4.77
2.85
NA
8.12
5.93
8.23
6.05
7.49
7.85
7.01
7.97
6.91

Mut

CN

Exp

Pac
SVM

Gem
SVM

Pac
MFA

Gem
MFA

48

46

49

49

44

45

44

1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
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SUM149PT
SUM159PT
SUM185PE
SUM52PE
T47D
UACC812
UACC893
ZR751
ZR7530
ZR75B

Basal
Claudin-low
Luminal
Luminal
Luminal
Luminal (Her2+)
Luminal (Her2+)
Luminal
Luminal (Her2+)
Luminal

8.03
8.24
6.64
8.20
8.02
8.08
7.93
7.76
7.66
7.38

7.84
7.99
6.44
8.15
6.02
7.75
3.54
7.45
NA
7.34

1
1
1
1
1
1
1
1
1
1

0
1
1
1
1
1
0
1
0
1

1
1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1
1

0
1
1
1
1
1
0
1
0
1

0
1
1
1
1
1
0
1
0
1

0
1
1
1
1
1
0
1
0
1

Pac = paclitaxel, Gem = gemcitabine, GI50 = -log(M), where M is the concentration of
drug to inhibit cell growth by 50%, Mut = mutation data (exome sequencing), CN = copy
number data (microarray), Exp = expression data (microarray), SVM = support vector
machine, MFA = multiple factor analysis. For Mut, CN, and Exp, 1 indicates the data
type was available for analysis, 0 indicates the data type was unavailable (from Daemen
et al. 2013). For the SVM and MFA columns, 1 indicated that the cell line was included
in the analysis, and 0 indicates that the cell line was not included (based on data
availability).
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Appendix S5.2
Paclitaxel
Genes
ABCB1
ABCB11
ABCC1
ABCC10
BAD
BBC3
BCAP29
BCL2
BCL2L1
BIRC5
BMF
CNGA3
CSAG2
CYP2C8
CYP3A4
FGF2
FN1
GBP1
MAP2
MAP4
MAPT
NFKB2
NR1I2
OPRK1
SLCO1B3
TLR6
TMEM243
TUBB1
TUBB4A

Genes Included in the study relevant to paclitaxel and gemcitabine drug disposition

Full Gene/Protein Name

Drug Disposition

ATP-binding cassette, sub-family B (MDR/TAP), member 1
ATP-binding cassette, sub-family B (MDR/TAP), member 11
ATP-binding cassette, sub-family C (CFTR/MRP), member 1
ATP-binding cassette, sub-family C (CFTR/MRP), member 10
BCL2-associated agonist of cell death
BCL2 binding component 3
B-cell receptor-associated protein 29
B-cell CLL/lymphoma 2
BCL2-like 1
baculoviral IAP repeat containing 5
Bcl2 modifying factor
cyclic nucleotide gated channel alpha 3
CSAG family, member 2
cytochrome P450, family 2, subfamily C, polypeptide 8
cytochrome P450, family 3, subfamily A, polypeptide 4
fibroblast growth factor 2
fibronectin 1
guanylate binding protein 1, interferon-inducible
microtubule-associated protein 2
microtubule-associated protein 4
microtubule-associated protein tau
nuclear factor of kappa light polypeptide gene enhancer in Bcells 2 (p49/p100)
nuclear receptor subfamily 1, group I, member 2
opioid receptor, kappa 1
solute carrier organic anion transporter family, member 1B3
toll-like receptor 6
transmembrane protein 243, mitochondrial
tubulin, beta 1 class VI
tubulin, beta 4A class IVa
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transporter (out of cell)
transporter (out of cell)
transporter (out of cell)
transporter (out of cell)
in target pathway (BCL2)
in target pathway
associated with resistance
direct target
in target pathway (BCL2)
associated with resistance
in target pathway
associated with resistance
associated with resistance
metabolizing enzyme
metabolizing enzyme
associated with resistance
associated with resistance
associated with resistance
direct target
direct target
direct target
associated with resistance
direct target
associated with resistance
transporter (into cell)
associated with resistance
associated with resistance
direct target
in target pathway (TUBB1)

In Capture
Array?
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
NO
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES

TUBB4B
TWIST1

tubulin, beta 4B class IVb
twist family bHLH transcription factor 1

Gemcitabine Genes
ABCB1
ATP-binding cassette, sub-family B (MDR/TAP), member 1
ABCC10
ATP-binding cassette, sub-family C (CFTR/MRP), member 10
AK1
adenylate kinase 1
CDA
cytidine deaminase
CMPK1
cytidine monophosphate (UMP-CMP) kinase 1, cytosolic
CTPS1
CTP synthase 1
DCK
deoxycytidine kinase
DCTD
dCMP deaminase
NME1
NME/NM23 nucleoside diphosphate kinase 1
NT5C
5', 3'-nucleotidase, cytosolic
RRM1
ribonucleotide reductase M1
RRM2
ribonucleotide reductase M2
RRM2B
ribonucleotide reductase M2 B (TP53 inducible)
solute carrier family 28 (concentrative nucleoside transporter),
SLC28A1
member 1
solute carrier family 28 (concentrative nucleoside transporter),
SLC28A3
member 3
solute carrier family 29 (equilibrative nucleoside transporter),
SLC29A1
member 1
solute carrier family 29 (equilibrative nucleoside transporter),
SLC29A2
member 2
TYMS
thymidylate synthetase
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in target pathway (TUBB1)
associated with resistance

YES
YES

transporter (out of cell)
transporter (out of cell)
nucleotide metabolism
metabolizing enzyme
direct target
direct target
metabolizing enzyme
metabolizing enzyme
metabolizing enzyme
metabolizing enzyme
direct target
in target pathway (RRM1)
in target pathway (RRM1)

YES
YES
YES
YES
YES
NO
YES
NO
NO
NO
YES
YES
YES

transporter (into cell)

YES

transporter (into cell)

YES

transporter (into cell)

YES

transporter (into cell)
direct target

YES
YES

Appendix S5.3

Copy Number Calling Methods

Copy number data were available as CEL files from Affymetrix Genome-Wide Human
SNP Array 6.0. CNV calls were generated with the PennCNV software1 (2011 June 16
version) using the software pipeline and commands found at
http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html.
PennCNV output with copy number changes for all cell lines and genes can be found in
Supplementary Table 5.1.

Appendix S5.4 DNA Sequencing Analysis Pipeline– Variant Calling
and Interpretation Methods
Whole exome aligned sequencing data were available in the form of .bam files from
Illumina

Genome

Analyzer

IIx

runs

aligned

to

an

hg19

genome

build

(“NCI60_WES_BAM_files:,” n.d.). Variants were detected using the software workflow
below (A-D). The Genome Analysis Toolkit (GATK)2was used for variant calling and
filtering with default parameters (exceptions): Realigner Target Creator, IndelRealigner,
Haplotype Caller, Variant Recalibrator (for indels, --minNumBadVariants was set to
5000 for LY2 and SUM159PT), and Apply Recalibration (ts_filter_level for indels was
set at 99.0 and for SNPs at 99.9). VariantSelect was called to exclude non-variant loci
and filtered loci with the default parameters for this purpose provided by GATK.
Annovar3 was used to annotate the variants (both single nucleotide changes and
insertions/deletions) and filter variants present in dbSNP 135. SIFT4 was used to predict
which mutations (SNPs and indels) are likely damaging to the protein product, which
were used in further analyses. Two software programs were used for splicing mutation
analysis: Shannon Pipeline5 was used to predict splicing mutations, and Veridical6 was
used to confirm aberrant splicing patterns in cell line-matched RNA-Seq data. In the
Multiple Factor Analysis (MFA), mutation status was depicted with a binary variable in
which the gene was assigned to be mutated or not. MFAs were also completed with total
counts of likely deleterious mutation per cell line, which affected 10 genes, but did not
alter the interpretation of the analysis.
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A) Bam File Processing

B) Bam File Realignment

D) Variant Analysis

287

C) Variant Discovery

Appendix S5.5

Reproducibility of Cell Line Data

Appendix S5.5.1 GI50 Studies
Growth inhibition (GI50) values represent the concentration of the chemical required to
inhibit cell growth by 50% in comparison with untreated controls, and the study was
carried out as previously described7. GI50 values were calculated using a sulforhodamine
B (SRB) assay, which provides a sensitive method to measure cellular protein content.
Cells were grown in 96 well plates for 24 hours, and then exposed to either paclitaxel or
gemcitabine for 48 hours. We repeated triplicate GI50 measurements for 5 NCI-60 breast
cancer cell lines: SKBR3, HS578T, BT549, MDAMB231, and T47D. Additionally, we
quantified cell densities, and determined growth inhibition in order to resolve druginduced cytotoxicity. Percent of cytotoxicity was calculated as 100 x (Cell Control –
Experimental) ÷ (Cell Control). GI50 was then derived using Graph Pad Prism. Data were
transformed using X = Log(X) and then a non-linear regression was performed using
options: “dose-response inhibition” and “Log [inhibitor] vs. response (variable slope).”

Appendix S5.5.2 CytoScan HD Array
The re-measured microarray analyses for 5 cell lines in our laboratory (MDAMB231,
HS578T, MCF7, T47D, and SKBR3) were completed using the CytoScan HD Array Kit
and Reagent Kit Bundle (catalog #901835) following the recommended manufacturer’s
protocol (Affymetrix, Santa Clara, CA). The AffymetrixGeneChip Command Console
Software was used with default options to analyze the .CEL files for copy number change
calls, which were visualized and manually confirmed using the Chromosome Analysis
Suite (version 2.1.0.16).

Appendix S5.5.3 Gene Capture and DNA Sequencing
Capture probes were designed (genomic coordinates of probes listed in Supplementary
Table 5.6, and then produced on a cleavable microarray using Custom Array Microarray
Synthesizer (Bothell, WA). Exons and 300 bp into the introns, for 44 of the 49 genes,
were targeted. Genomic DNA was sheared to ~300bp fragments using the Covaris S220
Focused-ultrasonicator. Library preparation was carried out using the KAPA Biosystems
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Standard High Throughput Library Preparation Kit and RNA bait from the capture array
probes was used to enrich for the genes of interest8. DNA samples were quantified using
qPCR (KAPA Library Quantification Kit for Illumina Platform) and then paired end
reads (70 bp each side) were obtained using the standard Illumina Genome Analyzer IIX
paired-end sequencing protocol.
Sequences of all exons (and 300 bp into each intron) for the 45 genes were
selected using an ab initio approach9. Probe sequences were selected using PICKY 2.2
software10 using the default settings with few exceptions (65ºC Tm, 30-70% GC content,
5 probes per sequence, 20 nt maximum overlap). MPI-BLAT was used to ensure the
probes align only to the targeted sequence.
Generation, Cleavage and Purification Microarray Oligos
The selected sequences, with primer binding sites added to each end (5’
ATCGCACCAGCGTGTN36-70CACTGCGGCTCCTCA), were then synthesized onto
two cleavable 12K microarray chips using a CustomArray Microarray Synthesizer
(Bothell, WA). Probes were cleaved from the microarrays with concentrated (14.5N)
ammonium hydroxide at 65ºC for 4 hours. Purified oligos were then amplified by 25
cycles of conventional PCR using KapaHiFi DNA Polymerase (KapaBiosystems).
Biotin-labelled RNA bait was generated from this product with nested PCR on the
amplified oligosusgin a MAXIscript SP6 in vitro transcription kit (Ambion) with a UTP
to biotin-16-UTP (Roche) ratio of 4 to 1.
Sample Preparation
Genomic DNA (gDNA) from the MDAMB231 cell line was diluted to 100 ng/μL in a
volume of 51 μL for S220 Focused-ultrasonicator (Covaris) shearing (150-300nt
fragments generated with the following settings: Time 120 sec, Duty cycle 10%, Intensity
5, and Cycles per burst 200).
Library Preparation and Capture
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The sheared samples were prepared using a KAPA Biosystems Standard
(KK8200) and High Throughput (KK8234) Library Preparation kits, following the
manufacturer’s protocol (KapaBiosystems). Genes of interest were captured using the
Tiled RNA bait, using the hybridization selection protocol from Gnirke et al (2009) with
1 to 2 ug of sample prep, 1.5 ug of RNA bait, and 75 uL of M-280 streptavidin
Dynabeads (Invitrogen). DNA samples were quantified using qPCR following the
protocol outlined by KAPA Library Quantification Kit for Illumina Platform (KAPA
Biosystems, catalog# KK4824). Samples were then treated to standard Illumina pairedend sequencing on a Genome Analyzer IIx, with 70 bp, then a 7 bp index (used during
multiplexing), and then 70 bp.
Bioinformatic Analysis
When sequencing was completed, data was demultiplexed (when necessary) and aligned
to the human reference genome (hg19) using CASAVA v1.8.2 and CRAC (v1.3.0). BAM
files were prepared for variant calling using Picard, and variant calling was performed on
both sets of aligned sequences using the UnifiedGenotyper tool in the Genome Analysis
Toolkit (GATK). Variants called outside of target regions were ignored. Variant analysis
was completed as outlined in Supplementary Methods IID.
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Appendix S5.6

Support vector machine feature selection

Adapted from Dash and Liu (1997)1
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Appendix S5.7

Partial-Least Squares Regression

A partial-least squares regression (PLSR) was also performed to attempt to relate
genomic findings to paclitaxel response, based on the fact that GI50 is a continuous
variable. The predictive error of the model was measured by taking the absolute sum of
the residuals (the actual GI50 minus the predicted GI50) of a leave-one-out crossvalidation. One cell line at a time was left out of the analysis and its paclitaxel GI50 value
was predicted using the beta values given by the regression line and then compared with
its measured GI50 value.
Using the absolute sum of error as a measurement of predictive accuracy, we randomly
selected subsets of genes ranging in number from 1 gene to 30 genes (out of a total of 31
genes) for 1,000 iterations each to attempt to find the most optimal number of genes. Of
the 9 paclitaxel genes with the lowest error, two million model iterations were performed
to find the best predictive subsets with the lowest error values. However, the lowest
absolute sum of residual errors was ~10. The high residual means imply a lack of
confidence that the genomic signature will reliably predict GI50. For this reason, we
discontinued

attempts

to

use

PLSR

to

predict

gemcitabine

(or

paclitaxel)

chemosensitivity.

Appendix S5.8 Gene expression and Copy Number analyses on
FFPE tumour blocks
Nucleic acids were extracted from the FFPE tissue samples using Qiagen’sAllPrep
DNA/RNA FFPE Kit (Cat. No. 80234, Venlo, Limburg, Netherlands). The recommended
protocol was used with the following exceptions: 1) Tissue used for the nucleic acid
extraction was obtained using 1 mm Miltex Sterile Disposable Biopsy Punches (Cat. No.
33-31AA-P/25, Plainsboro, New Jersey), as opposed to using thin slices of the full block.
Hematoxylin and eosin stained slides of each tissue block were marked by a pathologist
to identify cancerous lesions and direct specific regions to punch. Using a biopsy punch
allowed for targeted extractions, and minimized the amount of normal surrounding tissue
used in the analysis. 2) 75 μl of mineral oil was used for tissue deparaffinization at 90°C

292

for 20 minutes, as previously described12. 3) The first proteinase K incubation was
performed at 56°C for 2 hours.
cDNA was produced from tumour RNA using SuperScript II Reverse Transcriptase (Cat.
No. 18064-014, Invitrogen, Carlsbad, CA, USA) and 250ng IDT ReadyMade random
hexamer per reaction. (Cat. No. 51-01-18-25, San Jose, CA, USA). cDNA synthesis was
carried out following the manufacturer’s protocol, and purified using ethanol
precipitation with 0.1X sodium acetate and 2.5X 100% anhydrous ethanol. Every cDNA
sample used for gene expression measurement was then re-suspended in RNAse-free
water, and diluted to 20 ng/μl for gene expression measurement. Purified DNA from the
QiagenAllPrep columns were diluted to 9 ng/μl for copy number analysis.
qPCR (gemcitabine copy number genes only) and qRT-PCR (all expression genes) were
performed with the SensiFast SYBR No-ROX kit (Cat. No. BIO-98020, Bioline, London,
UK) using the recommended protocol. Primer pairs were designed using PrimerQuest
(Integrated DNA Technologies, Coralville, Iowa), spanning exons when possible (qRTPCR only). Each primer pair was optimized using duplicate 10 μl reactions for forward
and reverse primer concentrations, and in some cases annealing temperatures. Primer
sequences, annealing temperatures, and final concentrations used are listed in Table
S5.6.1. NT5C qPCR was performed with a 10-second denaturation and 20-second
extension in every cycle. All real-time PCR experiments used an Eppendorf Mastercycler
realplex machine and followed the program: 95°C for 2 min, and 40 cycles of 5 s at 95°C,
10 s at 60°C (copy number and some gene expression primers) or 64.5°C (only gene
expression primers), and 15 s at 72°C. A melting curve was measured for all reactions,
and any measurements with abnormal melting curve (ie. at a lower temperature due to
primer diming) were removed from any further analysis. Two 10 μl reactions were
performed per primer pair, per sample.
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Table S5.6.1
Amplicon
Size
PACLITAXEL - qRT-PCR
Gene Name

ABCC10

109

BCL2

90

BCL2L1

94

BIRC5

113

FGF2

86

FN1

120

MAP4

91

MAPT

93

NFKB2

101

TLR6

115

TMEM243

104

F/R

Anneal.
Temp.

Sequence

F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

TGGGAAGACATTTGATGCAC
CTTCTCCCCCACCTCTGTCT
CCTGTGGATGACTGAGTACCTGAA
GGGCCGTACAGTTCCACAAAG
CTTGGATGGCCACTTACCTGAATG
GCATTGTTCCCATAGAGTTCCACAA
GCAGTTTGAAGAATTAACCCTTGGTG
CCGCAGTTTCCTCAAATTCTTTCTTC
AGAAGAGCGACCCTCACATCAA
GTAACGGTTAGCACACACTCCTTTG
TTGGAGATTCATGGGAGAAGTATGTG
CAGGACCACTTGAGCTTGGATAG
TCCTCTCCTGGATGTTGATGAGAA
AGATGGAGTATCTTCAATCTGGCTAGT
GGCTCATTAGGCAACATCCATCATAA
CTTCGACTGGACTCTGTCCTTGA
AGATGACATTGAGGTTCGGTTCTATG
ACACAATGGCATACTGTTTATGCAC
CCGACGGAAATGAATTTGCAGTAGAC
AGCTCAGCGATGTAGTTCTGAGAC
AGGACTTTGCTACCAGGACCTAC
GCTGCCAACAACTAAATTGATGATTCG

F
R
F
R
F
R
F
R
F
R
F
R

TGGGAAGACATTTGATGCAC
CTTCTCCCCCACCTCTGTCT
GGGAAAGAGTAGTGGTAGGAGTGATG
ATTGGCTTTGTTGACTGAAGGTAGG
TACCATGATAGTGACGAGGCAACTG
GACAATCTTGCTGCACTTCGGTATG
CCTTCATTGCGATCAAACCAGATG
GATCTTCGGAAGCTTGCATGAATTT
ACTATTTATTATGGTGCTCTGGAAGCC
ACTGAAGAATTCCTTTGCTAACTGGAG
TCTGGCTAAAGAAGAGAGGTCTTATGC
ACAGTGAAGTCCTTCATCTCTGCTG

F
R
F
R
F
R

GAGAATAGTAGTAGCTTACCTTGTAG
CATGTATTCAGAGCTTACTTTGTG
CCTTGTCAGGATAATTCGTTCTAC
CCAAGTCCCTATCCCTGAAT
GTATGTCAGCCTTTCCCTTC
CAGTGAACACGAGAAACAAATC

F
R
F
R
F
R

TTGTTACAGGAAGTCCCTTGCC
ATGCTATCACCTCCCCTGTGTG
TGCTGTCTCCATGTTTGATGTATCT
TCTCTGCTCCCCACCTCTAAGT
TGCACCACCAACTGCTTAGC
GGCATGGACTGTGGTCATGAG

F
R
F
R

TTGTTACAGGAAGTCCCTTGCC
ATGCTATCACCTCCCCTGTGTG
GCCAGCTTCTGAATTATGGTCTTC
GAAACTCAATGGAACCTTCTGTTTC

64.5
64.5
64.5
64.5
64.5
64.5
64.5
64.5
64.5
64.5
64.5

Opt. Conc.
(nM)
400
900
400
900
900
400
900
900
900
900
900
900
900
900
900
900
400
400
900
900
900
100

GEMCITABINE - qRT-PCR
ABCC10

109

CMPK1

84

DCTD

96

NME1

120

RRM1

103

RRM2B

80

64.5
64.5
64.5
64.5
64.5
64.5

400
900
900
400
400
900
400
400
400
900
400
400

GEMCITABINE - qPCR
ABCC10

93

NT5C

126

TYMS

107

60
57.2
60

400
400
400
400
400
400

STANDARDS - qRT-PCR
ACTB

101

B2M

86

GAPDH

87

64.5
60
60

400
400
400
400
400
900

STANDARDS - qPCR
ACTB

101

RMND5A

99
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64.5
60

400
400
400
400

Expression values were normalized per sample based off of three genes: ACTB, B2M, and
GAPDH using the equation (as previously described13):
𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏𝒗𝒂𝒍𝒖𝒆 = 𝟐−∆𝑪𝒕 = 𝟐−(𝑪𝒕

𝒐𝒇 𝑮𝑶𝑰 – 𝑪𝒕 𝒐𝒇 𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒔)

Gene expression values for the FFPE samples were clustered as described in main
Methods.
For copy number, 5 or 6 dilutions from hgDNA (9, 3, 1, 0.33, 0.11, and in some cases
0.037 ng/µl) were used to construct a standard curve for each primer pair (Figure S5.6.1).
Two reference genes (ACTB and RNMD5A) were used to normalize for sample variation.
ACTB is a single copy gene (1 haploid gene), and RMND5A is a multicopy gene (3
haploid copies14). DNA from 9 lymph-node negative samples were used as normal
controls to adjust for differences in primer efficiencies. Copy number calling was
determined as previously described15:
Ct Values were measured using two 10 μl reactions for each sample and gene.
Raw copy values were derived from the equation of the standard curves for each gene
(Figure S5.6.1), where y = Ct and x = log(Q).
Copy number calibration was performed per gene for each sample (both tumour and
normal) by dividing the raw copy value call by the average of the copy value call of
ACTB and RMND5A for that sample. This adjusted for differences in Ct values between
samples.
𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =

𝑟𝑎𝑤 𝑐𝑜𝑝𝑦 𝑣𝑎𝑙𝑢𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 (𝐴𝐶𝑇𝐵 𝑎𝑛𝑑 𝑅𝑀𝑁𝐷5𝐴 𝑟𝑎𝑤 𝑐𝑜𝑝𝑦 𝑣𝑎𝑙𝑢𝑒𝑠)

Final copy number values were determined by adjusting for the average calibrated copy
numbers of the normal (lymph node negative) samples to adjust for differences in
primers/gene measurements.
𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =

𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 𝑝𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 9 𝑛𝑜𝑟𝑚𝑎𝑙𝑠
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Copy number gains and losses were determined if the copy number call was at least 3
standard deviations (of ACTB and RMND5A) from the mean copy number for that gene
(see Figure S5.6.2 for copy number changes highlighted in yellow, and Supplementary
Table 5.3 for copy number calls). Because no copy number changes were expected for
ACTB and RMND5A, the average standard deviation between the two, when calibrated
against each other, was used (standard deviation = 0.06269). Any copy number gains
were assumed to be a copy of 3, whereas losses were assumed to be 1.
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Figure S5.6.1 – Copy number standard curves
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Figure S5.6.2 – Copy number gains and losses per gene

Note: For illustrative purporses only. Each gene lists samples (x-axis) in a different order, and not all samples are labeled. See
Supplementary Table 5.3 for exact copy number calls per sample and gene.
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Appendix S5.9

Reproducibility of Data

To assess reproducibility of the data used to derive the genomic signatures for paclitaxel
and gemcitabine, we sought to determine the degree to which a sample of the cell line
data was consistent between cell line sources. We obtained a subset of the cell lines used
in the prior study by Daemon et al. from the Coriell Institute, and, redetermined their GI50
and copy number values as well as the variants present in the candidate gene sequences in
one of the lines. Growth inhibition studies were carried out for 5 breast cancer cell lines
(BT549, MDAMB231, HS578T, T47D, SKBR3) to determine the reproducibility of cell
line sensitivity to paclitaxel and gemcitabine (Figures 5.7.1 and 5.7.2). Re-measured GI50
values were compared to GI50s from Daemen et al. and those previously reported from
Ring et al., 2008. The standard deviations of the GI50 values between studies were low for
all measurements, except for the SKBR3 treated with gemcitabine (GI50 for SKBR3 was
not determined by Ring et al., 2008). Although the differences in cell line growth
inhibition were minimal (< 1 log10), our results were more similar to those reported by
Daemen et al., 2013. The standard deviations between replicates from the Ring et al.
study were more than twice our measurements for the same cell lines, except for BT549
paclitaxel and MDAMB231 gemcitabine GI50 values. In some instances, substitution of
our GI50 values (or those obtained by Ring et al., 2008) for those determined by Daemen
et al., 2013, could affect the subsequent classification of the cell line. For paclitaxel,
triplicate assays of 4 of 5 lines (all but HS578T) exhibit GI50 values close to the median
GI50 threshold for distinguishing sensitivity from resistance (-log10M = 8). For
gemcitabine, a single cell line (SKBR3, -log10M = 7) was close to this threshold. This
highlights the importance of conducting genomic analyses and GI50 studies on the same
source line, given that clonal variation and genetic evolution can occur in cancer cell
lines16.
Copy number data of 5 cell lines (MDAMB231, T47D, MCF7, HS578T, and SKBR3)
were measured using an AffymetrixCytoScan HD array and analyzed using the
Affymetrix

Chromosome

Analysis

Suite

(ChAS;

CytoScan

HD

data).

The

AffymetrixCytoScan HD array contains approximately 2.6 million copy probes and
750,000 SNP probes, whereas the Affymetrix SNP 6.0 array contains approximately
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946,000 copy number probes and 906,600 SNP probes. DNA from MDAMB231 was
extracted in May 2010 and again in February 2013 to compare different time
points/passages of the cell line from the same batch. The copy number calls of the SNP
6.0 DNA data from the Daemen et al., 2013 study analyzed by PennCNV, and reanalyzed by ChAS, were compared with our CytoScan HD data (Supplementary Table
5.11). Copy number changes between the two time points of MDAMB231 were the same
for all 49 genes. Copy number calls between the Daemen et al. and CytoScan HD data
were largely concordant. Of the 49 genes and 5 cell lines (total of 245 copy number
calls), 151 were the same (62%), and an additional 6 (2%) were concordant between our
CytoScan HD data and PennCNV, but not the Daemen et al. data analyzed by ChAS. 33
(15%) of the copy number calls were different between our CytoScanHD data and
Daemen data, but these appear to be real differences between the cell line karyotypes,
because PennCNV and ChAS were consistent for the Daemen et al. data. Conversely, 33
(15%) copy number changes were inconsistently called between the PennCNV analyses,
and the ChAS analyses of both data sets. In these cases, it is likely that PennCNV
miscalled the copy number state. None of these copy number changes occurred in NT5C,
ABCC10, and TYMS, which were present in the final SVM model for gemcitabine
resistance. Another 22 (9%) copy number calls were inconsistent between our CytoScan
HD data and PennCNV. Upon further analysis of the Daemen data set with ChAS, these
differences appear to be due to noise in the SNP 6.0 data. One possible explanation is
that SNP 6.0 probes neighboring conserved repetitive elements exhibit higher variation in
signal intensities than probes in the Cytoscan HD, which are located further away from
these sequences9. Inconsistencies may be also due to heterogeneous populations of
mixtures of tumour cells each with different copy numbers within these populations.
Concordant calls, the different noise levels in the data, and ambiguous copy number calls
(ie. between a copy number of 1 and 2), and actual copy number differences are indicated
in Figure 5.7.3.
The relevant gene sequences from MDAMB231 were derived using next generation
sequencing with a custom oligonucleotide enrichment reagent that targeted 44 of the 49
genes (Supplementary Table 5.12; CSAG2, CTPS1, DCTD, NME1, and NT5C are not
included).

Results

were

compared

with
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MDAMB231

exonic

sequences

(“NCI60_WES_BAM_files:,” n.d.).

In our analysis, which also includes newly

determined intronic sequences flanking each exon (300 nt), 59 mutations were detected
(Supplementary Table 5.12). Five variants were predicted to be damaging by SIFT and
37 were reproduced in both studies (36 SNPs and 1 insertion), of which 35 were known
variants present in greater than 1% of the population, and 2 were novel. None of the
damaging mutations were used in the MFA for MDAMB231, because the only likely
damaging mutations between the two data sets were known, frequent variants.
GI50s (GI50 drug concentrations are in –log10M) were re-measured for paclitaxel and
gemcitabine in cell lines BT549, HS578T, MDAMB231, T47D, and SKBR3, and then
compared to 2 sets of previously published values17,18. The yellow bar indicated the GI50
threshold for resistant (below the line) and sensitive (above) cell lines.
Figure 5.7.1 – GI50s for Paclitaxel

301

Figure 5.7.2 – GI50s for Gemcitabine

Figure 5.7.3 – MDAMB231 Copy Number Analysis
MDAMB231: Copy number analysis was performed using an AffymetrixCytoScan HD
with DNA extracted from MDAMB231 in February of 2013 (dark blue in screen shots),
and May of 2010 (pink). Both time points were compared to the Affymetrix SNP 6.0 data
from Daemen et al. (light blue). Screen shots from ChAS are displayed for ABCC10,
NT5C, OPRK1, and TYMS. Log 2 Ratios (green and red bars), copy number state, smooth
signal, and genes are displayed for all three analyses (top to bottom). Log2 Ratios are
displayed using a heat map between -1.5 and 1.5 (below).
Log2 Ratio Heat Map:

-1.5

0

1.5
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ABCC10 (at dotted line), chr6: 42,943,397 – 43,876,083, PennCNV call for Daemen data set: 2. A small deletion is detected by ChAS because the smooth
signal drops below 1.5.It isn’t clear whether it is a real copy number change because it is small, and the Log2Ratios are noisy (red and green bars).
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NT5C (at dotted line), chr17: 72,625,852 – 73,628,356, PennCNV call for Daemen data set: 2. Normal copy number of 2 is seen in all three analyses. There is a
larger range of log 2 ratios seen in the SNP 6.0 array.
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OPRK1 (at dotted line), chr8: 53,664,288 – 54,638,171, PennCNV call for Daemen data set: 2. A deletion of 1 copy is evident for the two re-measured sets, and
may be present in the Daemen et al. data. PennCNV called this region a copy number of 2, although the data is noisy and the smooth signal is between a copy of
1 and 2. This is an example where the noise in the data, or the cells are mosaic, may explain the discordant results between Daemen et al. and re-measured data.
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TYMS (at dotted line), chr18: 177,496 – 1,153,659, PennCNV call for Daemen data set: 2. This demonstrates an example where the copy number is different
between the Daemen data set and the re-measured data set. This appears to be a real change, as PennCNV and ChAS both clearly call a copy number of 2, but
there is one extra copy detected in the re-measured data.
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Appendix S5.10 MFA Criteria
Criteria (all are required for any given classification)
Classification

RV
coefficient
of Factor*

cos2 value
of Factor*

RV
Coefficient
of GI50

cos2 value
of GI50

% variance
explained

Strong Relationship
(Str Rel)^
>0.6
>0.4
>0.6
>0.4
>25%
Relationship (Rel)~
>0.5
>0.25
>0.5
>0.25
>25%
Possible
Relationship (Pos)
>0.3
>0.1
>0.5
>0.25
>25%
*gene expression, copy number or mutation status, ^all dimension 1, ~dimensions 1 and 2

Appendix S5.11 Multiple Factor Analysis
Appendix S5.11.1
Cell Line Numbers in the Multiple Factor
Analyses Individual Factor Maps:
Cell Line
184A1
184B5
600MPE
AU565
BT474
BT483
BT549
CAMA1
HCC1143
HCC1187
HCC1395
HCC1428
HCC1569
HCC1806
HCC1937

Pac
MFA
#

Gem
MFA
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Cell Line
HCC1954
HCC202
HCC2185
HCC3153
HCC38
HCC70
HS578T
LY2
MCF10A
MCF10F
MCF12A
MCF7
MDAMB134VI
MDAMB157
MDAMB175VII

Pac
MFA
#

Gem
MFA
#
16
17
18
19
20
21
22
23
24
25
26
27
28

29
30

N/A
29

Cell Line
MDAMB231
MDAMB361
MDAMB415
MDAMB436
MDAMB453
MDAMB468
SKBR3
SUM1315MO2
SUM159PT
SUM185PE
SUM52PE
T47D
UACC812
ZR751
ZR75B

Pac
MFA
#
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Gem
MFA
#
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Individual factor maps, correlation circles, and groups representations are all formatted
the same throughout the document. Factors (copy number, gene expression, mutation
status and GI50) are labeled in the correlation circle arrows (overlaid on the individual
factor map) and the groups representation. Cell lines are numbered according to the
legend in the table of contents. Additional quantitative details of the MFAs can be found
below.
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Appendix S5.11.2

Paclitaxel Example - MAPT

Individual Factor Map – Dimensions 1 and 2 (% variance explained in brackets)

Groups Representation
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Appendix S5.11.3

Gemcitabine Example - DCTD

Individual Factor Map – Dimensions 1 and 2 (% variance explained in brackets)

Groups Representation

309

Appendix S5.12 Paclitaxel Multiple Factor Analysis Results by Gene

Gene Name
ABCB1
ABCB11
ABCC1
ABCC10
BAD
BBC3
BCAP29
BCL2
BCL2L1
BIRC5
BMF
CNGA3
CYP2C8
CYP3A4
FGF2
FN1
GBP1
MAP2
MAP4
MAPT
NFKB2
NR1I2
OPRK1
SLCO1B3
TLR6
TMEM243
TUBB1
TUBB4A
TUBB4B
TWIST1
CSAG2

% VE
31%
41%
34%
43%
55%
39%
34%
39%
38%
35%
46%
43%
32%
29%
36%
32%
52%
31%
43%
33%
31%
38%
33%
35%
32%
50%
39%
43%
36%
38%

Dim 1
GI50 CN
0.77 0.08
0.54 0.61
0.22 0.82
0.28 0.80
0.23 0.90
0.77 0.00
0.40 0.16
0.36 0.63
0.67 0.70
0.14 0.77
0.77 0.28
0.72 0.75
0.74 0.76
0.76 0.11
0.75 0.29
0.75 0.53
0.54 0.75
0.43 0.32
0.38 0.74
0.81 0.11
0.68 0.72
0.74 0.74
0.57 0.82
0.55 0.49
0.69 0.44
0.04 0.87
0.66 0.49
0.30 0.78
0.75 0.33
0.75 0.53

GE
0.17
0.76
0.80
0.91
0.89
0.77
0.82
0.80
0.74
0.80
0.83
0.46
0.17
0.68
0.57
0.62
0.84
0.65
0.81
0.82
0.52
0.21
0.57
0.74
0.70
0.87
0.71
0.76
0.64
0.53

Mut
0.78
NA
0.08
0.39
NA
NA
0.72
NA
0.15
0.42
NA
NA
0.33
0.34
0.67
0.25
NA
0.72
0.60
0.10
0.06
NA
0.16
0.56
0.35
NA
NA
NA
NA
NA

Dim 2
% VE GI50 CN
28% 0.17 0.75
32% 0.75 0.63
27% 0.72 0.02
26% 0.38 0.48
33% 0.97 0.09
35% 0.28 0.94
26% 0.31 0.93
35% 0.83 0.58
32% 0.38 0.52
28% 0.89 0.00
34% 0.38 0.93
31% 0.35 0.21
25% 0.30 0.14
27% 0.17 0.69
26% 0.18 0.89
27% 0.25 0.30
30% 0.81 0.49
28% 0.55 0.73
27% 0.77 0.44
27% 0.32 0.45
29% 0.40 0.06
33% 0.12 0.16
26% 0.52 0.07
30% 0.68 0.70
27% 0.38 0.44
33% 1.00 0.06
32% 0.45 0.85
33% 0.95 0.11
34% 0.05 0.87
33% 0.00 0.71

GE
0.71
0.02
0.10
0.04
0.16
0.28
0.19
0.08
0.32
0.39
0.04
0.88
0.95
0.39
0.17
0.39
0.09
0.48
0.29
0.27
0.54
0.98
0.60
0.26
0.47
0.01
0.17
0.27
0.50
0.70

Mut
0.06
NA
0.76
0.81
NA
NA
0.24
NA
0.88
0.43
NA
NA
0.13
0.63
0.44
0.87
NA
0.22
0.45
0.83
0.83
NA
0.65
0.39
0.73
NA
NA
NA
NA
NA

Groups Representation Dim 1
GI50
CN
GE
Mut
0.60
0.01
0.03 0.61
0.29
0.37
0.58
0.05
0.67
0.64 0.01
0.08
0.65
0.83 0.15
0.05
0.81
0.80
0.59
0.00
0.59
0.16
0.02
0.66 0.52
0.13
0.39
0.63
0.45
0.49
0.55 0.02
0.02
0.59
0.63 0.18
0.59
0.08
0.70
0.52
0.56
0.21
0.55
0.57
0.03 0.11
0.58
0.01
0.46 0.11
0.56
0.08
0.33 0.45
0.56
0.28
0.39 0.06
0.29
0.56
0.71
0.19
0.10
0.43 0.52
0.14
0.55
0.66 0.36
0.65
0.01
0.67 0.01
0.46
0.52
0.27 0.00
0.55
0.54
0.04
0.32
0.67
0.32 0.03
0.30
0.24
0.55 0.31
0.48
0.19
0.49 0.12
0.00
0.75
0.76
0.43
0.24
0.50
0.09
0.61
0.58
0.56
0.11
0.41
0.57
0.28
0.29

Groups Representation Dim 2
GI50 Relationship ^
GI50
CN
GE
Mut
CN
GE
Mut
0.03
0.56
0.51 0.00
Str Rel (-)
0.57
0.40
0.00
Pos (+)
Rel (+)
0.51
0.00
0.01 0.57
Pos (+)
0.15
0.23
0.00 0.65
0.95
0.01
0.02
0.08
0.88
0.08
Str Rel (-)
0.10
0.86
0.04 0.06
0.70
0.33
0.01
Rel (+)
0.15
0.27
0.10 0.77
Rel (-)
Str Rel (-)
0.79
0.00
0.15 0.19
0.14
0.87
0.00
Str Rel (-)
0.12
0.04
0.78
Str Rel (-)
0.09
0.02
0.89 0.02 Str Rel (+)
0.03
0.48
0.15 0.40
Str Rel (+)
0.03
0.79
0.03 0.19
Rel (+)
Rel (-)
0.06
0.09
0.15 0.76
Rel (+)
Rel (+)
0.66
0.24
0.01
Rel
Rel (+)
0.31
0.54
0.23 0.05 Pos (+)
0.59
0.19
0.08 0.20
0.10
0.20
0.07 0.69
Str Rel (-)
0.16
0.00
0.29 0.69
Rel (+)
Pos (+)
0.01
0.03
0.96
Str Rel (+)
0.27
0.00
0.36 0.42
Pos
Pos(-)
Rel (+)
0.47
0.50
0.07 0.16
Rel (-)
Rel (+)
0.14
0.19
0.22 0.53
Pos
Str Rel (+)
1.00
0.00
0.00
0.20
0.73
0.03
Str Rel (+)
0.90
0.01
0.07
0.00
0.75
0.25
Pos
Str Rel (-)
0.00
0.50
0.50
Rel (+)
Rel (+)

SMV*

21.28

25.53
36.17
27.66
25.53

27.66
29.79

25.53
34.04
23.4

23.4
25.53
21.28

21.28
29.79

Negative (-) = Higher predictive variable is associated with lower GI50 value (ie. Increased resistance), Positive = Higher predictive
variable is associated with higher GI50 value (ie. Decreased resistance), CN = copy number, GE = gene expression, Mut = somatic
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mutations, % VE = % variance explained, Dim = dimension, SVM = support vector machine, * = percent of misclassification if the
gene is removed from the SVM, Str Rel = strong relationship to GI50, Rel = relationship to GI50, Pos = possibly a relationship to
GI50. ^ blank boxes indicate no relationship.

Appendix S5.13 Gemcitabine Multiple Factor Analysis Results by Gene
Gene Name
ABCB1
ABCC10
AK1
CDA
CMPK1
CTPS1
DCK
DCTD
NME1
NT5C
RRM1
RRM2
RRM2B
SLC28A1
SLC28A3
SLC29A1
SLC29A2
TYMS

% VE GI50
0.32 0.76
0.34 0.31
0.36 0.44
0.42 0.77
0.37 0.55
0.35 0.52
0.31 0.83
0.40 0.81
0.53 0.43
0.55 0.46
0.45
0.5
0.35 0.49
0.43 0.37
0.37 0.36
0.31 0.76
0.54 0.02
0.46 0.34
0.50 0.16

Dim 1
CN
0.31
0.20
0.35
0.79
0.63
0.77
0.57
0.51
0.85
0.84
0.82
0.66
0.86
0.73
0.16
0.90
0.87
0.87

GE
0.77
0.83
0.85
0.16
0.82
0.70
0.43
0.83
0.82
0.87
0.9
0.78
0.82
0.48
0.31
0.90
0.76
0.85

Mut
0.15
0.71
0.63
NA
0.29
0.18
0.15
0.11
NA
NA
0.24
0.32
0.41
0.76
0.73
NA
0.62
NA

% VE GI50
0.26 0.26
0.27 0.77
0.26 0.45
0.33 0.22
0.26 0.10
0.27 0.51
0.28 0.04
0.26 0.21
0.31 0.90
0.30 0.89
0.25 0.19
0.27 0.51
0.25 0.64
0.27 0.75
0.26 0.21
0.33 1.00
0.25 0.84
0.33 0.98

Dim 2
CN
0.59
0.67
0.65
0.01
0.42
0.33
0.31
0.18
0.15
0.30
0.31
0.52
0.12
0.25
0.75
0.05
0.08
0.00

Groups Representation - Groups Representation Dim 1
Dim 2
GE
0.17
0.06
0.03
0.98
0.07
0.22
0.73
0.19
0.31
0.17
0.07
0.18
0.19
0.63
0.62
0.07
0.14
0.18

Mut
0.79
0.22
0.65
NA
0.91
0.83
0.71
0.96
NA
NA
0.92
0.73
0.72
0.20
0.21
NA
0.53
NA

GI50
0.58
0.10
0.19
0.60
0.31
0.27
0.69
0.66
0.19
0.21
0.25
0.24
0.13
0.13
0.58
0.00
0.12
0.02

CN
0.10
0.04
0.12
0.63
0.40
0.59
0.32
0.26
0.73
0.70
0.67
0.44
0.74
0.53
0.03
0.81
0.76
0.75

GE Mut GI50 CN
0.60 0.02 0.07 0.35
0.70 0.51 0.60 0.45
0.72 0.39 0.20 0.43
0.03
0.05 0.00
0.67 0.08 0.01 0.18
0.49 0.03 0.26 0.11
0.18 0.02 0.00 0.09
0.68 0.01 0.04 0.03
0.68
0.81 0.02
0.75
0.79 0.09
0.81 0.06 0.03 0.1
0.62 0.10 0.26 0.27
0.67 0.16 0.41 0.01
0.23 0.58 0.56 0.06
0.10 0.54 0.04 0.56
0.81
1.00 0.00
0.57 0.38 0.71 0.01
0.73
0.97 0.00

Abbreviations for table listed in Appendix S5.12
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GI50 Relationship^
SVM*
GE Mut
CN
GE
Mut
Str Rel (-)
0.03 0.62
20.45 (Exp)
0.00 0.05 Str Rel (-)
31.82 (Exp), 25 (CN)
Pos (-)
0.00 0.42 Pos (-)
0.95
Str Rel (-)
Rel (-)
0.00 0.83 Rel (-)
18.18 (Exp)
Pos
Pos (-)
0.05 0.68
0.53 0.51 Rel (+)
0.03 0.93 Rel (+) Str Rel (+)
25 (Exp)
Pos (-)
Pos (-)
0.10
31.82 (Exp)
0.03
34.09 (CN)
0.01 0.85
20.45 (Exp)
Pos (-)
0.03 0.53 Pos (-)
Rel (-)
0.04 0.52
29.55 (Exp)
Str Rel (-)
0.40 0.04
Str Rel (+)
0.39 0.04
0.00
Pos (-)
0.02 0.28
0.03
25 (CN)

Appendix S5.14 Cell Line GI50 vs. SVM Classification Score
Appendix S5.14.1

Paclitaxel SVM

Support vector machine classification score plotted against the GI50 of the cell line for
paclitaxel. The vertical axis crosses the horizontal axis at the median GI50 of all cell lines
analyzed. Cell lines with scores >0 were classified as resistant, those with scores <0 are
classified as sensitive. Cell lines outlined in a blue box are those classified as resistant,
but are actually sensitive to the drug (false positives); cell lines outlined in purple box
were misclassified as sensitive (false negatives).
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Appendix S5.14.2

Gemcitabine SVM

Support vector machine classification score plotted against the GI50 of the cell line for
gemcitabine. The vertical axis crosses the horizontal axis at the median GI50 of all cell
lines analyzed. Cell lines with scores >0 were classified as resistant, those with scores <0
are classified as sensitive. Cell lines outlined in a blue box are those classified as
resistant, but are actually sensitive to the drug (false positives); cell lines outlined in
purple box were misclassified as sensitive (false negatives)
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Appendix S5.15 Single Gene paclitaxel and gemcitabine SVMs
using cell line data
SVM single variable
Subtype
ABCB1
ABCB11
ABCC1
ABCC10
BAD
BBC3
BCAP29
BCL2
BCL2L1
BIRC5
BMF
CNGA3
CSAG2
CYP2C8
CYP3A4
FGF2
FN1
GBP1
MAP2
MAP4
MAPT
NFKB2
NR1I2
OPRK1
SLCO1B3
TLR6
TMEM243
TUBB1
TUBB4A
TUBB4B
TWIST1
15 Genes:

Paclitaxel
Percent misclassified
30.6%
44.9%
44.9%
44.9%
44.9%
46.9%
34.7%
44.9%
44.9%
44.9%
44.9%
42.9%
44.9%
36.7%
44.9%
44.9%
42.9%
44.9%
36.7%
40.8%
44.9%
34.7%
32.7%
44.9%
44.9%
34.7%
38.8%
44.9%
44.9%
46.9%
44.9%
44.9%
18%

314

Hinge loss
0.69
0.90
0.90
0.90
0.90
0.95
0.87
0.90
0.90
0.92
0.90
0.86
0.90
0.80
0.90
0.90
0.91
0.85
0.77
0.86
0.90
0.81
0.85
0.90
0.90
0.78
0.81
0.90
0.90
0.94
0.90
0.90
0.64

SVM single variable
Subtype
ABCB1-GE
ABCC10-CN
ABCC10-GE
CMPK1-GE
DCTD-GE
NME1-GE
NT5C-CN
RRM1-GE
RRM2B-GE
TYMS-CN
All Genes:

Gemcitabine
Percent misclassified
45.5%
45.5%
47.7%
36.4%
40.9%
36.4%
45.5%
47.7%
38.6%
50.0%
45.5%
15%
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Hinge loss
0.95
0.94
0.95
0.90
0.87
0.90
0.91
1.01
0.95
0.98
0.91
0.66

Appendix S5.16 Multiple Factor Analysis– Entire and SVM Gene
Sets
(for dimensions 1 and 2, % variance explained in brackets)

Appendix S5.16.1

Paclitaxel – SVM Gene Set
Individual Factor Map

The individual factor maps generated with a multiple factor analysis using the gene set
derived from the respective SVMs are displayed for paclitaxel. Purple points are resistant
cell lines, blue points are sensitive cell lines. Cell lines outlined in a blue box are those
classified as resistant, but are actually sensitive to the drug (false positives); cell lines
outlined in purple box were misclassified as sensitive (false negatives). 9 of 49 cell lines
were misclassified for paclitaxel.
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Appendix S5.16.2

Paclitaxel – Entire Gene Set
Individual Factor Map
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Appendix S5.16.3

Gemcitabine – SVM Gene Set
Individual Factor Map

The individual factor maps generated with a multiple factor analysis using the gene set
derived from the SVM are displayed for gemcitabine. Purple points are resistant cell
lines, blue points are sensitive cell lines. Cell lines outlined in a blue box are those
classified as resistant, but are actually sensitive to the drug (false positives); cell lines
outlined in purple box were misclassified as sensitive (false negatives). 7 of 44 cell lines
were misclassified for gemcitabine.
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1.0

Appendix S5.16.4

Gemcitabine– Entire Gene Set
Individual Factor Map
Individual factor map
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Appendix S5.17 FFPE Samples – Gene expression measurements summary
Appendix S5.17.1

Number of measurements by gene compared to GTEx expression levels
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Appendix S5.17.2

Year of tissue block compared to number of measurements per sample
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Appendix S5.18 Patient Clustering Supplementary Results.
Clustering was performed as in main Methods. Each cluster derived from the MD
Anderson Patient Data was isolated and the tumours in each were summarized by
subtype, number of distance recurrences ("events"), and mean time to distant recurrence
(Tables S5.1-S5.3 – see below).
The 'grey' clusters were isolated and further clustered with similar stratification by gene
expression and outcome (Supplementary Figure VI. 1).

Appendix S5.18.1

FFPE Patient Samples

Figure VI.1 – Paclitaxel FFPE Clustering Results
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Expression heatmap of the paclitaxel SVM derived genes for our set of 32 FFPE samples,
as measured by qPCR. Each row represents a gene and each column a tumour. Red
indicates higher expression and blue represents lower expression, as shown by the colour
bar on the left. Clustering was done based on the similarity of each tumour's and gene's
expression profile. The dendrograms on the top and left indicate the relatedness of each
tumour and gene by the length and subdivision of the branches, with deeper branches
indicating a stronger relationship and branches in the same 'tree' being more closely
related to each other than data in other 'trees'.
Figure VI.2 – Gemcitabine FFPE Clustering Results

Figure legend as above (Figure VI. 3).
Note: sample 3A had an extremely high expression value for DCTD and distorted the row
view for that gene. It has been removed in this figure for ease of visualization.
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Appendix S5.18.2

Hatzis et al. Patient Data

Supplementary Figure VI.3 - Further Clustering of the 'Grey' Cluster

The 'grey' cluster from the previous clustering analysis was isolated and clustered further.
The leftmost cluster (shaded a lighter grey) is composed of 70% luminal tumours with a
mean survival time of 3.14 years. The rightmost cluster is composed of 43% basal
tumours with a mean survival time of 2.45 years. The leftmost cluster also contains only
3 distant recurrences, with two of those being classified by the MD Anderson signature as
"Sensitive". The 'light grey' cluster, meanwhile, is stratified very well on the basis of the
MD Anderson signature (results not shown). This mirrors the results of the clustering
analysis on the 'green' and 'purple' tumour clusters.
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Supplementary Figure VI.4 - Zoom on the 'purple' and 'green' clusters.

The clusters from Figure 11 in the main paper were isolated from the main heatmap for
easier visualization of the differential gene expression that distinguishes each cluster.
Figure legend as in the main paper.
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Table S5.1: Summary of tumours contained in each cluster.

Table S5.2: Summary of tumours contained in each cluster.
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Table S5.3: Summary of tumours contained in each cluster.

RD: recurrent disease

pCR: pathological complete response

Insensitive/Sensitive as predicted by Hatzis et. al. (2011)
Events: distant relapse

Time: time to distant relapse

Appendix S5.19 MAPT Expression Affects Prognosis in Luminal
Tumours.
MAPT is part of the PAM50 and clearly segregates the data into luminal and basal
subtype to a large extent. However, some luminal tumours express MAPT at a lower level
than the majority. Low MAPT expressing luminal subtypes fall into the low MAPT
expressing 'purple' cluster (Supplementary Figure VI. 4) and have a significantly worse
prognosis than higher MAPT expressing luminal tumours in the patient dataset
(Supplementary Figure VII. 1).

329

Supplementary Figure VII. 1 - Kaplan-Meier curves for low MAPT expressing luminal
tumours vs. higher MAPT expressing luminal tumours.

Proportion Free of Distant Relapse
Low MAPT
High MAPT

Percent

100

50

0

0

2

4

6

8

Time
'Low' vs. 'high' expression was stratified by median MAPT expression across all tumours,
regardless of subtype. Luminal tumours with expression values below the overall median
were classified as 'low MAPT' and those with values above were classified as 'high
MAPT'. There were 32 low MAPT expressing' luminal tumours in the low MAPT set and
123 high MAPT expressing luminal tumours. In the log-rank test, the Kaplan-Meier
results are significant (p = 0.037). The log-rank hazard ratio is 2.503 (95% CI of ratio:
1.071 to 9.203).
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Appendix S5.20 Creating SVM models using lung and hematopoietic
cell lines.
We initially investigated the possibility that the paclitaxel breast cancer SVM model
could predict cell line sensitivity to this drug in 22 other cancer cell line types. The
respective misclassification rates were higher than with the breast cancer cell lines. We
attempted to classify resistance with the SVM model in other neoplastic tissues, including
from autonomic ganglia (10 cell lines), biliary tract (1), bone (10), central nervous system
(27), endometrium (17), hematopoietic and lymphoid tissue (55), kidney (8), large
intestine (18), liver (15), lung (76), oesophagus (15), ovary (24), pancreas (25), pleura
(7), prostate (3), salivary gland (1), skin (35), soft tissue (11), stomach (14), thyroid (3),
upper aerodigestive tract (6), and urinary tract (12). As Daemon et al., 2013 reported,
clustering of individual tissue types dominates the analysis of chemosensitivity. The
tissue-specific gene expression program of the cell lines could explain why the breast
cancer signature was not transferable.

Appendix S5.20.1
Lines

Feature Selection Process – Lung Cancer Cell
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Appendix S5.20.2
Feature Selection Process – Hematopoietic
and Lymphoid Tissue Cancer Cell Lines

Appendix S5.20.3

Final SMV Gene Sets for Paclitaxel
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MFA Using Genes in SVM – Lung

Appendix S5.20.4
Resistant
Sensitive

68

9 28

●

2

●

20
●

41

75
●

●

0

●

−2

Dim 2 (15.49%)

55

●

39
15
51 43
● 64
69● 23
52● ●
●
4431 ● 73 53
●
● ●
●
●
36
13
●
16
●
●
30
32
50
●
●
●
●
2111
35
●
18
46
70
●
●
19 7●65 60
●
●
49
●
62
54
●
● ●
27
29●● 47● 74
Sensitive
25
72 58
Resistant
5●
● ●
●
24 ● 14●
●
●
12 22
●
●
●34
●
33
61
4
1
57
17 ●
●
●
40 ●
●
● ●
48
38 56 26
●
●
●
●
6● 2
●
●
10
63
66
●
●
●
8
●

3
●

67
●
45

71

●

42

●

●

●

37

59

−4

●

−6

76
●

−10

−5

0

5

1.0

Dim 1 (17.70%)

IC50
ABCB1
BAD

0.5

BCAP29
BIRC5
BMF

BIRC5

TMEM243

TUBB1

ABCB1

0.0

FGF2

BCAP29

MAP2

GBP1

SLCO1B3

MAP4

MAP2

OPRK1

MAP4

−0.5

OPRK1

GBP1

SLCO1B3

IC50.uM.

TUBB1
TWIST1

C7orf23
BMF

−1.0

Dim 2 (15.49%)

FGF2

BAD
TWIST1

−1.0

−0.5

0.0

0.5

Dim 1 (17.70%)

333

1.0

Appendix S5.20.5
MFA Using Genes in SVM – Hematopoietic
and Lymphoid Tissue
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